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No vaccines are available for hepatitis C virus (HCV) which infects over 71 million people 
worldwide. Current therapeutic options are very expensive and as a consequence, only around 
1% of those diagnosed with Hepatitis C receive treatment each year. Induction of neutralizing 
antibody (NAb) by vaccination will be important for the successful prevention of HCV 
infection. HCV envelope glycoproteins E1 and E2 are required for virus entry into host cells 
making these proteins attractive targets to prevent virus infection.  
DNA-based vaccines are appealing candidates for novel vaccine development because they are 
not infectious and are cost-effective to manufacture on a global scale. However, despite being 
licensed for veterinary use, DNA vaccine have not been highly immunogenic in large animals. 
Virus-like particles (VLP), on the other hand, which resemble native viruses but are non-
infectious because they lack viral genetic materials, have provided highly encouraging results 
in clinical trials. 
 In this thesis the immunogenicity of VLPs and the ease of production of plasmid DNA were 
combined by designing DNA vaccines encoding VLPs consisting of HCV-core, E1 and E2 
proteins (which can self-assemble into VLPs following expression). This vaccine also encoded 
a cytolytic gene perforin (PRF) to cause cell death and ensure the release of the VLPs from 
vaccine-targeted cells along with damage associated molecular patterns (DAMPs), which act 
as natural adjuvants. Bicistronic DNA vaccine constructs encoding HCV structural proteins and 
PRF were successfully generated and validated. Vaccination with the DNA construct encoding 
CoreE1E2-PRF generated higher adaptive immune responses in mice than vaccination with a 
construct unable to induce cell death, therefore confirming an adjuvant effect by PRF. However, 
these responses were weak compared to those reported in the literature. 
Antigen oligomerisation has been shown to improve vaccine immunogenicity. To improve the 
immunogenicity of a DNA vaccine encoding HCV-E1E2, a novel strategy that incorporates E1 
and E2 into heptamers by fusion with the oligomerisation domain of a chimeric C4 binding 
protein (namely IMX3133 or IMX313P) was used. As the adjuvanticity of IMX313 or 
IMX313P requires efficient secretion of the oligomerised protein, the leader sequence of the 
tissue plasminogen activator (tPA) was introduced upstream of the E1 or E2 proteins (tE1 or 
tE2) from which the transmembrane domains were removed. The use of tE1 and tE2 proteins 
as separate immunogens or as a single tE1tE2 polyprotein when fused to IMX313 or IMX313P 
was assessed in vaccination studies in Balb/c mice using prime-boost intra-dermal DNA 
immunisations. Vaccination with the DNA construct encoding tE1/tE2 fused to IMX313 or 
IMX313P resulted in increased antibody and cell mediated immune (CMI) responses compared 
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to the same dose of DNA without IMX313 or IMX313P, while fusion of tE1/tE2 to IMX313P 
resulted in the highest immune responses.  DNA prime/E1E2 protein boost or DNA 
prime/HCV-VLP boost approaches were then used to further improve the immunogenicity of 
tE1/tE2-IMX313P DNA constructs.  Boosting with E1E2 proteins improved overall antibody 
responses, compared to boosting with HCV-VLPs or plasmid DNA. However, experiments to 
examine the neutralisation of binding of labelled VLPs showed that the E1E2 or VLP boost did 
not improve the neutralising potency of these antibodies or the CMI responses.  
This thesis demonstrated that expression of heptamerised and secreted tE1/tE2 from DNA 
vaccine constructs significantly improved the antibody and CMI responses to HCV E1 and E2 
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Chapter 1. Literature Review 
1.1. HCV transmission and epidemiology  
HCV is an enveloped positive sense single-stranded RNA virus that is estimated to infect more 
than 71 million people (~1%) of the world's population, making HCV the leading cause of liver 
disease worldwide  [9, 10]. In developing countries, HCV infections are largely transmitted by 
parenteral exposure to contaminated blood or blood products in the form of transfusion, unsafe 
therapeutic injections and intravenous drug use [11, 12]. After widespread screening for HCV 
was implemented in the 1990's in economically developed countries, new cases of transfusion- 
and organ transplant-associated infections were nearly eliminated, and the vast majority of 
newly acquired infections are now spread through intravenous drug use and/or needle sharing 
[13]. The risk of transmission from sexual contact is believed to be low [14].  
The incidence of HCV infection is difficult to determine as most acute infections are 
asymptomatic and therefore remain undetected [15]. HCV infection rates worldwide are 
believed to be underestimated as prevalence data from many geographical areas are unavailable 
[16]. In addition, these areas have both limited screening of blood donations and limited HCV 
testing available [13] suggesting that they might have increasing incidences of HCV infection.  
The prevalence of HCV infection is much higher (up to 15%) in some African and Asian 
countries compared to the USA (1.7%) and Europe (1.03%) [13, 17, 18]. Egypt for example 
has a prevalence of up to 20% which is the highest reported prevalence rate for HCV [13, 17].  
HCV is genetically diverse and is currently subdivided into seven major genotypes which are 
at least 30% divergent in nucleotide sequences, and each of these genotypes is subdivided into 
numerous subtypes [19, 20]. Based on current evidence, these genotypes appear to have evolved 
separately in different geographical regions despite displaying similar pathology and 
transmission characteristics [19, 20]. Genotypes 1, 2 and 3 are prevalent in North America, 
Europe and Asia, with genotype 1 being the most endemic in these regions. Genotype 4, on the 
other hand, is predominantly found in the Middle East and Africa but has recently been reported 
in several European countries [21-23]. Genotypes 5, 6, and 7 are rare. The most common 
genotypes in Australia are genotypes 1a and 1b (54% prevalence) and 3a (37% prevalence) [24, 
25]. In addition to their geographical distribution, HCV genotypes also differ in severity of the 
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1.2. HCV Pathogenesis  
HCV is largely a silent disease as the acute phase remains largely asymptomatic. Although 
approximately 20% of infected individuals are able to spontaneously clear the virus, the 
majority of cases develop chronic infection and these individuals are at high risk of acquiring 
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serious liver damage including steatosis, liver cirrhosis and hepatocellular carcinoma (HCC) 
[23]. 
During the first 6 months after infection which is considered the acute phase, most infections 
remain undiagnosed. The development of non-specific symptoms including decreased appetite, 
fatigue, malaise, jaundice, anorexia and fever have been reported from patients who acquired 
infection via needle stick injury or following transfusion [26]. Elevated serum alanine 
aminotransferase (ALT) levels and viral RNA (usually detected within 1 to 2 weeks following 
exposure) are common features of acute infection [26, 27].  
HCV infection persisting for more than six months is defined as chronic infection [28]. The 
outcome of infection depends on a number of viral and host factors including the age of the 
patient at the time of infection, ethnicity, gender, lifestyle, underlying disease, the viral 
genotype, viral quasispecies diversity and importantly the efficiency of the infected individual's 
immune response. During the chronic stage patients may remain symptomless but a proportion 
will eventually develop conditions such as hepatic steatosis, progressive fibrosis, compensated 
and later decompensated cirrhosis and ultimately HCC [26, 29]. Once cirrhosis is established, 
the risk of developing HCC is approximately 4% each year. It is believed that hepatocellular 
damage likely reflects destruction of HCV-infected cells by cytotoxic CD8+T cells, resulting 
in proliferation of other hepatocytes.  However immunosuppressed patients suffer a more severe 
course of liver disease than immunocompetent patients, possibly due to unrestrained virus 
replication (caused by immunosuppression) resulting in increased intracellular levels of virus 
that result in cytotoxicity [10, 26]. 
1.3. HCV life cycle and molecular biology 
The HCV enters host cells via clathrin-mediated endocytosis and pH-dependent release from 
early endosomes (Fig. 1.1) [30, 31]. The virus mainly infects hepatocytes by binding to various 
cell-associated receptors. Based on their function these can be divided into attachment receptors 
or post-attachment receptors. HCV attachment to cells is believed to be initially mediated by 
the binding of cellular apolipoprotein E (apoE) and phosphatidylserine (PS) incorporated on 
the viral envelope to heparan sulfate (HS) proteoglycans (HSPGs) (containing syndecans 
(SDCs)-1/SDC-2 core proteins) and T cell immunoglobulin and mucin domain-containing 
protein 1 (TIM-1) respectively on the surface of hepatocytes [32, 33]. 
Post attachment receptors, on the other hand, do not play critical roles in cell attachment but 
are important for HCV cell entry and uncoating [34, 35]. These receptors include the tetraspanin 
CD81 [36], the Niemann-Pick C1–like 1 cholesterol absorption receptor (NPC1L1) [37], the 
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scavenger receptor class B type I (SR-BI) [38] and the tight junction proteins claudin (CLDN) 
and occludin (OCLN) [31, 39] which interact with the envelope protein 1 (E1) and E2. 
CD81 was the first HCV co-receptor described to interact with the envelope protein E2 [7, 36, 
40]. Studies using retrovirus pseudotyped with E1/E2 (HCVpp) [41-43] and cell culture derived 
HCV (HCVcc) made by transfecting full-length HCV RNA into Huh 7 cells [7, 44, 45] have 
provided valuable information about the interaction between E2 and CD81. These studies have 
demonstrated that the large extracellular loop (LEL) of CD81 is an important host cell factor 
for viral entry as it contains several amino acids residues critical for CD81-E2 binding [46-50]. 
E2 amino acids residues at positions 415, 420, 527, 529, 530, and 535 have been shown to be 
important for virus particle–CD81 interaction [51, 52]. 
SR-BI binds to a variety of lipoproteins and is involved in bi-directional cholesterol transport 
at the cell membrane [38]. The SR-BI extracellular loop has been shown to interact with E2 
HVR1 [38] and its amino acids at positions 70–87 are thought to be required for E2 recognition 
[53]. 
CLDN1 is expressed in all epithelial tissues but predominantly in the liver [54]. It is localised 
to the tight junction of hepatocytes and may also be localised to the basolateral surfaces of these 
cells [55]. Studies have suggested that non-junctional CLDN1 may be involved in HCV entry 
during post-binding steps [39, 56].  
OCLN, a four transmembrane protein expressed in tight junction of polarized cells, is another 
host cell factor critical for HCV entry [57-59]. OCLN is believed to be one of the HCV host 
entry factors responsible for the species specificity of HCV as expression of human OCLN has 
been shown to be required for infection of mouse cells [57]. However, no evidence of a direct 
interaction with HCV has been reported. Although these receptors confer species specificity, in 
vitro replication of HCV in non-liver cells such as neuroepithelial cells has been described, 
arguing that HCV might not be strictly hepatotropic [60, 61].  
Since it is of positive polarity, the HCV RNA functions directly as mRNA in the cytoplasm of 
the host cell, where protein translation is initiated through an internal ribosomal entry site in 
the 5’ untranslated region (UTR) (Fig.1.1) [62]. The RNA contains a single open reading frame 
flanked by two UTRs that encodes a polyprotein which is co- and post-transitionally processed 
by viral and cellular proteases into structural proteins (core, E1 and E2) and non-structural (NS) 
proteins (p7, NS2, NS3, NS4A, NS5A and NS5B) (see Fig. 1.2) [63]. Following synthesis and 
maturation, viral RNA and the NS proteins form membrane-associated replication complexes, 
which appear as a perinuclear membranous web [64]. These replication complexes can then 
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catalyse the transcription of negative-sense RNA intermediates from which progeny positive-
strand RNA molecules are generated [64]. Capsid proteins and genomic RNA assemble to form 
a nucleocapsid, which buds through the membranes of the endoplasmic reticulum into 
cytoplasmic vesicles [10, 65]. Enveloped, mature virions leave the cell via the secretory 
pathway. However, this final step is still not well understood and is an exciting area for future 
research. 
 
The core protein is the main structural component of the viral nucleocapsid, while the E1 and 
E2 glycoproteins form a functional heterodimer that mediates viral entry and fusion [66, 67].  
The E1 glycoprotein contains a C-terminus transmembrane domain (TMD) with five 
glycosylation sites, which anchors the ectodomain to the virion (Fig. 1.3). E1 has been shown 
to be critical for viral entry and the correct assembly and stability of the E1/E2 heterodimer. 
However, the function of E1 in entry is still unknown [42]. 
Figure 1.1. The HCV lifecycle. Extracellular virus particles enter hepatocytes by interacting with cell surface 
receptors, followed by receptor-dependent endocytosis. Upon arrival in early endosomes the HCV 
glycoproteins mediate fusion of the viral envelope with the endosome and the viral genome is released into 
the cytoplasm. The viral RNA is then translated to generate the large polyprotein that is processed into 10 
mature HCV proteins. Replication complexes formed through the association of the NS proteins with ER-
derived membranes replicate the genome. A portion of the newly synthesised positive-sense RNA is packaged 
into viral capsids in the ER, the resultant nucleocapsid is enveloped by the virus envelope glycoproteins, and 




The E2 glycoproteins contains 11 largely conserved N-linked glycosylation sites and 18 
conserved cysteines (Fig. 1.3). The E2 receptor binding domain (RBD; residue 384-661), is 
linked through a conserved C-terminal stem to the TMD and folds independently of other E1/E2 
sequences [68]. The binding site for CD81 consists of highly conserved segments within the E2 
RBD [36, 51, 68-70] which interact with the LEL of CD81 through Ale182, Asn184, Phe186 



















Located within the RBD of E2 there are three regions with increased genetic variability 
characterised as hypervariable regions (HVR) -1 and 2, and the intergenotypic variable region 
(igVR) (Fig. 1.3). HVR1 is 27 amino acid long [72] and has been attributed to evasion from 
neutralising antibodies (NAbs) as replication by the error-prone RNA-dependent RNA 
Figure 1.2. The organisation of the HCV genome and protein topology. (A) The HCV genome is a 
single-stranded RNA encoding a single large open reading frame (ORF) of roughly 3,000 amino acids, 
flanked by structured 5′ and 3′ UTRs. The translation of the open reading frame, via the activity of an IRES 
element in the 5′ UTR, generates a large polyprotein that is organized with structural proteins in the amino-
terminal third of the polyprotein, followed by the NS proteins required for replication. The polyprotein 
undergoes a complex co- and post-translational series of cleavage events, catalysed by both host and viral 
proteases, to produce the 10 individual HCV proteins. (B) The topology of the HCV proteins relative to the 
ER membrane (adapted from [6, 7]). 
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polymerase results in high viral quasispecies variability as a consequence [73]. Despite the high 
sequence variability, the overall basic charge of this region is preserved, probably to maintain 
interaction with SR-B1 [74] as deletion of HRV1 from the RBD abolishes the interaction with 
SR-B1 [75]. HRV2 is a region (residue 461-481) downstream of HRV1 flanked by conserved 
cysteine residues [76]. Another cysteine -flanked variable region igVR (residue 570-580) has 
been described [77]. This region exhibits a high degree of intergenotypic variation [77]. HRV2 
and igVR are believed to be essential to the virion-incorporated E1/E2 structure as deletion of 
either region is not tolerated and causes E2 to fail to form a heterodimer with E1 resulting in 
non-infectious HCV particles [78]. No evidence has so far been found to suggest that HRV2 
and the igVR are targeted by antibodies and therefore are less likely to be under immune 
pressure [77]. 
The hydrophobic p7 protein as well as NS2 are required for assembly and release of infectious 
particles [79, 80]. The serine protease residing in the amino-terminus of NS3 forms a stable 
complex with the NS4A cofactor and catalyses polyprotein cleavage at the NS3-4A, NS4A-B, 
NS4B-5A and NS5A-5B sites (see Fig. 1.2) [81]. NS5A is required for RNA replication and 
virion morphogenesis [82], while NS5B is a conserved RNA-dependent RNA polymerase 
(RdRp) required for RNA synthesis [83, 84]  
Figure 1.3. Schematic representation of glycoprotein E1 and E2. The locations of conserved 
glycosylation sites are represented with trees and the transmembrane domains are shown in yellow. 
Regions that are involved in CD81 binding are shown in green. The location of the hypervariable regions 
in E2 are shown in red and the E2 stem region is indicated in grey. Regions possessing antibody 
epitopes are shown in black. The alignment of the HCV gene sequence is based on the genotype 1a, 
H77c (GenBank accession no. AF011751). (Adapted from [4, 5]). 
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1.4. Immune Responses to HCV Infections 
The success of most vaccines depends on the induction of adaptive immune responses, which 
in the context of viral infections are crucial to either prevent or limit infections. Antigen 
presenting cells (APC), particularly dendritic cells (DCs), link innate immune responses to 
adaptive immune responses, and are capable of priming naïve T cells and producing large 
quantities of cytokines [85, 86]. DCs can capture pathogen proteins and present these to major 
histocompatibility complex (MHC) restricted helper T (Th) cells in the lymph nodes. With the 
assistance of CD4+ T cells, B cells secrete antibodies with the potential to neutralize the virus 
by binding to the proteins on the virus envelope that are necessary for entry into host cells. If 
the neutralisation is unsuccessful and infection proceeds, then with the help of CD4 T cells, 
CD8 T cells (also known as cytotoxic T lymphocytes (CTL)) can directly eliminate virus-
infected cells by releasing toxins such as perforin and granzyme or antiviral cytokines like 
interferons (IFN)-γ and tumour necrosis factor (TNF)-α (Fig. 1.4). Perforin (PRF) is a soluble 
calcium-dependent, pore-forming cytolytic glycoprotein that is crucial for the function of 
cytotoxic lymphocytes (CTL and natural killer (NK) cells). Once a virus-infected or 
transformed cell is recognised by CTL, they form an immunological synapse which leads to the 
fusion of cytotoxic lymphocyte granules (in which perforin is sequestered along with granzyme 
serine proteases) with the plasma membrane of the CTL, releasing the cytotoxic granules 
contents into the synapse. In the synapse, perforin binds to the target cell membrane forming 
transmembrane pores and these allows the diffusion of granzyme into the target cell [87-89]. 
Once in the target cell, granzymes can then initiate caspase-dependent and caspase-independent 
apoptotic pathways, which rapidly lead to target cell death [89]. 
Various innate and adaptive immune components play a crucial role in clearing HCV infection. 
The innate immune response which includes a network of cells including NK cells, monocytes, 
macrophages, leukocytes and DCs together with the production of type I interferons and other 
interferon stimulated genes (ISGs) by hepatocytes present the first line of defence during HCV 
infection. The innate immune response is activated early during infection and limits progression 
of infection until the adaptive immune response is activated. The development of antigen-
specific adaptive cell mediated immunity [90] has been shown to be crucial for HCV clearance 
[91]. Vaccines rely on adaptive immune responses to confer long-term specific protection 
against pathogens of interest. Regardless of the outcome of the infection, the majority of HCV-
infected patients develop antibodies against HCV some of which can neutralise viral particles 
and therefore may have an important function in limiting viral spread [26, 92]. Despite the 
ability of HCV to evade the host immune responses (see section 1.4.1), ~20% of HCV-infected 
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patients with acute infection experience spontaneous resolution of viraemia, suggesting that the 
development of an effective vaccine is likely possible [26, 93]. 
 
1.4.1. Innate immunity  
Early host control of HCV or other virus infections relies on the innate immune response to 
inhibit virus spread immediately after infection and is crucial in the development and the 
shaping of adaptive immunity [94, 95]. To detect invading pathogens, the host immune cells 
rely on recognition of pathogen-associated molecular patterns (PAMPs) through pattern 
recognition receptors (PRRs) found on innate immune cells including NK cells and DCs. 
Currently, four different classes of PRR families have been identified. These families include 
transmembrane proteins such as the Toll-like receptors (TLRs) and C-type lectin receptors 
(CLRs), as well as cytoplasmic proteins such as the Retinoic acid-inducible gene (RIG)-I-like 
receptors (RLRs) and nucleotide-binding oligomerisation domain (NOD)-like receptors 
(NLRs) [96-98]. PRRs are a family of transmembrane pattern recognition receptors that 
Figure 1.4. Immune responses to viral infections. Humoral immune responses involve B cells that 
differentiate into antibody secreting plasma cells on encounter with antigen. The cellular immune 
response involves antigen uptake and processing by DCs and antigen presentation to CD4 and CD8 
T cells which drives their differentiation into effector cells (Adapted from [2]). 
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recognise microbial PAMPs and are capable of activating the expression of genes involved in 
inflammatory and immune responses [96, 99]. Viruses that are not detectable by the endosomal 
entry pathway can be detected by the cytosolic pathway triggered by binding of viral RNA to 
the RIG-1 and melanoma differentiation antigen 5 (MDA5) [100, 101]. These viral sensors in 
turn rely on downstream adaptor proteins to promote the antiviral signalling program. Antiviral 
type I IFNs (comprising several IFN-α and one IFN-β) and type III IFNs (IFN-λ1, - λ2, and λ3; 
also designated IL-29, IL-28A, and IL-28B), as well as other proinflammatory cytokines can 
be triggered as a downstream effect of this signalling, depending on the incoming virus and 
activation pathway.  
During HCV infection, HCV-infected liver cells trigger the earliest host responses. Type I and 
III IFNs from both HCV-infected hepatocytes and immature DCs [94], are the main cytokine 
responsible for the induction of an intracellular antiviral state, and for the activation and 
regulation of the cellular components of innate immunity such as NK cells [102]. Once 
produced, IFN-I is secreted from the cell and acts in an autocrine or paracrine fashion to 
promote an antiviral state in infected and neighbouring hepatocytes [102]. IFN-β produced by 
infected hepatocytes is initiated by TLR3 and RIG-I which recruits the adaptor molecules IFN-
β promoter stimulator protein 1 (IPS-1; also referred to as CARD adaptor inducing IFN-β 
(CARDIF), virus-induced signalling adapter (VISA), and mitochondrial antiviral signalling 
protein (MAVS)) and Toll-IL-1 receptor domain containing adaptor inducing IFN-β (TRIF). 
These processes result in downstream signalling, nuclear translocation of IFN regulatory factor 
(IRF3), and synthesis of IFN-β [103]. Type II IFN (IFN-γ) on the other hand is produced by 
NK and NKT cells as part of the innate immune system, and by antigen-specific T cells CD4+ 
and CD8+ T lymphocytes. Type I IFNs are believed to bind to a heterodimer receptor consisting 
of the interferon-α/β receptor (IFNAR)1 and IFNAR2 [104], while type III IFNs bind a 
heterodimer receptor consisting of IL10-R2 (also known as IL10RB) and IL28RA. These genes, 
collectively facilitate the clearance of virus from infected cells and protect uninfected 
neighbouring cells.  
Despite the activation of innate immune response, evidence suggest that HCV has developed 
several strategies to overcome these host responses at multiple levels. The viral NS3/4A 
protease cleaves important components of the type I IFN activation cascade, such as TRIF [105] 
and IPS-1 (MAVS) [106], blocking the activation of several interferon-stimulated genes and 
thereby preventing TLR3 and RIG-1 signalling [107]. Furthermore, the core protein interferes 
with Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling and 
impairs interferon-stimulated gene (ISG) expression [95, 108]. The NS4B protein induces 
alterations of the membranous web and suppresses RIG-I mediated IFN-I signalling by binding 
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to Stimulator of Interferon Genes (STING) [79, 80]. Another key player in HCV-associated 
immune system attenuation is HCV NS5A which inhibits the ISGs 2'-5' oligoadenylate 
synthetase (2'-5' OAS) and induces interleukin (IL)-8 which inhibits overall ISG expression 
[109]. NS5A forms heterodimers with protein kinase R (PKR) and also inhibits cyclophilin A 
activity thereby blocking IFN effector function [110, 111], while E2 acts as decoy target to 
PKR [112]. As cytokines which are normally produced during the innate immune response 
trigger the activation of adaptive immunity, the attenuation of innate immune signalling 
profoundly affects the subsequent activation of the HCV-specific adaptive immune response.  
As noted above, DCs link innate immune responses to adaptive immune responses. These cells 
process and display antigenic peptides in a complex with MHC on their surface and activate T 
cells. If infected by viruses, DCs have the ability to process the viral antigens and efficiently 
present them to T cells, thereby activating these cells. This process in known as direct 
presentation [3]. Many viruses, however, infect only one or a few cell types and could therefore 
potentially avoid recognition by not infecting DCs. To overcome this, DCs use cross-
presentation, whereby they acquire antigens from extracellular fluids through the process of 
endocytosis or phagocytosis followed by MHC-class I-restricted presentation to CD8+ T cells 
(Fig. 1.5).  
Figure 1.5. Central role of DC in the activation of immune response. DCs respond to three known 
groups of maturation stimuli including damage associated molecular patterns (DAMPs), pathogen 
associated molecular patterns (PAMPs), as well as other innate lymphocytes, such as NK cells, NKT 
cells and γδ T cells through cell-cell contact and cytokines. Once activated DCs can then interact with 
CD4 and CD8 T cells to drive their antigen-specific activation and proliferation (Adapted from [3]). 
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A successful vaccine must target DCs and/or otherwise direct the immunogen to DCs for cross 
presentation [113]. Vaccination with HCV antigen-loaded DC may constitute an efficient and 
important antiviral therapy for HCV. Several approaches involving DC-based vaccines have 
been developed and these strategies been shown to effectively induce HCV-specific CD4+ T-
cell response as well cytotoxic lymphocytes (CTL) in mice [114-116] and in a phase I human 
clinical trial [117], suggesting that this might be a successful approach for the priming or 
boosting of anti-HCV CD8+ T cell responses to aid in the clearance of the virus [117, 118]. 
Nonetheless during HCV infection, the maturation and functional differentiation of DCs are 
altered leading to insufficient T cell priming and delayed HCV-specific T cell response [119, 
120]. Similarly, the frequency of plasmacytoid DCs (pDCs) as well as their ability to produce 
IFN-α upon stimulation are impaired in chronic HCV patients [121, 122]. It is possible that 
HCV proteins play a role in suppressing protective immunity through interaction with DCs as 
well as other immune cells, however the mechanisms whereby HCV affect DC function remain 
elusive [123]. 
NK cells are another type of innate effector cell that frequently reside in the liver and can rapidly 
exert cytotoxicity and release cytokines. While NK cells potentially contribute to the initial 
control of HCV infection, there is little evidence that this innate and adaptive immunity can be 
exploited for vaccine-induced immunity against subsequent viral infection [124]. HCV E2 
protein is believed to inhibit NK cell function directly by crosslinking CD81 [125, 126]. 
However it has also been reported that HCV E2 does not efficiently crosslink CD81 on NK 
cells when it is a component of infectious virions and NK cell function remained intact after in 
vitro exposure to HCV-antibody complexes [127].  
Collectively, these data suggest that HCV interacts with and affects the function of different 
cells of the innate immune response. This interference differs with regard to cellular levels, 
targets and outcomes, and results in a deficient adaptive immune response and loss of pathogen 
elimination function. Nevertheless, the fact that some individuals are able to clear the infection 
suggest that the cytokine milieu produced by DCs along with the efficacy of costimulatory 
pathways between DCs and T-cells are important in priming a strong antigen-specific adaptive 
response, capable of clearing HCV infection [128]. Thus, raising the prospect of targeting this 
arm of immune response in vaccine development. 
1.4.2. Adaptive immunity  
Unlike innate immunity, the adaptive immune response is specific and can take weeks to 
develop following infection. The main components of the adaptive immune response include 
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the cell mediated immune response (comprised of T lymphocytes) and the humoral immune 
response (comprised of B lymphocytes). 
1.4.2.1. Humoral immunity  
Humoral immunity against HCV is characterized by B cell-mediated production of NAbs. 
NAbs have the ability to prevent viruses and intracellular bacteria from entering host cells by 
binding to the proteins on the pathogen surface that are necessary for entry into host cells. 
Although the effectiveness of all current licensed viral vaccines relies on the production of 
NAb, these antibodies were initially thought to play minor roles in the outcome of HCV 
infection [129-131]. Their role in viral clearance and disease progression is not well defined, 
largely due to the lack of assays to measure and quantify their activity [132]. Recent clinical 
and experimental data have highlighted the importance of NAbs and their contribution to both 
HCV clearance and protection from reinfection [133-135]. Broadly specific NAb elicited early 
during infection were shown to correlate with viral clearance [134-136] while individuals who 
failed to make NAbs progressed to chronic infection. NAbs were detected in a majority of 
reinfected individuals who managed to clear the virus but was not detected in those HCV-
infected patients who progressed to chronic infection [129].  
The frequency of B cells which secrete immunoglobulin (Ig) G as well as the overall 
concentration of IgG in blood are increased during chronic hepatitis C [137]. A small subset of 
HCV-specific antibodies, usually detectable between 8-20 weeks after infection, can prevent 
virus binding, entry, or post-entry steps of the viral lifecycle, and therefore prevent viral 
infection and spread to uninfected cells [131, 132, 137]. However, this response is often delayed 
during infection, possibly due to a defect in the priming mechanism of B and T cells [132, 137]. 
A study using homologous viral assays associated acute-resolving HCV infection with early 
development of NAbs [134]. Moreover, cross-reactive NAbs have been detected in the sera of 
HCV-infected patients who subsequently cleared the virus after re-exposure, suggesting that 
NAbs might also be important in protection from re-infection [138]. NAbs have been shown to 
have a protective role in the chimpanzee animal model of HCV infection [139], however 
evidence of a similar protective role in patients with acute-resolving infection was not 
confirmed by some researchers despite the detection of NAbs  [132, 140]. Nevertheless, HCV 
can be cleared in some infected individuals in the absence of NAbs, even in 
immunocompromised (e.g., hypogammaglobulinemic) patients [140, 141] suggesting the 
involvement of adaptive cellular immunity. 
Although antibodies produced during HCV infection target epitopes within both structural and 
NS proteins, NAb target epitopes within E1 and E2 proteins, or the E1E2 heterodimer. 
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Glycoproteins E1 and E2 form a heterodimer that mediate viral entry and NAbs AR4 and AR5 
have been shown to recognise conformational epitopes on the E1E2 heterodimer with broad 
neutralising cross-reactivity between diverse HCV genotypes [142]. 
Few NAb that specifically target E1 have so far been identified [4, 143].  However, It is still 
unclear whether this is due to the poor immunogenicity of E1 as E1-specific antibodies have 
been detected only at low levels in HCV patients [134, 144]. Despite their low titres in vivo, 
E1-specific antibodies have been reported to contribute largely to the overall neutralisation of  
HCVpp in vitro [145]. Moreover, anti-E1 antibodies have been found to be difficult to induce 
with vaccines expressing the E1E2 heterodimer but are more efficiently induced following 
separation of E1 from E2. This suggests that E2 is more immunogenic or that E1 neutralising 
epitopes are masked by E2 [146, 147]. Two monoclonal antibodies, IGH505 and IGH526 (Fig. 
1.3), isolated from a patient who cleared a genotype 1b infection, were found to recognise 
overlapping but distinct epitopes within E1 residues 307-340 and neutralise genotype 1a, 1b, 
4a, 5a, and 6a viruses [148]. Additional neutralising epitopes within E1 have been discovered 
and include residues 192-202 [149] and 264-327 [145, 148, 150].  
Most NAb target linear and conformational (discontinuous) epitopes located within the 
glycoproteins E2 and more specifically regions located in and close to the HVR1 of E2 [66, 69, 
151] including the binding site for CD81 [152]. Located at the amino terminus of E2, HRV1 is 
an interesting target for NAbs as it is likely involved in virus entry due to it interaction with 
SR-BI [153, 154]. The most effective NAbs recognise epitopes located on the C-terminus of 
E2 where the E2/SR-BI interaction occurs [43, 154, 155]. Moreover, antibodies that recognise 
HRV1 show poor cross-neutralisation across different isolates of HCV of the same genotype 
due to the HRV1 high mutation rate [135, 156, 157]. NAbs targeting the less variable region 
(residues 412-421) directly downstream of HRV1 have also been found [158-160]. Monoclonal 
antibodies AP33, 3/11, HC33.4, HCV1 and H77.39 all recognise residues in the region 413–
420 (Fig.1.3). However, this region has been suggested to be less immunogenic in vivo because 
NAbs targeting this region have been detected in only less than 5% of spontaneous resolvers 
[161]. As previously mentioned, E2 interacts with cellular proteins needed for viral entry 
including CD81 [162], SR-BI [38], NPC1L1 [37], and OCLN [31, 39]. Some NAbs 
(particularly AR3A, AR3B and AR3C) target epitopes spanning multiple conformation-
sensitive regions, while NAbs 2/69, HC84.1, HC84.27 and 1/39 target epitopes in the region 
427–447 (Fig. 1.3). A number of NAbs, including H77.31, H77.36, 1:7 and A8, have been 
found to target the CD81-binding loop of E2 (E2 amino acids residues at positions 519 to 535 
of the HCV H77 consensus sequence) [48, 76, 142, 152, 163, 164].  
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NAbs contribute to the spontaneous clearance of infection, however the majority of infected 
patients progress to chronicity. Several mechanisms have been suggested to contribute to 
evasion of sterilising antibody-mediated clearance. Some of these include sequence changes, 
decoy epitopes, epitope masking, lipid shielding and cell-to-cell HCV transmission. 
The high HCV sequence variability permits the virus to rapidly escape from Ab-mediated 
pressures. An estimated 1012 new HCV virions are believed to be generated daily in the infected 
liver [165] and thousands of mutant virions bearing all possible single and double nucleotide 
substitution pre-exist before treatment [166]. This viral sequence evolution, especially in E2, 
has been associated with NAb escape in chronic infection [73, 135, 140, 167]. The host NAb 
response lags behind the rapidly mutating E2 sequences within the quasispecies [73, 135], while 
continuing to exert selection pressure on viral variants and thereby contributing to selection of 
escape variants throughout the course of infection [73, 140].  
The HRV1 region of E2 is highly immunogenic but is not vital for viral entry/infection. HRV1 
deletion mutant have been shown to more sensitive to NAb responses, suggesting that HRV1 
acts as an immunological decoy concealing epitopes sensitive to neutralisation [143, 168-170]. 
Moreover, NAb selection has been shown to drive HRV1 sequence evolution in chronically 
infected patients, while HRV1 remains stable overtime in Ig-deficient patients [171-173]. 
E1 and E2 proteins are heavily glycosylated with E2 containing up to 11 N-linked glycosylation 
sites most of which are highly conserved across the different genotype (Fig. 1.3). The glycan 
of the E1E2 ectodomain are estimated to contributing to almost half the apparent molecular 
weight of these proteins and have been shown to be essential for the structure and function of 
E1E2 and play an important role in viral entry [174-177]. These glycans are reported to prevent 
NAbs from accessing key neutralising epitopes [178, 179] as the removal of this glycan shield 
increases the sensitivity of HCVpp to NAb [176]. 
HCV is associated with high density lipoproteins [180, 181] causing interference with NAb 
activity. This association reduces HCV’s buoyant density resulting in an increase in infectivity 
[182, 183] and cloaks the virus thus protecting it from NAbs [184, 185]. Additionally, the high-
density lipoproteins (HDL) are thought interfere with NAb activity by interacting with the cell 
surface protein SR-B1 leading to enhanced viral entry into hepatocytes [66, 186]. 
HCV can spread by cell-to-cell transmission [180, 184] allowing the virus to bypass 
extracellular fluid, preventing NAb from accessing the viral particles [187, 188]. Induction of 
interfering Abs which compete with NAb for the same epitopes or is another mechanism 
thought to contribute to virus NAb evasion [189, 190]Overall, the findings of recent studies 
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suggest that the development of a NAb response correlates strongly with viral clearance. NAb 
responses alone were previously believed to be insufficient to confer protection against HCV, 
however passive transfer of broadly neutralising monoclonal or polyclonal NAbs to 
experimental animals protects against viral challenge [152, 191, 192]. These findings suggest 
that NAbs potentially play a vital role in neutralizing and reducing viral loads in infected HCV-
infected patients and hence the induction of NAbs is an attractive target for prophylactic vaccine 
development [192]. An effective HCV vaccine would need to target multiple antigens from 
various genotypes in order to generate multi-antigenic, broad and highly reactive immune 
response during the initial stages of the infection before the virus can employ its many immune 
evasion mechanisms. 
1.4.2.2. Cell-mediated immunity  
CD4+ and CD8+ T lymphocytes are the main components in the cell-mediated immune 
response and appear 5-10 weeks post infection. HCV-specific CTL can eliminate virus from 
infected hepatocytes by secreting antiviral cytokines which are capable of inhibiting replication 
of the virus without destroying virus-infected cells and can eliminate infected cells by injecting 
toxins such as perforin (PRF), granzymes and granulysin into the virus-infected cells  leading 
to their destruction [193].  CD4+ T cells on the other hand assist other immune cells in 
immunologic processes, including maturation of B cells into plasma cells and memory B cells, 
and activation of CD8+ T cells (see Fig. 1.4) [194]. 
Currently there are no correlates of protective immunity, however evidence suggests that during 
the acute phase of the infection, spontaneous HCV viral clearance has been linked to strong 
broadly directed and sustained HCV-specific CD4+ T cell responses [195, 196]. A weak 
antiviral CD4+ T cell response, on the other hand, is observed in HCV-infected patients who 
subsequently develop chronic HCV infection [197, 198]. Together these observations suggest 
that HCV specific CD4+ T cells play an important role in HCV control. Nevertheless, IFN-γ 
production by HCV-specific CD8+ T cells [26] and their accumulation in the liver [199] have 
also been shown to coincide with a rapid reduction in viraemia and the emergence of a HCV-
specific CD4+ T cells response and finally viral elimination. The pivotal roles of CD8+ T cells 
in HCV clearance is also supported by the observation that following antibody (Ab)-mediated 
depletion of CD8+ T cells in chimpanzees, HCV viraemia increased for a prolonged time period 
[200, 201]. These data correlate with the concept that HCV-specific CD8+ T cells are the main 
antiviral effector cells, while HCV-specific CD4+ T cells have important helper functions and 
help to prevent viral escape from the CD8+ T cell response [202-204].  
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During acute infection, multi-specific, virus-specific CD8+ T cells are typically detectable in 
the peripheral blood 6-8 weeks after infection [93, 199] and this has been shown to be due to 
delayed priming of HCV-specific CD8+ T cells rather than delayed homing of the HCV-
specific CD8+ T cells to the liver [205]. The mechanisms behind the CD8+ T cell failure are 
not well understood; however growing evidence suggests that CD8+ T cell exhaustion 
(characterised by impairment in CD8+ T cell effector functions) and viral escape contribute to 
this failure [93, 206, 207]. T cell exhaustion is defined by impaired CD8+ T cell effector 
functions, including a reduced ability of CD8+ T cells to secrete antiviral cytokines and to 
proliferate in response to antigen stimulation [206] as well as the co-expression of several 
inhibitory receptors such as programmed cell death 1 (PD-1), CD244 (also known as 2B4) and 
CD160 [207]. It is important to note that unlike CD8+ T cells, failure of CD4+ T cell responses 
are rarely linked to viral escape and this must be largely explained through other mechanisms 
[208, 209].  
The low proportion of HCV-infected patients who successfully clear the virus illustrates the 
effectiveness of HCV immune escape strategies and makes development of an effective HCV 
vaccine a significant challenge, as these strategies may have important implications in vaccine 
development. 
1.5. Model Systems to study HCV 
1.5.1. In vivo models 
HCV is known to only infect human and chimpanzees and for more than a decade the 
chimpanzee was the only animal model to study the course of HCV infection [210]. In contrast 
to human acute infection that can rarely be studied, the chimpanzee provided a model in which 
the progression of HCV disease could be monitored from beginning to end. Consequently, the 
chimpanzee model has provided valuable information on different aspect of the cellular immune 
responses and their role in disease outcome [211]. However, chimpanzees are expensive and 
due to ethical considerations are extremely limited in availability for experimental use.  
Chimeric (xenograft) mice harbouring human hepatocytes are the most common small animal 
models in HCV research. These include urokinase plasminogen activator (uPA) and severe 
combined immunodeficiency disorder [212] mice (uPA-SCID) [213] as well as the Fah-/-Rag2-
/-IL2rg-/-(FRG) model [214]. These mouse models are immunodeficient and characterised by 
hepatocyte degeneration due to an engineered genetic alteration [213, 215]. Once infected with 
HCV, these animals can be used to evaluate neutralisation and prevention of infection by 
antibodies, as well as the effects of antiviral compounds [152, 213, 215]. These animals have 
also contributed to our understanding of aspects of HCV biology such as viral entry, the role of 
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anti-HCV antibodies and infectious particle composition [191, 216, 217]. The uPA mice have 
been shown to be effective in the pre-clinical evaluation of antiviral compounds, and can 
generate similar outcomes to those observed in human clinical trials [218]. Combination 
therapy of NS3-4A and NS5B inhibitors using uPA mice was recently reported to eradicate 
HCV from animals with stable high-level viraemia [219]. This is in agreement with phase 2 
clinical trials in which dual therapy with the NS5A inhibitor, daclatasvir, and the NS3 protease 
inhibitor, asunaprevir, led to a sustained virological response (SVR) [220] [221]. SVR is 
defined as the loss of detectable HCV RNA during treatment and its continuing absence at least 
6 months after withdrawal of therapy. These findings support the utility of uPA transgenic mice 
for studying several aspects of the HCV life cycle and therapy. 
Another animal model used for HCV studies is based on the deficiency of fumaryl acetoacetate 
hydrolase (FAH) mice crossed to an immunodeficient RAG2−/− IL-2Rγnull background (FRG 
mice) to allow engraftment of human hepatocytes [222].  FAH is an enzyme in the tyrosine 
catabolic pathway and mice lacking the enzyme (FAH−/− mice), die from liver failure due to 
the accumulation of metabolites that are hepatotoxic [223]. However, treatment with a drug, 
Nitisinone (also known as NTBC), can block a different enzyme in this tyrosine breakdown 
pathway upstream of FAH and when mice are maintained on NTBC they remain fertile and 
viable [222]. Similar to studies with antivirals in the uPA model, treatment with IFN-α and a 
cyclophilin inhibitor transiently lowered viraemia in this model [214, 224]. Unlike the uPA 
mouse model which requires larger breeder colonies due to the infertility of homozygous mice, 
the FRG animal model has the ability to breed mutant mice on the drug NTBC, induce liver 
injury at any age by withdrawing NTBC, and is amenable to surgery on healthy mice [210, 
225]. However, one drawback is the requirement in FRG mice for large numbers of human 
hepatocytes to achieve the high chimerism required for HCV infection. Unfortunately, the use 
of these mice in vaccine development is limited by a high mortality rate as well as the absence 
of a functional adaptive immune system [152, 215].  
Other humanised mouse models such as AFC8-huHSC/hep [226] and Rosa26-Fluc [227] have 
been developed. The AFC8-huHSC/hep model is of particularly interest, as it allowed for dual 
engraftment of fetal hepatoblasts and autologous human hematopoietic stem cells giving rise to 
a liver chimeric animal harbouring components of a matching human immune system [226]. 
Nevertheless, these mice can currently only be used to study specific steps in the HCV life cycle 
and support limited (if any) viral replication.  
Yu et al. recently developed a challenge model to examine the efficacy of HCV-specific cell 
mediated immunity elicited by a vaccine, including T cell trafficking to liver [228]. HCV 
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proteins were expressed in mouse hepatocytes after hydrodynamic injection of a plasmid 
encoding the HCV NS3/4A protein and secreted alkaline phosphatase (SEAP), which was 
detected in the mouse serum. Expression of NS3/4A in hepatocytes correlated with SEAP 
expression in serum. In a challenge experiment using this model, vaccinated mice showed 
accelerated clearance of SEAP and thus of NS3/4A positive hepatocytes and this coincided with 
an increased number of CD8+ lymphocytes in the liver [228].  
Transgenic mice in a ICR background harbouring both human CD81 and occludin genes 
(C/OTg) were reported to be permissive to HCV infection at a chronicity rate comparable to 
humans [229, 230]. In this mouse model, HCV accomplished its replication cycle, leading to 
sustained viraemia and infectivity for more than 12 months post infection with expected fibrotic 
and cirrhotic progression. This recapitulates, for the first time in immune-competent mice, 
chronic HCV infection with a complete replication cycle and hepatopathologic manifestations 
[229, 230]. 
More recently, a HCV/GB virus B (GBV-B) chimeric virus carrying the major nonstructural 
proteins NS2 to NS4A (HCV NS2-4A chimera) was generated to infect common marmosets 
(Callithrix jacchus) [231]. Six of the seven HCV NS2 - 4A chimera-infected marmosets 
exhibited consistent viraemia while one showed transient viraemia during the course of follow-
up detection. All infected animals with persistent circulating viraemia presented characteristics 
typical of viral hepatitis, including viral RNA and proteins in hepatocytes and histopathological 
changes in liver tissue. Viraemia was consistently detected for 5 to 54 weeks of follow-up. 
FK506 (Tacrolimus) immunosuppression facilitated the establishment of persistent chimera 
infection in the marmosets. An animal with chimera infection spontaneously cleared the virus 
in blood 7 weeks following the first inoculation, but viral-RNA persistence, low-level viral 
protein, and mild necroinflammation remained in liver tissue [231]. These chimera-infected 
marmosets represent as a suitable small-primate animal model for studying novel antiviral 
drugs and T-cell-based vaccines against HCV. 
Animal models have contributed to studies of infection and are important for testing the in vivo 
relevance of in vitro findings. Chimpanzees, although no longer commonly used for HCV 
research, have particularly contributed to the study of the immune response, while humanised 
mice have been important for the study of the virus life cycle. Recently developed animal 
models, including the mice expressing humanised CD81 and Occludin genes and the 
HCV/GBV-B chimera-infected marmoset model represent potential tools for future 
development of novel antiviral drugs, immunotherapies, and vaccines against HCV infection. 
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1.5.2 In vitro models 
1.5.2.1. Replicons 
The development of subgenomic and selectable HCV replicons was as major breakthrough 
toward the establishment of a robust and reliable cell culture system for HCV [232]. The first 
HCV replicon, a nucleic acid that is capable of autonomous replication (designated Con1) was 
developed as a bicistronic construct with the first cistron encoding the neomycin 
phophotransferase (neor) gene under the control of the HCV IRES to allow selection for 
resistance against the drug G418. The second cistron encoded the HCV replicase genes (NS3-
NS5B) directed by a heterologous EMCV IRES. Transfection of Huh-7 cells with in vitro 
synthesized replicon RNA and selection with G418, resulted in a few surviving cell colonies. 
This was thought to be partly because it was necessary for replicon RNAs to acquire adaptive 
mutations for efficient replication in the Huh-7 cells. Adaptive mutations tended to cluster 
within NS3, NS4B, NS5A and NS5B proteins [233]. Replication was enhanced with the 
introduction of adaptive mutations in the parental replicon, although some proved detrimental 
for infection in vivo [233-237]. 
1.5.2.2. HCV pseudoparticles (HCVpp) 
HCVpp are engineered viral particles in which HCV E1-E2 glycoproteins are assembled on 
lentiviral or retroviral core particles in producer cells. Pseudotyping which is defined as the 
incorporation of heterologous viral glycoproteins into retrovirus particles, allowed the 
engineering and production of numerous chimeric VLPs derived from lentivirus (SIV) or 
oncoretrovirus (MLV). The development of infectious HCVpp by pseudotyping HCV 
glycoproteins onto a MLV-Gag retroviral core particle has enabled the study of viral entry [41]. 
A reporter gene, such as luciferase or green fluorescent protein (GFP) is also included to enable 
the detection and quantification of infected target cells. HCVpp harvested from transfected 
human embryonic kidney 293T (HEK293T) cells can be used to infect Huh-7 cells, while the 
infection process can be blocked by anti-E1 or anti-E2 specific antibodies [43, 155]. HCVpp 
representing glycoproteins of all major genotypes have been generated and have resulted in a 
further understanding of virus binding, attachment and internalization as well as identification 
of novel HCV receptors [40, 238]. 
1.5.2.3. Cell culture derived HCV (HCVcc) 
The identification of JFH1, a genotype 2a subgenomic replicon that does not require adaptive 
mutations for efficient RNA replication in culture represented the first full-cycle HCV culture 
system [239]. It was later shown that transfection of JFH1 full-length genomes into Huh-7 cells 
resulted in the production of viral particles that were infectious in cell culture and animal 
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models [7, 44, 240]. However, infectivity titers attained with JFH1 were moderate. Much effort 
was made to improve the system and higher virus titers were produced when virus chimeras 
comprised of the JFH1 NS3 to NS5B regions fused to the core to NS2 region of other HCV 
isolates was found to be more infectious than authentic JFH1 [241]. Higher virus titers were 
obtained when JFH1 was propagated in Huh-7 cell clones such as Huh-7.5.1 and Huh-7-
Lunet/CD81 high cell-lines which are more permissive for HCV replication [240, 242, 243]. 
The human hepatoma cell line LH86 was also shown to be susceptible to HCV infection [244]. 
Studies have shown that HCVpp and HCVcc share the same pH-dependent internalisation and 
fusion steps of the entry process [245]. Since the development of chimeric virus clones, viable 
JFH1 chimeras representing all major genotypes have been generated [246]. 
1.6. Diagnosis of HCV infection 
HCV infection is rarely diagnosed during the acute phase of the infection. The diagnosis of 
HCV infection involves both serological and virological detection methods. Enzyme 
immunoassays are used to detect antibodies against different HCV epitopes provided that 
seroconversion has occurred and antibody titers are sufficiently high. However, the detection 
of HCV-specific antibodies cannot determine whether the infection is ongoing [247]. To 
confirm current infection, HCV RNA can be detected from the serum using RT-PCR, 
transcription mediated amplification (TMA) or branched deoxyribonucleic acid (DNA) (b-
DNA) assay to provide both qualitative and quantitative analysis of viral load [247]. These 
methods can be used to determine the virus genotype, information which may be important to 
determine the dose and duration of treatment. Finally, a negative HCV RNA result is required 
on multiple occasions to confirm clearance of infection in a treated patient. 
1.7. Treatment of HCV infection 
Approximately 20% of acute HCV infections are cleared spontaneously by the host immune 
response, although this is extremely rare once the infection becomes chronic. Until recently the 
standard of care (SOC) for chronic HCV was a combination of pegylated-interferon-alpha and 
ribavirins (pegIFNα/RBV). The therapy is administered for a period of 24 (genotype 2 or 3) or 
48 weeks (genotype 1, 4 or 6) [248]. This treatment resulted in a SVR in 40% to 50% (genotype 
1 or 4) to 80% (genotype 2 or 3) of patients [249]. Recently, the IL28B gene has been reported 
to be involved in the immune response to certain viruses, including HCV. Three IL28B 
subtypes: CC, CT, and TT have been identified. Individuals with the CC genotype have a 
stronger immune response and respond better to treatment against HCV infection than those 
with non-CC genotypes [250, 251]. Other factors such as patient gender and age, HCV 
genotype, viral load and stage of liver fibrosis are also predictive of treatment outcome. 
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However increased side-effects including fever, headache, myalgia, haemolytic anaemia and 
severe depression have been reported with the combination of these drugs [252].  
The mechanisms by which IFN and Ribavirin exert their therapeutic effect remains not well 
understood.  IFN-α is believed to induce expression of numerous genes which trigger an 
antiviral innate response [253]. Ribavirin is a guanosine analogue and is only active against 
HCV when in combination with IFN-α. It has been hypothesised that Ribavirin may inhibit 
HCV replication after incorporated into nascent viral RNA by the HCV polymerase during 
RNA synthesis [253]. Ribavirin is also thought to act as RNA mutagen causing an accumulation 
of mutations that may lead to the collapse in viral fitness (termed 'error catastrophe' [254]). 
New direct acting antivirals (DAA) are more effective, resulting in a cure for 90-95% of 
individuals with very few side-effects and allow shorter treatment periods (8-12 weeks). 
Telaprevir and boceprevir, which are inhibitors of the HCV NS3/4A protease, were the first 
DAAs to be licensed. They were administered together with the pegIFN/RBV combination as 
the SOC. This combination has been reported to improve the SVR but was still associated with 
side effect [255, 256] and therefore this combination is no longer recommended. Simeprevir 
and paritaprevir are new generation NS3/4A protease inhibitors and are administered in 
combination with other DAAs primarily to prevent the rise of drug resistance and increase 
antiviral potency. Another distinct class of DAAs that block HCV replication include NS5A 
inhibitors, namely, daclatasvir, ledipasvir, and ombitasvir. The NS5B polymerase inhibitors 
such as sofosbuvir and dasabuvir, represent the third class of DAAs that inhibit replication of 
viral RNA [257-259]. 
For HCV-infected patients who develop liver cancer, transplantation is the only treatment 
option available. Nevertheless, many infected individuals seek medical attention only when the 
disease has progressed to a late stage. Moreover, the high cost of therapy and the sophisticated 
clinical monitoring required for these therapeutic strategies makes their use, particularly in 
developing countries, unlikely. Therefore, the current standard of treatment and clinical practice 
is unlikely to have an immediate impact on the worldwide burden of HCV infection.  
Vaccination has been the most successful and cost-effective strategy to prevent viral infection 
and virus-associated disease worldwide. The vaccine for another hepatotropic virus, hepatitis 
B virus (HBV), is estimated to have prevented over 1,000,000 deaths across the world as well 
as reduce the incidence of HBV-induced HCC [260].  
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1.8. Vaccines against HCV 
Vaccination is a process of administering safe material (e.g. recombinant DNA, virus or 
proteins) to induce long-lived and protective adaptive immune responses against pathogens of 
interest. Many successful viral vaccines currently in use such as measles, mumps, rubella 
(MMR), oral poliovirus, varicella virus and yellow fever virus are predominantly based on live 
attenuated or inactivated viruses. Live attenuated viral vaccines have limited replication and 
pathogenic capacity in the host following immunisation but yet can induce protective immune 
responses against the respective wild-type virus [261-263]. These viruses are likely to be 
cytolytic and can possibly cause the release of specific PAMPs and/or damage-associated 
molecular patterns (DAMPs) from infected cells to trigger effective immune responses. 
However, live attenuated virus vaccines can cause severe complication for some patients 
(particularly immunocompromised patients) and secondary mutations have been reported to 
cause reversion of the attenuated virus to wild-type virulence [262, 264]. Compared to live 
attenuated virus vaccines, inactivated viral vaccines are rendered replication incompetent 
making them safer. However, inactivated viral vaccines lack the self-boosting quality of live 
attenuated virus vaccines as antibody titers decline over time and therefore require 3-5 doses 
[264, 265].  
1.8.1. HCV vaccine clinical trials 
Several prophylactic and therapeutic vaccines against HCV are currently under development. 
Research for prophylactic vaccines against HCV has particularly focused on the induction of 
NAbs in order to prevent in HCV-infected patients [192]. Other researchers are also developing 
therapeutic vaccines with an initial aim of priming and boosting functional T-cell responses in 
the periphery leading to the migration of these activated cells to the infected liver [266]. 
Currently several therapeutic vaccines are under development against HCV using a wide range 
of vaccine strategies. The composition of some of these vaccines are summarised in table 1.2. 
Intercell AG (ICLL) (now Valneva Austria GmbH) in partnership with Novartis developed a 
therapeutic peptide vaccine (IC41) which consists of at least 4 HLA-A2-restricted CD8+ CTL 
epitopes and 3 highly promiscuous CD4+ helper T-cell epitopes derived from HCV genotype 
1 core, NS3 and NS4 in combination with and T helper cell (Th)1/Tc1 adjuvant poly-L-arginine 
[268-270].  The vaccine is currently in its second phase II clinical trial. Although not significant, 
preliminary data in chronically infected genotype 1 patients who received 8 ID injections of the 
IC41 vaccine at biweekly intervals showed a 40% reduction of viral load compared with 
baseline [271]. The vaccine has also been shown to induce IFN-γ secreting CD4+ and CD8+ 
T-cells in patients with chronic HCV who had relapsed after- or failed to respond to- standard 
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GlobeImmune is developing GI-50005, a Tarmogen (targeted molecular immunogen) 
therapeutic vaccine consisting of whole, heat-killed recombinant Saccharomyces cerevisiae 
yeast expressing a HCV NS3-Core fusion protein [273]. Phase I treatment in chronic HCV-
infected patients showed safety and significant immune responses correlating with viral load 
reductions. Another study was undertaken in 144 chronic HCV-infected patients to compare 
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efficiency of GI-5005 combined with PEG-IFN/ribavirin versus PEG-IFN/ribavirin alone. The 
combined therapy showed 15% greater efficacy in declining viral load and improved liver 
function for the treated patients (based on ALT normalizations) [274].  
The vaccine TG4040 (Transgene) currently in clinical trials, uses a non-replicative modified 
poxvirus (Ankara strain) encoding HCV NS3, NS4 and NS5B from a genotype 1b viral strain 
[275]. The vaccine has been shown to have a good safety profile, induced HCV-specific cellular 
immune responses in 5 of the 15 patients (33%), and 8 patients showed a transient drop in HCV 
viraemia (from -0.52log to -1.24log) [275]. Recently, the efficacy, safety, and 
immunotherapeutic properties of TG4040 in combination with PEG-IFN/ribavirin was tested 
in patients with chronic HCV infection. The study showed that a higher proportion of patients 
with chronic HCV infection who received immunotherapy with TG4040 followed by TG4040 
and PEG-IFN/ribavirin achieved a complete early virologic response (defined as HCV-RNA 
level less than 10 IU/mL after 12 weeks of PEG-IFN/ribavirin treatment) compared with 
patients who received only PEG-IFN/ribavirin therapy. This suggests that immunotherapies that 
activate T cells may be effective in patients with chronic HCV infection [276]. 
A DNA vaccine designed to induce T cell immunity has been developed by Tripep AB 
(Sweden). The vaccine known as ChronVac-C® is based on a codon optimised HCV NS3/4A 
gene (genotype 1) expressed under the control of the CMV immediate-early promoter. Results 
from a phase I/IIA clinical trial revealed that the vaccine was well tolerated and no adverse 
reactions were observed in any of the dosing arms. Two patients had viral load reductions which 
coincided with the development of HCV-specific T cell responses [277]. Recently the vaccine 
has been tested in mice to examine the concept of heterologous prime/boost vaccination by 
priming with ChronVac-C® and boosting with TG4040 [278]. Significantly higher levels of 
IFN-γ or IL-2 ELISpot responses were observed in the prime boost regimen compared with 
each vaccine alone, independent of the time of analysis and the time interval between 
vaccinations. A significant increase in polyfunctional IFN-γ/TNF-α/CD107a+ CD8+ T cells was 
detected following ChronVac-C/TG4040 vaccination (from 3% to 25%) [278]. These studies 
have provided proof-of-concept for DNA-based vaccines as an additional therapeutic agent to 
the current SOC, as well as combining two HCV therapeutic vaccines to improve their 
immunogenicity. 
1.8.2. Preclinical vaccine research 
Many successful viral vaccines currently in use (eg: oral polio, smallpox, and yellow fever 
vaccines) function by inducing strong NAb response against viral structural proteins to inhibit 
viral entry and thus prevent productive virus infection. Although many HCV vaccines strategies 
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focus on inducing T cell immunity, the ultimate aim for an effective preventative vaccine is to 
induce strong and broadly cross-reactive CD4+ and CD8+T-cell responses,  and NAb responses 
[152, 279] capable of protecting against different genotypes. Viral proteins such as core, NS3 
and NS5 [120, 280]) are commonly used in HCV vaccine design, as they are the prime targets 
of T cell-mediated immunity during natural infection. The two envelope proteins E1 and E2 
targeted by NAbs, are also often included in order to induce both NAbs and T cell response [76, 
281, 282].  
1.8.2.1. Viral subunits  
Various HCV subunit-based vaccines have been developed due to their potential to stimulate 
immune responses and control of HCV infection. The first encouraging results from subunit 
vaccine were obtained in the early 1990s after chimpanzees were immunised with purified HCV 
E1E2 glycoproteins [283]. Purified E1 and E2 mixed with MF59 adjuvant were also shown to 
produce NAb.  All seven immunised animals exhibited strong humoral responses and five were 
completely protected from challenge after homologous HCV challenge. Although two of the 
chimpanzees became infected, the disease was less severe compared to control animals that 
were not vaccinated [283]. More recently the effect of immunisation with HCV E1E2 proteins 
(genotype 1a) with MF59C.1 adjuvant was investigated on 60 healthy volunteers [282]. The 
vaccine was safe and generally well tolerated, and detectable levels of NAbs as well as CD4+ 
T cell proliferation responses to E1E2 were reported.  
A 40nm matrix composed of saponins, cholesterol and phospholipids (ISCOM) has also been 
used in HCV vaccine studies, using HCV core protein, purified from E.coli, absorbed onto 
ISCOMATRIXTM. The resulting particles were able to stimulate strong long-lived, CD4+ and 
CD8+ T cell responses, and induced Th1 and Th2 cytokines as well as anti-core antibodies in 
rhesus macaques [280]. The efficacy and tolerance of a vaccine based on the HCV core protein 
with ISCOMATRIXTM adjuvant was recently evaluated in thirty healthy volunteers [284]. 
Specific anti-core antibody responses were detected in 23 of the 24 vaccinated volunteers and 
T-cell cytokines in 7 of the 8 volunteers receiving the highest dose. A CD8+ T cell response 
was only detected in two of the volunteers [284].   
Although these data are promising, lack of proper folding/functionality of the peptides as well 
as low immunogenicity are some of the major challenges facing the subunit approach [285]. In 
addition, difficulties involved in the purification steps as well as the extraction of sufficient 




1.8.2.2. Viral vectors  
Viral vector vaccines are recombinant viruses encoding targeted HCV proteins or peptides and 
have been shown to be highly immunogenic. These vectors have proven useful in stimulating 
immune responses against cancer specific antigens [286] as well as protection against animal 
viral diseases such as small pox and monkey pox virus [287, 288]. Pox viruses and adenoviruses 
are the major viral vectors used in HCV vaccine development. Since adenoviral infections are 
common, the vectors more commonly used are based on rare serotype such as the human 
adenovirus 6 (Ad6) or the chimpanzee adenovirus 3 (ChAd3) in order to avoid interference by 
pre-existing NAbs in vaccinated individuals  [289].  
The vaccines based on these vectors have been designed to elicit T cell immune responses and 
thus HCV NS proteins have been included in the vaccine candidates [289-291]. Immunisation 
with the Merck adenovirus serotype 6 (MRKAd6)-NSmut vector with or without a later boost 
with an electroporated plasmid DNA encoding the HCV NS proteins, resulted in the induction 
of broad CD4+ and CD8+ T cells as well as a 2 to 4 fold increase of the these responses 
following the plasmid DNA boost [292]. Although all animals became HCV-infected after viral 
challenge, those that received the vaccine presented a 100 times lower average peak of viraemia 
than controls [292]. A phase I clinical trial of a combination of both Ad6-NSmut and ChAd3-
NSmut (HCV genotype 1b) was tested on 40 healthy volunteers. Immunised volunteers 
generated CD4+ and CD8+ T cells secreting multiple cytokines such as IL-2, IFN-γ, and TNF-
α which targeted multiple epitopes and recognised heterologous 1a and 3a HCV strains albeit 
with differing magnitudes [291].  Together, these data indicate that the viral vector strategy can 
induce sustained T cell responses of a magnitude and quality associated with protective 
immunity and can be used for studies of prophylactic and therapeutic vaccines for HCV. 
Although viral vectors have been shown to be effective and relatively safe, there are issues with 
large scale manufacturing and maintaining the genetic stability of the vaccine. The immune 
response against the viral vectors, although favourable in immune priming, can be a limitation 
due to pre-existing immunity in the host due to previous infection or vaccination. Viral vectors 
are therefore often not effective for repeated immunisation and more often viral vectors are 
used to boost an immune response after priming with DNA vaccine. 
1.8.2.3. DNA vaccines 
Recombinant DNA vaccines are bacterial plasmids constructed to express an encoded gene (i.e. 
antigen(s)) of interest) in cells. DNA vaccines are under development for several pathogens, 
cancer, autoimmune disorders and allergies. Currently, no DNA vaccine has been approved for 
use in humans, but four successful DNA plasmid products have been approved for animal use: 
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one for the treatment of West Nile virus in horses [293], one against hematopoietic necrosis 
virus in salmon [294], one for the treatment of melanoma in dogs [295], and a growth hormone-
releasing hormone (GHRH) gene therapy for swine [296]. There are various reasons why DNA 
vaccines have not been approved for humans and one of the main reasons is lack of potent 
immunogenicity [266]. 
The use of DNA vaccines has several advantages compared to the traditional killed or live 
attenuated viral vaccines. DNA vaccines are known to induce cell mediated and humoral 
immune responses and result in antigen expression and processing in a way that mimics viral 
protein production after virus infection. Unlike protein or recombinant virus vaccines, DNA 
vaccines do not induce vector-specific immunity [297]. DNA vaccines produce immunological 
responses with none of the risks associated with live attenuated virus vaccines. Furthermore, 
DNA vaccines can be engineered to include specific immunogens that could optimise and 
amplify desirable immunological responses [298]. One concern has been the integration of the 
delivered DNA into the host genome, however studies have shown that the frequency of this 
event is much lower than that of spontaneous genome mutations, suggesting that this may not 
be a major concern [299-301]. DNA vaccines are highly stable (can be stored at room 
temperature), quite inexpensive and rapidly manufactured, therefore simplifying the handling 
and worldwide distribution of the vaccine and raising hopes that even developing countries can 
benefit from this type of vaccine [302, 303]. 
The concept for DNA vaccination against HCV is the production of non-viable, non-replicating, 
non-spreading antigens that can induce not only CD4+ and CD8+ T-cell immunity, but also B-
cell immunity. After plasmid DNA is introduced into the body, it directly transfects muscle, 
skin or mucosal cells depending on the injection site, or circulating professional APCs. The 
endogenous expression and post-translational modification of vaccine antigen are major 
advantages of DNA vaccine priming since it mimics a natural infection, ie. endogenous 
expression of the immunogen. APCs have a dominant role in the induction of immunity of DNA 
vaccine by processing and presenting the antigen on MHC I molecules for activation of CD8+ 
T cells [1]. The majority of nucleated cells are able to present foreign antigens on MHC I and 
thus can be a target for CD8+ CTLs. Secreted antigens or apoptotic/necrotic bodies from 
transfected cells, are taken up or phagocytosed by APCs then processed and presented on MHC 




To ensure effective antigen expression within the host cells, a strong promoter such as the 
cytomegalovirus (CMV) promoter and an effective termination of transcription sequences such 
as the bovine growth hormone (BGH) polyadenylation signal are routinely used [304, 305]. 
Different organisms have different preferred codon usage and codon optimisation is another 
factor that has been shown to enhance both the gene expression levels and the immunogenicity 
Figure 1.6. Induction of Cellular and Humoral Immunity by DNA Vaccination. Steps 1-4 represent 
the different ways that antigen becomes available to APCs. Steps 5-7 show migration of APCs to 
draining lymph node where they can present antigen and activate CD4 and CD8 T cells [1]. 
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of DNA vaccines [306].  Codon optimisation has been reported to effectively enhance the 
overall protein production of several viral proteins including HCV NS3/4A and the human 
immunodeficiency virus (HIV) gag protein [307-309]. Vaccination with a synthetic codon-
optimised NS5A (genotype 1b) construct resulted in high IgG titers as well as polyfunctional 
NS5A-specific CD8+ T cells responses in wild type and immunologically tolerant NS5A-Tg 
mouse models  [310]. 
DNA vaccine strategies encoding HCV structural proteins have been shown to induce antibody 
as well as CD4+ and CD8+ T cell responses to HCV in mice [297, 302, 303, 311]. Despite 
having great potential in small animals, DNA vaccines have failed to demonstrate sufficient 
immunogenicity in human clinical trials and this is independent of body mass since DNA 
vaccines are now licensed for use in horses and salmon [312]. DNA vaccines however have 
been shown to be more immunogenic with alternative delivery methods [313], and as a prime-
boost regimen coupled with a live virus vector [278, 292, 314-316]. DNA vaccination with 
HCV NS3 with adjuvants such as unmethylated CpG motifs and Quil A appear to induce strong 
antibody responses as well Th1 immune responses [317]. Phase I studies of a DNA vaccine 
containing a mixture of core/E1/E2-expressing plasmids with a recombinant HCV core protein, 
Co.120 (CICGB-230), showed safety, immunogenicity and improvement of liver histology in 
treated chronic HCV patients [318]. However, intramuscular (IM) immunisation with CICGB-
230 of 15 chronically infected patients who were nonresponders to previous treatment with 
pegIFN-α/RBV resulted in no significant improvement in hematological and biochemical 
parameters including ALT levels between the baseline and post-treatment state, despite the 
induction of cellular immune responses [319]. Another HCV DNA vaccine encoding NS3/4A 
was efficiently expressed after codon optimisation and primed Th1 and CD8+ CTL responses 
in transgenic mice models [320, 321]. 
Taken together, DNA vaccination against HCV infection seems to be an efficient immunisation 
practice, particularly for therapeutic purposes. However, to date there is no DNA vaccine 
approved for use in humans and this is partly due to the low immune responses observed in 
larger animals including humans. Therefore, much effort has been made to find new techniques 
to deliver the DNA in more efficient way. Several other enhancements under investigation in 
addition to the delivery route include further optimisation of the vaccine construct as well as 
the use of adjuvants to enhance the immune priming. Advances in recombinant viral 
technologies have led to additional strategies that may generate safer approaches to viral based 
vaccine regimens.  
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1.9. Routes of immunisation of DNA vaccines 
DNA-based vaccines are suitable for worldwide application because they are stable, heat-
resistant, economical and easily manufactured. However as previously mentioned, the 
immunisation efficiency particularly in large animals is very low. Therefore, effective delivery 
is critical to the development of an effective DNA vaccine. 
1.9.1. Intramuscular routes 
Most vaccines, including the vaccines for influenza, hepatitis A, HBV, measles, mumps and 
rubella, are administered via the IM route [322, 323]. Traditionally the buttocks were thought 
to be an appropriate site for vaccination, but the layers of fat do not contain the cells necessary 
for the initiation of the immune response. Furthermore, it might take longer for the antigen to 
reach the circulation after being deposited in fat which might cause a delay in the antigen 
processing by APCs and eventually presentation to B and T cells [324].  Muscle cells express 
MHC I and MHC II molecules under inflammatory conditions in vivo and have been shown to 
possess the ability to present antigens to both CD4 and CD8 cells [325, 326]. However, the 
cellular biochemistry of antigen processing and presentation by muscle cells is still not clear 
[326]. Resident immune cells such as macrophages, DC and T cells are present in the muscle, 
but are relatively few in number compared to other organs which is one of the reasons that other 
administration routes are being investigated, particularly for DNA-based vaccines. 
1.9.2. Subcutaneous routes 
The epidermis and dermis are highly populated by DCs (Fig. 1.7) [8, 327]. The subcutaneous 
(SC) route of vaccination involves the delivery of vaccine into the region located beneath the 
dermis. The SC route has been used to administer various vaccines including the smallpox 
vaccine (vaccinia), measles vaccine and for immunotherapeutic vaccines to control asthma and 
allergy [8, 328]. The SC route has been shown to preferentially induce a Th2 type response 
when compared to the IM and intradermal (ID) routes [329]. A study in humans comparing 
administration of MVA vaccine via the SC and ID routes revealed that the dermal route induced 
equivalent NAb at a 10-fold lower dose compared with the SC route [330]. These data suggest 




1.9.3. Intradermal routes  
The rationale for ID vaccination is to deliver the antigen to the dermal layer of the skin located 
below the epidermis, that is rich in various immune cells including Langerhans cell, 
macrophages, mast cells as well as dermal DCs (Fig. 1.7). After administration via the ID route, 
immature DCs residing in the dermis can capture and process antigen, present peptides in the 
groove of MHC I/II on the cell surface before maturing and migrating to regional lymph nodes 
where they activate naïve CD4 and CD8 T cells [327]. Moreover, it has been shown that the 
recruitment of DC precursors from the bloodstream into the dermis and subsequent migration 
Figure 1.7. Innate immune response to antigen in the skin. Pathogen invasion leads to the release 
of primary cytokines and the activation of resident innate immune cells (Langerhans cells (LCs), 
dermal DCs and mast cells), stimulating downstream activation cascades. Activated LCs and dermal 
DCs mature and migrate to the draining lymph node, carrying antigen for presentation to T cells [8].  
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to the lymph nodes is improved by administration of antigen via the ID route [331, 332]. 
Vaccination by the ID route has been shown to induce similar immune responses to IM 
vaccination with a lower dose of antigen [333]. Low dose ID influenza vaccines have been 
demonstrated to be safe, well tolerated and equally immunogenic as standard dose IM vaccines 
[334, 335]. ID injection of a DNA vaccine encoding the HCV NS3 fused to a DC-targeting 
molecule, scDEC, (a single-chain antibody against the murine DC cell surface molecule 
DEC205), in combination with electroporation resulted in robust NS3-specific antibody and T 
cell immune response [336]. Nevertheless administration of three doses of 4 µg of non-
adjuvanted E1 vaccine via the ID route, induced much weaker humoral and cellular immune 
responses in healthy subjects and chronic HCV patients than the IM administration of 20 µg E1 
formulated on alum [337].  
Although ID vaccination is an appealing strategy to maximise the immune response to the 
antigen, it is technically challenging to deliver the vaccine formulation precisely. Currently 
researchers are investigating novel technologies to improve ID delivery.  
1.9.4. DNA vaccine delivery systems 
1.9.4.1. Physical DNA delivery  
The principal of physical gene delivery systems is to use mechanical, ultrasonic, electrical, 
hydrodynamic or laser-based energy in order to create temporary weak points in the membrane 
of the targeted cell to make it more permeable for the DNA to enter by diffusion [338]. 
Electroporation induces uptake of injected DNA into the cell, by increasing the permeability of 
the cell membrane through exposure to controlled electric field [339, 340]. However, 
electroporation results in high cell mortality and therefore may not be suitable for clinical use. 
The Gene gun method uses accelerated particle carrier biocompatible heavy metals such as 
gold, tungsten or silver to deliver the transgene into the target cell and tissues [341, 342]. Gene-
gun delivery improves DNA vaccine delivery compared to needle-based methods. However, 
particle bombardment is restricted to local expression in the dermis, muscle or mucosal tissue 
and surgery is often necessary for direct exposure of target tissue. As the skin is rich in resident 
DCs it provides increased transfection of the DNA directly into professional APC, regardless 
of whether the antigen is delivered via injection, gene-gun delivery, or electroporation. 
1.9.4.2. Chemical DNA delivery 
Liposomal delivery systems have emerged as one of the most versatile tools for the delivery of 
DNA vaccines. Liposomes are structures that consist of an aqueous compartment enclosed in a 
phospholipid bilayer. Depending on the composition and method of preparation, liposomes can 
take various forms, small unilamellar vesicles (with a diameter less than 50 nm) large 
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unilamellar vesicles (with a diameter of 50-500 nm) and multilamellar liposomes (with a large 
diameter up to 10,000 nm) [343]. Liposomes have been used for the delivery of anticancer drugs 
and can be used for DNA vaccine delivery by entrapping the vaccine inside the aqueous core 
or by complexing to the phospholipid lamellae [344]. Liposomes can load large amounts of 
DNA and increase the stability of DNA in the body, i.e. they can circulate in the bloodstream 
without causing any health concerns. However, there are many drawbacks that limit their 
application in vivo as they might form large aggregates at high concentration and also suffer 
from instability in the presence of serum. Cationic liposome formulations have been 
demonstrated by numerous studies to deliver different plasmid constructs to a wide range of 
cells, both in vivo and in vitro. They consist of three parts: hydrophobic anchor, a hydrophilic 
positively charged head, and a spacer (connecting the anchor to the head). Cationic lipids 
commonly used are 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), N-(1-(2,3-
dioleyloxy) propyl)-N, N, N-trimethylammonium chloride (DOTMA), 2,3-dioleoyloxy-N-(2-
(sperminecarboxamido)ethyl)-N, N-dimethyl-1-propanaminium (DOSPA), dioctadecyl amido 
glycil spermine (DOGS), and 3,(N-(N, N-dimethylethylenediamine)-carbamoyl)cholesterol 
(DC-chol) [345]. However, the use of these methods results in poor efficiency and cytotoxicity 
from the lipoplex-positive charge.  
The most common method for the delivery of a DNA vaccine is injection with syringes and 
needles through IM, IV and ID routes. As route of immunisation affects the magnitude of the 
immune response, researchers have been developing methods to improve the delivery of 
vaccine antigen to target cells. Advances in the development of DNA-based therapeutics and 
chemical synthesis would allow the development of DNA delivery platforms that prevent 
degradation of DNA and facilitate targeting to specific tissues and cells.  
1.9.4.3. Prime-boost regimens 
Repeated vaccination is one approach used to generate strong immunity to specific pathogens 
[346]. Repeated administrations with the same vaccine (homologous boosting) have proven 
very effective. However, DNA vaccination using this approach has proven relatively inefficient 
in humans. Viral vector delivery has been more effective in priming a strong immune response, 
however this approach is relatively inefficient at boosting cellular immunity because prior or 
induced immunity to the vector itself might lead to a rapid clearance of the vector by the 
immune system. This may impair robust antigen presentation and the generation of appropriate 
inflammatory signals. One approach to circumvent this problem has been heterologous prime-
boost strategies, using two different antigen-delivery systems generally administered weeks 
apart. The prime boost strategy has been shown to be effective in generating high levels of T-
cell memory [346, 347]. Several studies have demonstrated the efficacy of prime-boost 
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vaccination with an initial vaccination using plasmid DNA to prime a broad immune response 
followed by a boost using a viral vector to generate cellular immunity to a variety of pathogens 
including HCV, HIV and other organisms [90, 348-350]. For vaccines designed to induce strong 
antibody responses, priming using plasmid DNA followed by a boost with recombinant protein 
might be effective. Ideally homologous immunisation with a competent adjuvant should be used 
to avoid delivery, manufacturing and distribution issues using several different vaccine 
components. 
1.10. Adjuvants 
Adjuvants have been used to improve the delivery and immunogenicity of vaccines. Adjuvants 
can stimulate both innate and adaptive immunity resulting in an earlier onset and prolonged 
duration of immunity, a higher magnitude of the immune response, and occasionally in a shift 
of the type of immune response. Adjuvants have been used to specifically target immune cells, 
recruit immune cells to the immunisation site or to facilitate the delivery of the vaccine antigen 
across barriers, such as the mucosal surfaces. Several adjuvants currently under development 
include: 1) immunostimulants that directly act on the immune system to increase responses to 
antigens including: TLR ligands, cytokines, saponins; 2) vehicles that present vaccine antigens 
(or immunostimulants) to the immune system in an optimal manner, including controlled 
release and depot delivery systems to increase the specific immune response to the antigen. 
Examples include: mineral salts, oil and water emulsions (such as MF59), liposomes, virosomes 
(nanoparticles made of viral proteins such as influenza hemagglutinin and phospholipids) 
biodegradable polymer microspheres as well as immune stimulating complexes (i.e. ISCOM, 
ICOSOMATRIXTM). Some adjuvants currently used in approved human vaccines include 
Alum, MF59TM, MPL, VLP, Immunopotentiating Reconstituted Influenza Virosomes (IRIV) 
[351, 352]. 
1.10.1. Alum-based adjuvants 
Aluminium salt based adjuvants, referred to as Alum, are components of several human 
vaccines including HBV [353]. It is believed that the aluminium salts may function by 1) 
causing a depot formation allowing the continuous antigen release; 2) particulate structure 
formation promoting antigen phagocytosis by APC such as DC, macrophages and B cells and 
3) induction of inflammation resulting in recruitment and activation of macrophages and 
increased MHC class II expression and antigen presentation [354, 355]. Alum adjuvants have 
various advantages including safety, and often result in faster, higher antibody titers as well as 
long lasting antibody responses. However, their inability to induce Th1 or CTL responses that 
are required to control intracellular pathogens such as HCV makes alum less useful for DNA-
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based vaccines. Other disadvantages of Alum adjuvants include loss of potency if frozen and 
causing granulomas at injection sites. 
1.10.2. Other mineral salt adjuvants 
Salts of calcium, iron and zirconium have also been used to enhance immune responses against 
antigens. Calcium phosphate in particular has been used in diphtheria tetanus pertussis (DTP) 
vaccines. Although calcium phosphate has similar properties to alum salts, it has the advantage 
of being a natural compound and is therefore exceptionally well-tolerated [356, 357]. It has the 
capacity to elicit enhanced systemic IgG responses and does not increase IgE production [357]. 
1.10.3. Complete Freund's adjuvant (CFA) 
Complete Freund's adjuvant has been considered the most effective adjuvant available for 
raising antibodies in animal models for several decades. The adjuvant contains heat-killed 
mycobacteria, which is a primary agent responsible for stimulating antibody production. 
However, the use of CFA has been attributed to a number of undesirable side effects including 
increased pain, suffering and morbidity in inoculated animals and potentially serious health and 
safety threats [358]. Nevertheless, CFA is effective in stimulating cellular immune response 
and may lead to the production of IgG [359-361].  
1.10.4. Adjuvant emulsions 
Due to the shortcomings of alum-based adjuvants, other several novel adjuvants are under 
development to enhance the immune response to vaccines. These include oil-in-water (o/w) or 
water-in-oil (w/o) emulsions such as incomplete Freund's adjuvant (IFA) [362], montanide, 
MF59 and adjuvant 65.  
The IFA water-in-oil emulsion is prepared from non-metabolised oils. The IFA induces immune 
responses through the formulation of a depot at the injection site and the stimulation of antibody 
production [363]. Adjuvant 65 is advantageous over the mineral oils used in IFA as it can be 
metabolised [361]. 
Montanide is a family of oil-based adjuvants that include ISA, 50V, 20G and 729. These have 
been used with natural, recombinant and synthetic antigens in mice, rats, dogs and cats. 
Montanide has been used in trial vaccines in humans against HIV, malaria and breast cancer 
[361]. 
Submicron oil and water emulsions such as MF59TM contain squalene and varying amounts of 
muramyl tripeptide phosphatidyl-ethanolamine (MTP-PE) and is used as an adjuvant with 
influenza vaccines as well as HBV vaccines [364]. MF59 has been shown to induce higher 
antibody responses to HBV compared to alum in baboons and humans [365, 366]. The adjuvant 
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permits fewer doses, stimulates stronger antibody responses and generates marked memory 
responses, with a mixed Th1-Th2 cell phenotype [367-369]. MF59 induces local stimulation, 
recruitment of DCs, granulocytes, and differentiation of monocytes into DCs as well as 
increased uptake of antigen by DCs [370, 371]. 
Immunostimulatory complexes (ISCOMs) are nanoparticles composed of saponins (Quil-A) 
purified from the bark of a Quillaja saponaria tree, formulated with cholesterol, phospholipid, 
and antigen, held together by hydrophobic interactions. Protein antigens can be incorporated 
into the particles. An advantage of ISCOMs is their capacity to induce CD8+ specific cytotoxic 
responses. ISCOMs enhance antigen uptake and prolong retention by DCs in the lymph nodes, 
activate DCs and lead to increased antibody and T cell responses [372, 373]. The 
ISCOMATRIX adjuvant is identical to ISCOMs but does not contain antigen. This adjuvant 
can be mixed with antigens and like ISCOMs can target the antigen to APCs. ISCOMATRIX 
has been shown to induce good mucosal IgA responses. However, unlike ISCOM-based 
vaccines which induce a mixed Th1/Th2 response, vaccination with ISCOMATRIX induced a 
Th2-like response [374-376]. 
1.10.5. Cytolytic proteins as immune adjuvants 
As previously mentioned DNA-based vaccines are poor inducers of T cell immunity. Deliberate 
induction of cell death to induce a cascade of different signals pathways that will activate innate 
responses in order to enhance antigen uptake by DCs can be used to improve immune responses 
and act as adjuvant for vaccines [115, 377, 378]. Following necrotic cell death, DAMPS such 
as heat shock proteins (HSP), Adenosine triphosphate (ATP), uric acid and high mobility group 
box 1 (HMGB-1) are released, providing danger signals to the immune system that can activate 
immature DCs [379, 380]. Dead cells are a rich source of DAMPs and the uptake of viral 
antigen-positive dead or dying cells by DCs and other APC represents a fundamental 
mechanism to elicit immunity against pathogens that do not intrinsically infect DC [381, 382]. 
Indeed, this mechanism has been investigated in cancer immunotherapy [383-387]. Currently 
there is little work exploiting this natural mechanism to ensure vaccine efficacy.  
The body clears infected or damaged cells via apoptosis and necrosis. Although both apoptosis 
and necrosis ultimately lead to the same outcome (i.e., death of infected cells), the two processes 
differ significantly. In apoptosis, the entire affected cell, including the nucleus, separates into 
numerous fragment called apoptotic bodies. The genetic material of apoptotic cells 
simultaneously is fragmented and each apoptotic body is surrounded by a cell membrane. It is 
believed that the cells continue to produce proteins and adenosine triphosphate (ATP) and as a 
result, the apoptotic bodies contain intact, functional cell components [388].  Necrosis on the 
37 
 
other hand, is characterised by the loss of metabolic functions and the integrity of the cell 
membrane. During necrosis, the cell ceases to produce ATP, the organelles swell and become 
non-functional. Eventually, the cell membrane ruptures, resulting in the release of the cellular 
components (including DAMPs) into the surrounding tissues. This subsequently induces 
inflammation and immune activation [388, 389]. It is generally reported that in comparison to 
apoptotic cells which retain DAMPs within the cell, necrotic cells are more immunogenic as 
they release the cell contents including any immunogen, thereby ensuring DC targeting of the 
antigen. However, the mechanisms underlying the activation of DCs following both process are 
not well understood. Moreover, apoptotic cells that are not phagocytosed undergo secondary 
necrosis and currently there are no markers that can distinguish between primary and secondary 
necrosis following apoptosis [379, 389].  
Both necrotic and apoptotic cells can be phagocytosed by DCs, however a secondary signal is 
required for DC maturation. It has been reported that exposure to necrotic but not apoptotic 
cells provides the necessary maturation signals [379]. Nevertheless, others have reported that 
increasing the ratio of apoptotic cells to DCs resulted in increased upregulation of markers of 
DC maturation including MHC class II and co-stimulation molecules CD80, CD86 and CD40, 
as well as secretion of inflammatory cytokines such as IL-12, TNF-α and IL-1β 
[390],suggesting that the number of dying cells is also important for complete activation of 
DCs. However, this can also be explained by the fact that high numbers of apoptotic cells might 
not be immediately phagocytosed by DCs and then undergo secondary necrosis, thus supplying 
the necessary signals for DC activation. Some cellular components released by necrosis that 
have been identified as a cause of inflammation include HMGB-1, uric acid and SAP130 [391-
393]. A recently-characterized C-type lectin, Clec9A (also known as DNGR-1), has been 
identified as one receptor by which DC recognize a preformed signal that is exposed on necrotic 
cells [394]. Clec9A is found on mouse and human CD8α+ DC and was originally reported to 
be involved in endocytosis, activation, and pro-inflammatory cytokine production [394]. 
Clec9A is not required for uptake of necrotic fragments but is necessary for subsequent cross-
presentation and priming of naive CD8+ T cells. Further investigation revealed F-actin as the 
protein that is recognised on necrotic cells and acts as a ligand that binds to Clec9A [395-397]. 
Collectively, these studies suggest a novel way to indirectly target DCs by inducing cell death 
of antigen-positive cells leading to the recruitment of the adaptive immune system during 
infection as a strategy to enhance immune responses generated by vaccines. 
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1.10.5.1. Cytolytic genes as cancer therapy 
As noted above, necrotic cells are highly immunogenic and this mechanism has been 
investigated for cancer immunotherapy. The fundamental concept underlying cytolytic gene 
therapy is to target cancerous cells to directly eliminate the tumours and to induce an adaptive 
T cell response against tumour antigens that will lead to further elimination of cancer cells.  
The most intensively studied gene system is the Herpes Simplex Virus Thymidine Kinase (HSV 
TK) and the prodrug Ganciclovir (GCV). In this system HSV TK is introduced to the target 
cells where it catalyses phosphorylation of GCV to ganciclovir monophosphate. Ganciclovir 
monophosphate is in turn converted to di- and tri -phosphate derivatives by cellular kinases.  
The triphosphate is incorporated into replicating DNA by cellular DNA polymerases, resulting 
in DNA chain termination and apoptosis [398, 399]. This system has been used to enhance 
tumour clearance by inducing cell death in tumour cell lines in vitro, and in animal models in 
vivo, as well as in various clinical trials for cancers such as glioblastoma and prostate cancer 
[387, 400-404]. Other suicide gene systems used for cancer therapy include: Cytosine 
Deaminase/5-FU [405], Carboxyl Esterase/Irinotecan [406, 407], Nitroreductase Nfsb/ 5-
(Aziridin-1-Yl)-2 4-Dinitrobenzamide [408]. 
1.10.5.2. Cytolytic genes as adjuvant for vaccines 
Although inducing cell death has been investigated in cancer immunotherapy, there are 
however only a few studies using this mechanism to enhance the immune response to vaccines. 
[383-387]. 
A DNA construct encoding Listeriolysin O fused to SIV gag was used to immunise mice 
resulting in enhanced immunogenicity to the vaccine [409]. Analysis of the immune responses 
to the DNA constructs showed higher levels of both CD4 and CD8 T cell responses against 
Gag. DNA constructs encoding secreted Gag proteins were also more effective in eliciting 
antibody responses against SIV Gag. These results demonstrated that the C-terminal segment 
of Listeriolysin O can be effectively employed to enhance both cellular and humoral immune 
responses in the context of a DNA vaccine. The authors hypothesised that Listeriolysin O may 
act on the endosomal membrane of APCs and allow the release of gag protein into the cytoplasm 
where it could be processed for antigen presentation [409]. They however did not investigate 
the exact mechanism of the toxin. 
Other studies have focused on the use of molecules such as Fas to induce apoptosis at the site 
of vaccination [410]. By engineering Fas-mediated apoptotic death of antigen positive cells in 
vivo, the authors observed that the death of antigen-bearing cells resulted in increased antigen 
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acquisition by APCs including CD11c DCs. This strategy led to enhanced antigen-specific 
CTLs, and the amplification of Th1 type cytokines and chemokines.  
Other approaches have focused on the expression of caspases 2 and 3 [381]. Administration of 
vectors co-expressing influenza virus hemagglutinin (HA) or nucleoprotein [411] genes and 
mutant caspase genes markedly increased both CD8+ and CD4+ T-cell responses, as well as B-
cell responses to a lesser degree. The adjuvant activity was restricted to partially inactivated 
caspases that allowed immunogen expression before the generation of apoptotic bodies [381]. 
However, some studies have shown that preventing cellular apoptosis post vaccination with 
DNA enhanced the adaptive immune responses [412, 413] suggesting that apoptosis inhibits 
the immune response to vaccine antigens. Studies conducted in the Gowans laboratory have 
shown that targeted killing of antigen-positive cells via the necrotic or lytic pathway compared 
to the apoptotic pathway, resulted in improved immunogenicity of the DNA vaccines [414-
418]. This suggests that the use of cytolytic genes represents an effective mechanism to induce 
inflammation and activate DCs which are crucial for the activation of the adaptive immune 
response to vaccine antigens [89, 416, 419]. 
1.11. Virus-like particles as a HCV vaccine candidate 
This section has been written as a manuscript for publication in the journal Frontiers in 




































































1.12. Thesis aims 
The main focus of the work described in this thesis was to generate HCV DNA vaccines capable 
of inducing HCV-specific NAbs. These DNA vaccines encoded HCV structural proteins 
core/E1/E2 to induced HCV-specific immunity. To improve the immunogenicity of the DNA 
vaccine candidates, a cytolytic gene, PRF was encoded on the DNA constructs. Alternatively, 
in other studies HCV envelope proteins were fused to IMX313 or IMX313P to generate E1E2 
heptamers. Detailed investigations of the subsequent immune responses to these optimised 
vaccines were then performed. This work attempts to realise the potential of DNA vaccines as 
a safe, stable and cost-effective prophylactic vaccine against HCV. 
The specific aims of the thesis are to: 
1) Construct a lytic DNA-based VLP vaccine encoding core/E1/E2 and PRF and evaluate the 
immunogenicity of these DNA vaccine in mice (See Chapter 3). 
2) Construct DNA vaccines encoding E1E2 heptamers by fusing E1/E2 to IMX313 
oligomerisation domains and assess their immunogenicity in mice (See Chapter 4). 
3) Design DNA vaccines encoding E1E2 heptamers by fusing E1/E2 to the oligomerisation 
domain IMX313P and assess the effect of this oligomerisation on the subsequent immune 
response (See Chapter 5). 
4) Evaluate the immunogenicity of DNA prime/DNA boost, DNA prime/E1E2 recombinant 
protein boost or DNA prime/HCV VLP boost regimens, using DNA encoding E1/E2 fused to 
IMX313P, E1E2 recombinant protein or HCV VLPs (see Chapter 6). 
5) Assess the neutralising ability of the antibodies generated by the different prime/boost 

































Chapter 2. Material and Methods 
2.1. Materials 
























Chemical/Reagent  Manufacturer  
2-mercaptoethanol  Sigma-Aldrich  
30% Acrylamide/Bis Solution  BioRad  
Absolute Ethanol Sigma-Aldrich 
Acetic acid  Thermofisher Scientific  
Agar  AMRESCO  
Agarose  AMRESCO  
Albumin (bovine)  Sigma-Aldrich  
Ammonium chloride  Sigma-Aldrich  
Antarctic Phosphatase NEB #M0289S 
APS (Ammonium persulfate) Sigma-Aldrich  
Ampicillin  Sigma-Aldrich  
Boric acid  Sigma-Aldrich  
Brefeldin A ebioscience 
Bromophenol blue  Sigma-Aldrich  
BSA (Bovine Serum Albumin) Sigma-Aldrich 
Calcium chloride  Sigma-Aldrich  




DMSO  Sigma-Aldrich  
EDTA  Sigma-Aldrich  
Ethanol  Sigma-Aldrich  
Fetal calf serum (0.1um filtered)  ThermoScientific  
GenElute  Life Technologies  
Glucose  Sigma-Aldrich  
Glycerol  Sigma-Aldrich  
Glycine  Sigma-Aldrich  
HEPES  Life Technologies  





























Imidazole  Sigma-Aldrich  
Isopropanol  Sigma-Aldrich  
Kanamycin  Sigma-Aldrich  
Lipofectamine® LTX with Plus™ Reagent ThermoFisher Scientific 
Magnesium chloride  VWR International  
Magnesium sulphate  VWR International  
Manganese chloride  Sigma-Aldrich  
Non-fat dried milk  Black and Gold  
optiMEM  Life Technologies  
OptiPrep™ Density Gradient Medium (Iodixanol) Sigma-Aldrich 
Phosphate-buffered saline  Life Technologies  
Potassium acetate  ACE chemical company  
Potassium bicarbonate  Sigma-Aldrich  
Potassium chloride  Thermofisher Scientific  
Potassium hydroxide  Thermofisher Scientific  
Protein G Agarose Roche Diagnostic 
Complete mini EDTA-free protease inhibitor Roche Diagnostic 
PVDF membrane  Millipore  
RPMI 1640  Life Technologies  
Sodium acetate  AMRESCO  
Sodium azide  Sigma-Aldrich  
Sodium Chloride (NaCl) ChemSupply  
SDS (Sodium Dodecyl Sulphate) Sigma-Aldrich  
Sodium hydroxide  Sigma-Aldrich  
Sodium pyruvate  Life Technologies  
N,N,N',N'-Tetramethylethylene-diamine (TEMED)  Sigma-Aldrich  
Triton-X  BioRad  
Trizma-base  Sigma-Aldrich  
Trizol  Life Technologies  
Trypsin  Life Technologies 
(Gibco)  
Tryptone  Becton, Dickinson and 
Company  





Equipment  Manufacturer  
Agarose gel imager  BioRad Gel DocXR system  
Bacterial incubator  Labmaster Anax Division  
Bacterial shaker  Ratek Orbital mixer incubator  
Bacterial spectrophotometer  BioRad Smartspec 3000  
Cell culture incubator  SANYO CO2 incubator  
EliSpot plate reader  Autoimmun DiagnostikaELISPOT reader  
Flow cytometer  BD Biosciences FACScanto  
Fluorescence microscope  Zeiss AxioLab inverted microscope  
Heat block  BioRad Digital dry bath  
Large centrifuge  Beckman T2-21M/E centrifuge  
Large table-top centrifuge  Eppendorf centrifuge 5810R  
Nanodrop spectrophotometer Thermo Scientific 
Platform shaker  Heidolph Instruments  
Real-time PCR cycler  Corbett Rotor-Gene 3000  
Small table-top centrifuge  Sigma 1-15PK  
Western blot imager  FujiFilm LAS-4000  
2.1.3. Kits 
Kit Manufacturer 
E-Toxate (Limulus Amebocyte Lysate) test kits Sigma-Aldrich 
Pierce™ BCA Protein Assay Kit ThermoFisher Scientific 
PureLink® Quick Gel Extraction and PCR 
Purification Combo Kit 
Life Technologies 
PureLink® Quick Plasmid Miniprep Kit Life Technologies 
KAPA high fidelity PCR kit KAPA Biosystems 
KAPA Taq PCR kit KAPA Biosystems 
LDH Cytotoxicity Assay Kit ThermoFisher Scientific 
Pierce™ LDH Cytotoxicity Assay Kit  ThermoFisher Scientific 
Whatmann filter paper  Whatmann International 
Ltd  




2.1.4. Cell lines 
Cells Description 
Huh7 Human Hepatoma cell line 
HEK-293T Human Embryonic Kidney cell line 
2.1.5. Antibodies 
2.1.5.1 Primary Antibodies 
2.1.5.2 Secondary Antibodies 
Antibody Class Raised in Source Catalogue 
number 
Anti-core Monoclonal Mouse ViroStat 1851 
Anti-E1 Monoclonal Mouse ViroStat 1879 
Anti-E2 Monoclonal Mouse ViroStat 1876 
Anti-HCV Pooled HCV genotype 
1 patient sera 
Human Inhouse  
Anti-PRF Monoclonal Rat Abcam CB5.4 
Anti-actin Ab-5 Monoclonal Mouse BD Biosciences 612656 
Antibody Source Catalogue 
Number 
Alexa-fluor (AF) 555 conjugated donkey anti-
goat IgG 
Invitrogen A21432 
AF 555 conjugated goat anti-human IgG Invitrogen A21433 
AF 488 conjugated goat anti-human IgG Invitrogen A11013 
AF 555 conjugated goat anti-mouse IgG Invitrogen A21127 
Cy5 conjugated goat anti-rat IgG Life Technologies A10525 
Alexa-fluor 555 conjugated goat anti-human IgG Invitrogen A21431 
Horse Radish Peroxidase (HRP) conjugated goat 
anti-human  
Millipore AP112P 
HRP conjugated goat anti-mouse IgG Antibodies Australia GAM.2.2 
HRP conjugated goat anti-rabbit IgG Antibodies Australia GAR.2.2 
HRP conjugated goat anti-mouse IgG Invitrogen 62-6520 
HRP conjugated donkey anti-goat Life research L00180020 
HRP conjugated goat anti-mouse IgG Antibodies Australia GAM.2.2 
HRP conjugated rabbit anti-mouse IgG2a ThermoFisher  scientific 61-0220 







2.1.6.1. Bacterial Expression 
2.1.6.2. DNA Manipulation 
Solution Components 
DNA 6× loading dye 25 mg bromophenol blue, 25 mg xylene cyanol FF, 
3.3 ml glycerol, 6.7 ml ddH2O 
1× Tris/Borate/EDTA (TBE) buffer 10.8 g Tris, 5.5 g Boric acid, 4 ml 0.5 M 
Na2EDTA (pH 8.0), 900 ml ddH2O 
2.1.6.3. SDS-PAGE 
Solution Components 
Running Gel Buffer 40 mM Tris, 185 mM Glycine, 0.1% SDS 
Resolving Gel Buffer 2 M Tris HCl pH8.8, 10% SDS, 30% Acrylamide 
Stacking Gel Buffer 2 M Tris HCl pH6.8, 10% SDS, 30% Acrylamide 
5× SDS loading buffer (Reducing) 100 mM Tris-HCl pH6.8, 2% SDS, 2mL 10% 
glycerol, 5% β-mercaptoethanol, 1µg/ml 
bromophenol blue 
Solution Components 
Luria-Broth (LB) 10 g tryptone, 10 g NaCl, 5 g yeast extract, 950 ml H2O 
LB-agar 10 g tryptone, 10 g NaCl, 5 g yeast extract, 950 ml H2O, 15 g agar 
SOC Media 
 
20g Tryptone, 5g Yeast Extract, 0.58g NaCl, 0.19g KCl, 2.03g 
MgCl2, 2.46g MgSO4, 3.6g Glucose 
(Final volume 1 L using MQ H20) 
TfbI solution 
 
2.94g KAc 30mM, 7.45g KCl 100mM, 1.47g CaCl2 10mM, 9.85g 
MnCl2 50mM, 150ml Glycerol 15% - Adjust the pH to 5.8 with 
acetic acid (Final volume 1 L using MQ H20) 
TfbII solution 
 
0.209g MOPS 10mM, 1.1g CaCl2 75mM, 0.075g KCl 10mM, 
15ml Glycerol 15%  




6g Yeast Extract, 24g Tryptone, 6g MgSO4  
- Adjust the pH to 7.6 with KOH (Final volume 1.2 L using MQ 
H20) 
Psi-b Agar  2.8g of agar added to 200ml of Psi-a media 
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2.1.6.4. Western Blot Analysis 
Solution Components 
Running buffer  6.25mL pH8 Tris, 6.25mL pH8.8 Tris, 10mL 10% SDS, 
14.4g glycine, to 1L MQ H2O 
Wet Transfer Buffer  14.4g glycine, 3.03g Trizma Base, to 1L MQ H2O 
Skim milk solution 200mL PBST (1xPBS + 0.05% Tween), 10g skim milk 
powder, 1g BSA 
 
2.1.6.5. Cell Lysis 
Solution Components 
ACK Lysis Buffer 0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA (pH 7.2-7.4) 
NP-40 Lysis buffer 150 mM NaCl, 1% NP-40, 50 mM Tris-Cl (pH 8.0) 
RIPA Buffer, Triton X-100 50 mM Tris-HCl (pH 7.4), NaCl 150 mM, 1% Triton X-
100, 0.5% Sodium deoxycholate, 0.1% SDS (pH Value: 7.4) 
 
2.1.6.6. Tissue Culture 
 
2.1.7. Oligonucleotide Synthesis 
Oligonucleotides were purchased from GeneWorks and Integrated DNA Technologies 
 
Solution Source Catalogue number 
Trypsin-EDTA (0.25%), phenol red Life Technology 25200-056 
Dulbecco's modified Eagle's medium 
(DMEM) 
Life Technology 21969-035 
Minimum Essential Medium (MEM) Life Technology 11095-080 




2.2.2. Molecular Cloning 
2.2.2.1 DNA Constructs 
All DNA vaccine constructs were based on two vectors; the pVAX1 plasmid (Life 
Technologies) and a bicistronic vector, pJ, generated by modifying the pVAX1 vector to insert 
the SV40 promoter, a novel multiple cloning site and the SV40 polyadenylation site [415]. 
Codon-optimised genes (Gene Art, Germany) encoding Core, E1 and E2 (GenBank accession 
number AF139594.2) were used as template in a series PCRs. 
2.2.2.2. Primer Design 
Primers were designed from each of the genes of interest to amplify the entire gene and 
introduced start (ATG) or stop (TGA) codons where necessary. A Kozak sequence 
(GCCACCATGG) was also introduced by the primers for enhanced mammalian cell expression 
and novel restriction enzyme sites were also introduced so that the DNA amplicon of the gene 
of interest could be digested and ligated into the plasmid backbone. The primers also contained 
a short sequence of approximately 20 bases complementary to the target DNA. Primers were 
purchased from Geneworks Pty Ltd or Integrated DNA Technologies and were <100 bases. 
Primers were designed to avoid primer dimerization, primer hairpins, and multiple binding sites 
on the template, and aimed for a melting temperature (Tm) between 55 - 65 °C with the primer 
pair Tm to fall within 5 °C of each other. The Tm was calculated using the following equation: 
Tm = 2 °C (# A + T pairs) + 4 °C (# G + C pairs).  
A complete list of primers used in this thesis is shown in appendix I. 
2.2.2.3. PCR Amplification 
2.2.2.3.1 PCR Amplification 
For direct sequencing, the required gene or gene fragments were amplified using the KAPA 
high fidelity (HiFi) Taq polymerase enzyme PCR kit (KAPA Biosystems). Each reaction mix 
contained a final volume of 50 µl and consisted of 1X KAPA HiFi Buffer, 0.3 mM of each 
dNTP, 0.3 μM forward primer, 0.3 μM reverse primer, 10 ng DNA template and 0.5 U KAPA 
HiFi DNA polymerase. Each reaction was amplified at: 
Number of Cycles  1  30 1  
Temperature (°C)  95  98  Up to 65*  72 72 
Time (minutes)  2  0.3  0.2  1 minute/kb  5 
* The annealing temperature is dependent on the length and composition of the primer. 
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Following amplification, the entire reaction was subjected to agarose gel electrophoresis 
(section 2.2.2.5) and the band of interest purified by gel extraction (section 2.2.2.6) using the 
PureLink® Quick Gel Extraction and PCR Purification Combo Kit (Life Technologies). 
2.2.2.3.2 Overlapping PCR Amplification 
The overlapping PCR amplification was performed in three stages: extension PCR, overlap 
PCR, and finally purification PCR. During an extension PCR, individual fragments encoding 
genes with overlap sequences to allow hybridisation were amplified. PCR products were then 
electrophoresed on a 0.8% agarose gel, which was stained with gelred.  
The PCR products purified by agarose gel electrophoresis were used as template DNA for the 
second stage-overlapping PCR without primers and subjected to the following amplification 
conditions: 1 cycle of 95°C for 2 minutes; 35 cycles of 95°C for 30 seconds, 72°C for 1 minute, 
and 72°C for 3 minutes; and a single extension of 72°C for 5 minutes. In this process, strands 
with overlapping complementary base pairs (20 bases) acted as primers for each other. In the 
third PCR, the combined (larger) fragment gene was amplified using primers on the extreme 5’ 
and 3’ ends of the PCR product. The forward primer contained a Kozak sequence, a start codon 
and restriction enzyme and a reverse primer contained a stop codon and restriction enzyme 
sites.  
2.2.2.4. Restriction Enzyme Digestion 
PCR products of the genes of interest and the plasmid backbone were both digested with the 
appropriate restriction enzymes (NEB). Restriction enzyme digests were performed for at least 
3 hours at 37°C (to ensure complete digestion) unless otherwise specified by the manufacturer. 
Reactions were typically carried out in 50µL volume using 10 units of each enzyme per µg 
DNA. All reactions were performed using the appropriate enzyme buffers and BSA if 
necessary. The vector backbone was de-phosphorylated using Antarctic Phosphatase (NEB). 
Following digestion, the gene insert and the vector backbone were ligated (section 2.2.2.7). 
2.2.2.5. Agarose Gel Electrophoresis 
This method was used to isolate and purify DNA fragments amplified by PCR or DNA 
fragments produced by restriction enzyme digestion. Typically, larger fragments (>500bp) were 
separated on 0.8% agarose gel and smaller fragments (<500bp) on 2% agarose gel. The agarose 
gels were prepared in 1× TBE buffer. DNA fragments to be loaded on the gel were first mixed 
with 0.1 volume of 6× DNA loading dye and gels were typically electrophoresed at 100 V in 
1× TBE buffer. DNA fragments were electrophoresed alongside 1kb ladder (GeneSearch Pty 
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Ltd). To excise digested DNA fragments and PCR products, the fragments were visualised 
using long wave UV light followed by purification (section 2.2.2.6.). 
2.2.2.6. Purification of DNA from Agarose Gel 
Following agarose gel electrophoresis, the band of interest was extracted and purified using the 
PureLink® Quick Gel Extraction and PCR Purification Combo Kit (Life Technologies). 
Excised gel slices containing digested DNA fragments were dissolved in buffer 1 (solubilisation 
buffer) at a ratio of 1:3 and incubated at 50°C for 15 minutes. The dissolved DNA fragment 
was then mixed with 1 gel volume of isopropanol to increase DNA yield. DNA in the gel 
solution was then bound to a quick spin column by centrifugation at 13,000 rpm for 1 minute. 
The column was washed once with 750 µl buffer PE (washing buffer) and centrifuged again at 
13,000 rpm for 1 minute. DNA was eluted from the column by the addition of 30-50 µl of buffer 
EB (elution buffer) followed by further centrifugation at 13,000 rpm for 1 minute. 
2.2.2.7. DNA fragment Ligation 
Gel purified DNA fragments following restriction enzyme digestion were ligated for 16 hours 
at 16 °C in 10µl reactions containing: the gene insert and plasmid backbone mixed at a ratio of 
3:1 (at a final concentration of 100ng) with 1× ligase buffer and 2 units of T4 DNA ligase. Final 
DNA concentrations were calculated using the following formula: ng insert = ((insert size 
(kb)/vector size (kb)) × ng vector) × 3. Following ligation, 2 µl DNA was used for 
transformation into competent E. coli (section 2.2.2.9). 
2.2.2.8. Preparation of heat-competent bacterial cells 
DH5α cells were streaked from a frozen stock on a psi-b plate and incubated overnight at 37°C. 
A single colony was picked and inoculated into 10 ml psi-a medium with shaking at 37°C until 
OD550 to 0.3 was reached (about 4 hours). 5ml of the culture was then added to 100ml of pre-
warmed psi-a medium and incubated at 37°C with shaking until the OD550 was 0.48 (about 3 
hours). The culture was chilled on ice for 5 minutes followed by centrifugation at 4500 rpm for 
5 minutes at 4°C. The pellet was resuspended in 40ml chilled Tfb-I solution and chilled on ice 
for 5 minutes followed by centrifugation at 4500 rpm for 5 minutes at 4°C. The pellet was then 
resuspended in 4ml chilled Tfb-II solution and incubated on ice for 15 minutes before being 
snap frozen in liquid nitrogen in 50µl -100µl aliquots and stored at -80°C. 
2.2.2.9. Bacteria cells Transformation 
The ligated DNA was then transformed into heat-competent DH5α E. coli cells. 2 µl (50ng) of 
plasmid or ligated DNA was added to 50 µl heat-competent E. coli cells. The cells were 
transformed using the heat shock method by incubating the mixture of DNA and E. coli cells 
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on a preheated heat block at 42°C for 45 seconds. Transformed cells were then resuspended in 
0.5 ml SOC media and incubated at 37°C with shaking at 180 rpm for 1 hour before being 
plated on kanamycin (50µg/mL) Luria-Broth (LB)-agar plates and grown overnight at 37°C. 
DH5α cells transformed with 3:1 ligation mix were compared to a 0:1 ligation mix to calculate 
colony background levels. 
2.2.2.10. Positive Colony Selection 
The identification of bacterial colonies containing the correct insert was performed by colony 
PCR, diagnostic digest or DNA sequencing. 
2.2.2.10a. Colony PCR 
Colonies were selected and diluted in 50μl of MQ H20. Colony PCR was performed using 
KAPA taq polymerase (KAPA Biosystems). The total number of colonies tested depended on 
the number of colonies on the vector-only negative control plates. The colony PCR master mix 
contained 0.25 U KAPA taq polymerase, 1X KAPA taq buffer, 0.2 mM of each dNTP, 0.4 μM 
forward primer, 0.4 μM reverse primer and 2 μl diluted bacteria colony. 
Thermo Cycler Conditions using the DNA Engine PCR machine (BioRad) were as follows; 
Number of Cycles  1  30 1  
Temperature (°C)  95  95  Up to 65*  72  72  
Time (min)  2  0.3  0.30  1 min/kb  2  
*The annealing temperature is dependent on the length and composition of the primer. 
The colony PCR products were analysed by electrophoresis on a 0.8% agarose gel to confirm 
the correct product size. 
2.2.2.10b. Restriction Enzyme Digestion of Cloning Products 
Restriction enzyme digestion of the cloned products was performed to verify positive colonies. 
DNA isolated with a mini-preparation kit (see section 2.2.2.11) was digested with the 
appropriate restriction enzyme to identify the insert in the vector. The digested DNA was 
analysed by electrophoresis on a 0.8% agarose gel to confirm the size of the insert and vector. 
2.2.2.11. Small Scale Plasmid Preparation (Mini-preparation) 
A positive bacterial colony was picked from the antibiotic-supplemented agar plate and grown 
in antibiotic-supplemented LB media for 16 hours at 37 °C with vigorous shaking at 180 rpm. 
Plasmid DNA was purified from these bacterial cultures using the Invitrogen Quick plasmid 
mini-preparation kit protocol (Life Technologies) according to the manufacture’s protocol. The 
DNA concentration was determined by a Nanodrop spectrophotometer. Purified plasmids were 
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re-digested with appropriate restriction enzymes and analysed by agarose gel electrophoresis to 
confirm that the gene of interest was present. The correct sequences of the positive clones were 
further confirmed by DNA sequencing (section 2.2.2.13). 
2.2.2.12. Large Scale Plasmid Preparation from Transformed Bacteria 
A single colony was picked from a freshly streaked selective agar plate to inoculate a 500 ml 
culture of LB with kanamycin (100µg/ml) and cultured overnight at 37°C with vigorous 
shaking (180 rpm). A large-scale DNA preparation was then made from the bacterial pellet 
harvested by centrifugation at 3000g for 10 minutes at 4°C. The pellet was resuspended in 30 
ml buffer P1 (cell suspension buffer) by pipetting,30 ml of buffer 2 (lysis buffer) was added to 
the suspension and mixed by vigorously inverting the tube 5-6 times.  The suspension was 
incubated at room temperature (RT) for 5 minutes before adding 30 ml of buffer 3 (precipitation 
buffer) and further mixing by inversion. The lysate was then centrifuged at 3000g for 10 
minutes and the supernatant was transferred to new labelled tubes. To precipitate the DNA, 1 
volume of isopropanol was added to each tube and mixed by inverting the tubes for a few times 
before being centrifuged at 3000g at 4 °C for 10 minutes. The supernatant was discarded and 
the pellet air dried for 10-20 minutes. To remove cellular proteins, the pellet was resuspended 
with 1-2ml TE buffer + RNase (100 μg/ml) and pipetted up and down several times to 
completely dissolve the pellet. An equal volume of phenol: chloroform (Life Technologies) was 
added and gently mixed to extract the DNA followed by centrifugation at 15,000g for 
15minutes at 4°C. The top layer of the mixture (containing DNA) was transferred to a clean 
tube and the DNA was precipitated by adding 4mls of 95% ethanol, 100ul (1/10 volume of 3M 
sodium acetate), 10μl glycogen (20mg/ml) (Life Technologies) and incubated at -80°C for 
30minutes followed by centrifugation at 15,000g for 30 minutes at 4°C. The DNA pellet was 
air-dried and dissolved in 1-2ml of TE buffer. To remove endotoxins, 100-200µl of 3 M sodium 
acetate solution was added to the extracted DNA and incubated on ice for 5 minutes. 200-400µl 
of cold Endotoxin Removal Solution (Sigma Aldrich cat. No E4274) was then added to the mix 
and incubated on ice for 10 minutes followed by an additional incubation at 37 °C for 20-30 
minutes (or until the phases separated). The mixture was then centrifuged for 5 minutes at 3000g 
and the upper (colourless) phase carefully transferred to a clean centrifuge tube. The endotoxin 
removal steps were repeated twice. To precipitate the DNA, 0.6 volume of 2-propanol was 
added and mixed before centrifugation at 15,000 x g for 30 minutes at 4 °C. The DNA was then 
washed by adding ~500μl cold 70% ethanol and centrifuged at maximum speed for 10 minutes 
at 4°C and the pellet air-dried. In the final step the DNA pellet was dissolved in 1-2ml of 
endotoxin free water or TE buffer. The DNA concentration and endotoxin levels were 
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determined using a Nano-Drop and E-TOXATE (Endotoxin testing) kit (Sigma #ET0200) 
respectively. 
Alternatively, DNA constructs were prepared using the QIAGEN Plasmid Giga Kit (Qiagen 
#12191) following the manufacturer’s instructions.  
2.2.2.13. Nucleotide Sequencing 
Sequencing of the genes of interest in the DNA vaccine constructs was performed by SA 
Pathology IMVS DNA sequencing facility. 1µM of a single forward or reverse primer, and 
200ng of plasmid DNA were required for the sequencing reaction. The BLAST nucleotide 
alignment was used to confirm that the sequence in the plasmid DNA construct matched the 
known sequence of the gene of interest. 
2.2.1. Cell Culture and transfections 
2.2.1.1. Cell culture and storage 
All components of cell culture media were supplied by Invitrogen. Huh7 and HEK-293T cells 
were grown in DMEMcomplete (Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% fetal calf serum (FCS) (heat inactivated at 56oC for 30 minutes), 1% 
penicillin/streptomycin) and maintained at 37oC in an atmosphere of 5% CO2. Cell lines were 
typically grown in T75 or T150 tissue culture flasks. At reaching about 90% confluency, cells 
were washed gently with DPBS followed by their removal with trypsin (Life Technology). 
Cells were resuspended in 10mL of DMEMcomplete before re-seeding or use in experiments. 
For cell storage, cells were trypsinised, pelleted and re-suspended in 1 ml of 10% DMSO in 
FCS and transferred to a cryovial. The cells were then transferred to a freezing container 
(Nalgene) and stored at -80 °C overnight then transferred to liquid nitrogen. 
Vials of cells were thawed in a 37°C water bath and then transferred to a 10mL falcon tube; 9 
ml of pre-warmed media was then added and the cells were pelleted by centrifugation at 1500 
rpm for 5 minutes. The supernatant was removed, and the cells were re-suspended in fresh 
media and plated. 
2.2.1.2. Transient cell transfections 
HEK293T cells were seeded at 6×105 cells per well in a 6 well plate and allowed to grow and 
adhere overnight, then maintained at 37°C in an atmosphere of 5% CO2 resulting in 
approximately 60-70% cell confluency on the day of transfection. Cells were then transfected 
with 2.5μg DNA/well using Lipofectamine LTX according to the manufacturer’s protocol.  A 
control well transfected with DNA encoding the reporter gene eGFP was used to confirm 
transfection efficiency. The transfected cells were incubated for 36 hours at 37 °C with 5% CO2 
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and protein produced in transfected cells was detected by western blot, flow cytometry or 
immunofluorescence. 
2.2.3 Protein Detection 
2.2.3.1 Protein purification and quantification 
2.2.3.1a Protein Purification by Affinity Chromatography 
The HCV E1E2 proteins were purified under native conditions on a nickel-nitrilotriacetic acid 
(Ni-NTA)-agarose column according to the manufacturer’s protocol (Qiagen). Briefly, 
HEK293T cells were transfected with the construct encoding 6 x His-tagged secreted E1E2 
polyprotein (p-tPAtE1tE2-Histag, see chapter 3 – section 3.3.6.2 and chapter 4 – section 4.3.1) 
in serum free media. The cell culture media was harvested 48 hours post transfection, 
centrifuged for 5 minutes at 4000 rpm to remove detached cells before filtration through a 
0.45µm filter to remove remaining cell debris. Proteins in the clarified supernatants were 
concentrated by ultrafiltration through a 70,000-molecular-weight cutoff filter (70K MWCO; 
Amicon) for 20 minutes at 4000 rpm. The concentrated proteins in the supernatant was applied 
on the Ni-NTA column (Qiagen). Following three washes by buffer B (30 mM Immidazol, and 
pH 8), purified protein was eluted with 300 mM imidazole elution buffer (pH 8). Purified E1E2 
proteins were analysed by PAGE (section 2.2.3.2) and western blot (section 2.2.3.3). 
2.2.3.1b Protein quantification 
Protein concentration was determined by bocinchonimic acid (BCA; ThermoScientific) or 
Bradford (Bio-Rad protein assay) assays. The BCA protein assay was conducted according to 
the manufacturer’s instruction using standards of bovine serum albumin (BSA) in a range of 25 
– 2000μg/mL. The absorbance was measured at 562 nm on the FLUOstar OPTIMA plate reader 
(BMG LabTech). For the Bradford assay, 10μL of each sample was transferred into the wells 
of 96well plate. 10μL of the buffer was used as a blank. 200μL of Bradford dye reagent were 
added to each well, mixed with the proteins and incubated at RT for 5 minutes followed by OD 
measurement of at 595nm. Measurements were performed in duplicate or triplicate for each 
sample and the average was taken for the calculation of the protein concentration. Unknown 
sample concentrations were calculated based on the standard curve of the protein standards 
according to the manufacturer’s instructions. 
2.2.3.2 SDS-PAGE 
For SDS-PAGE, cells were lysed directly in Triton-X 100 lysis buffer. The lysates were then 
spun briefly (13,000 rpm for 1 minute) to remove cell debris and the clarified lysates were 
mixed with 5×SDS loading buffer. For secreted proteins, cell culture media was harvested, 
centrifuged to remove detached cells before filtration through a 0.45µm filter to remove 
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remaining cell debris. The proteins in the clarified supernatants were then concentrated by 
ultrafiltration through a 70,000-molecular-weight cutoff filter (70K MWCO; Amicon). All 
samples were denatured by boiling at 95°C for 5 minutes before use. Resolving gels were 
prepared using acrylamide solution at a final concentration of 10-14% in 1 x resolving gel 
buffer. Stacking gels were prepared using acrylamide at a final concentration of 5% in a 1 x 
stacking gel buffer. Polymerisation of gels was initiated by the addition of APS (0.1%) and 
TEMED (to 0.8%). A 10-tooth comb was typically used to form wells in the stacking gel. 
Denatured proteins were loaded onto the gel alongside a protein marker (Sigma) for size 
determination. Fractionation was performed at 120 V in gel running buffer. Upon separation, 
gels were removed from the apparatus and the proteins were transferred onto polyvinylidene 
difluoride (PVDF) membrane.  
For non-denaturing PAGE, the samples were lysed in native sample buffer (Bio-Rad) and were 
not denatured before electrophoresis. Native gel electrophoresis was performed in the same 
manner as SDS PAGE, except that SDS was omitted from the gels and buffers to ensure that 
proteins retained their activities. 
2.2.3.3 Western Immunoblotting 
Proteins separated on polyacrylamide gels were transferred to PVDF membrane using a BioRad 
transblot semi-dry blotting device. Transfer was carried out at 25 V for 15 minutes. Following 
transfer, membranes were incubated for 1 hour at RT or overnight a 4°C in PBST containing 
5% dried milk powder to block non-specific binding of antibody. Membranes were washed 3 
times in PBST and probed with the appropriate antibody (see section 2.1.5 for a list of the 
antibodies used) diluted in skim milk for 1 hour at RT. The membranes were washed as above 
and incubated with the appropriate HRP conjugated secondary antibody (diluted in skim milk) 
for 1 hour at RT. Finally, the membranes were washed as above and bound antibody was 
detected using Western Lightning Ultra (PerkinElmer) reagents I and II in equal ratio. Bands 
were visualised by LAS-4000 westernblot imager (FujiFilm). 
2.2.3.4 Indirect Immunofluorescence 
Immunofluorescence (IF) was used to visualise the intracellular expression of HCV proteins 
following transfection. Cells were first fixed in 4% paraformaldehyde (PFA) for 15 minutes at 
RT before being permeabilized with 100% methanol at -20°C for 20 minutes. Subsequently 
cells were washed 3 times with PBS, blocked at 37°C for 2 hours in blocking buffer (PBS 
containing 1% bovine serum albumin (BSA)) and incubated at 37°C for 1 hour with primary 
antibody (see section 2.1.5.1) diluted appropriately in the blocking buffer. Cells were then 
washed 3 times with PBS and stained with the appropriate fluorophore-conjugated secondary 
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antibody (directed against the primary antibody, see section 2.1.5.2) for 1 hour at 37°C in the 
dark. Finally, cells were washed 3 times with PBS and then stained with DAPI (4’,6’-
diamidino-2-phenylindole; Life Technologies). The cells were visualized by fluorescence 
microscopy (Zeiss LSM-700) and digitised using the Zen software (Zeiss).  
2.2.3.5 GFP Protein Expression Visualisation 
GFP-positive cells were visualised on an Eclipse TE2000 inverted microscope (Nikon) and 
digitised on the NIS Elements imaging software (Nikon). 
2.2.3.6 Flow Cytometry for protein detection 
The mean fluorescence intensity of GFP expression was examined by flow cytometry of 
HEK293T transfected cells. The cells (1×106) were harvesting by pipetting, transferred to a 5 
ml round bottom tube (BD Biosciences) and pelleted by centrifugation at 1500 rpm for 5 
minutes. The cells were resuspended in 100μL flow cytometry buffer (2% v/v FCS, 0.05% wt/v 
sodium azide, 2mM EDTA in PBS) and analysed on a BD FACSCanto II system (BD 
Biosceinces) using the forward and side scatter gate to remove cell debris and doublets. The 
cells were then analysed for the mean fluorescence intensity using the FACSDiva software (BD 
Biosciences) and results calculated using FlowJo software (Treestar Incorporated). 
2.2.3.7 Lactate dehydrogenase (LDH) release assay 
LDH activity assay was performed on HEK293T cells using the Pierce™ LDH Cytotoxicity 
Assay Kit (ThermoFisher Scientific; Catalogue number: 88953) according to the 
manufacturer’s protocol. Cells were cultured in 96-well plates at 1×105 cells/well and grown to 
a confluence of 70–80%. The cells were then transfected with the DNA constructs. As a control 
cells were treated with Doxorubicin. Following treatment, the LDH cytotoxicity assay was 
performed according to the manufacturer’s instructions. Briefly, 100μl cell culture supernatant 
was transferred from each well to a 96-well plate and 100μl freshly prepared reaction mixture 
was added to each well. Following 30 minutes incubation at RT in the dark, the absorbance was 
determined at 490 nm using a FLUOstar OPTIMA plate reader. The quantity of LDH was 
expressed as a percentage compared with the total quantity of LDH present in cells treated with 
2% Triton X-100. 
2.2.4 HCV-VLP Based Work 
2.2.4.1 Immunoprecipitation of HCV proteins 
HEK293T transfected with vaccine constructs were lysed 72 hours post transfection by 3× 
freeze-thaw cycles (by placing the tube in liquid nitrogen or dry ice to freeze and thawing at 
37°C). Cell culture media was also harvested, centrifuged to remove detached cells before 
filtration through a 0.45µm filter to remove remaining cell debris. The proteins in the clarified 
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supernatants were concentrated by ultrafiltration through a 70,000-molecular-weight cutoff 
filter (70K MWCO; Amicon). 500 µl of the cleared supernatant or cell lysate was incubated 
with 50 µl protein G-agarose (Roche Diagnostic) at 4°C for 3 hours to reduce the background. 
The supernatant was then incubated with anti-core or anti-E2 antibodies (both diluted 1:200) 
for 16 hours at 4°C and then with 50 µl of protein G-agarose (Roche Diagnostic) for 4 hours at 
4°C with mixing. The beads were washed repeatedly, and the bound proteins were released and 
denatured by heating for 5 minutes at 95°C in SDS sample buffer. The immunoprecipitated 
proteins were analysed by electrophoresis on a 12% polyacrylamide gel. After protein transfer 
to PVDF membranes, the blots were probed with anti-core (diluted 1:200) or anti-E2 (diluted 
1:200) antibody followed by horseradish peroxidase-conjugated anti-mouse immunoglobulin 
antibody (diluted 1:10,000), with subsequent chemiluminescence detection (see section 
2.2.3.3).  
2.2.5 Immunisation of mice 
2.2.5.1 Mice 
Six to eight weeks old female Balb/C mice were obtained from the University of Adelaide 
Laboratory Animal Services. Mice were housed in HEPA-filtered individually vented cages in 
The Queen Elizabeth Hospital animal house and were used in accordance with the SA 
Pathology, Women’s and Children’s Health Network and University of Adelaide animal ethics 
committee guidelines. 
2.2.5.2 DNA vaccine administration 
Female 6-8 weeks old Balb/C mice were injected into the dermal layer of the ear (intradermal 
injection) with 50μg of endotoxin-free DNA in a final volume of 100μl PBS (50μl or 25ng of 
DNA per ear). For the cocktail DNA vaccines, each group of animals received a total of 20.65 
picomoles per dose per animal. The vaccine dosage was determined using 50μg DNA of the 
smallest construct (encoding HCV antigens) p-tPAtE1 to set the baseline molecular mass for 
vaccinations. This ensured that each vaccination received at least 50μg total DNA per dose. The 
molar concentration for each vaccine construct was calculated using the following equation, 
where the average molecular mass of one base pair = 660 g/mol: 
Picomoles/µl =
DNA Concentration(µg/ml)
(0.66 × DNA Size(bp))
 
The vaccinations were administered at 2 or 3 weekly intervals. All interventions were 
performed under isofluorane anaesthesia to ensure the mice were immobile to allow accurate 
vaccinations. The mice were weighed and monitored visually following all vaccinations. 
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2.2.5.3 Tissue collection 
2.2.5.3a Blood samples 
Blood samples were collected from the facial vein of a mouse. Approximately 100μL of blood 
was taken per mouse per time point. Serum was isolated from the blood by allowing the blood 
to clot at RT for 30 minutes followed by centrifugation at 13000 rpm for 30 minutes. The serum 
was collected and stored at -20 °C until required.  
2.2.5.3b Spleen collection 
Following the last bleed, the mice were culled and spleens were removed and homogenized 
using a 70μm cell strainer (BD Falcon) to generate single cell suspensions. Erythrocytes were 
lysed from splenocytes preparations by incubating the cell suspensions in 2mL of pre-warmed 
ACK lysis buffer (NH4Cl 0.15 M, KHCO3 10 mM, EDTA 0.1 mM in MQH20, adjusted to pH 
to 7.2-7.4) at 37°C in 5% CO2 for 1 minute. 5mL of R10 media (RPMI 1640 media containing 
10% FBS, 2 mM L-glutamine, 50 μM β-mercaptoethanol, 1 mM sodium pyruvate, 10 mM 
HEPES buffer, pen/strep) was added to the suspension to stop the reaction, followed by two 
washes in R10 media. These samples were assayed immediately after the last wash for T cell 
responses. 
2.2.6 Immunological Assays 
Immunological assays were performed to determine the levels of immune responses induced in 
mice vaccinated with DNA. 
2.2.6.1 Enzyme-linked immunosorbent assay (ELISA) 
ELISA was performed to determine antibody responses against HCV E1 and E2 proteins. High 
protein binding 96 well plates were coated with 2μg affinity purified E1E2 proteins (section 
2.2.3.1) by incubation overnight at 4°C. The plates were washed with PBS and blocked with 
2.5% BSA/PBS for 2 hours at 37°C. The plates were washed with PBS, mouse sera from 
vaccinated animals, diluted in 2.5% BSA/PBS, were added and the plates were incubated for 4 
hours at 37°C or overnight at 4°C. Pre-vaccination mice sera were used as negative controls. 
The plates were washed with 0.01% Tween 20 in PBS (PBS-T), and a polyclonal HRP-
conjugated goat anti-mouse immunoglobulin antibody (Invitrogen) diluted 1: 3,000 in 2.5% 
BSA/PBS was added. The plates were incubated for 1 hour at 37°C, washed with PBS-T, and 
developed using 1-Step™ Ultra TMB-ELISA substrate (ThermoFisher Scientific). The plates 
were left for approximately 5 minutes at RT in the dark, and colour development was then 
stopped by adding 2.5M HCl. Absorbance at 450 nm was determined on a FLUOstar OPTIMA 
plate reader (BMG LabTech). Endpoint titres were determined as the reciprocal of the highest 
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serum sample dilution with an OD reading above the cut-off, set as 2 standard deviations (SD) 
above the mean OD of serum samples from pre-vaccinated- or naïve- mice. 
2.2.6.2 Interferon gamma (IFN-γ) enzyme-linked immunosorbent spot (ELISPOT) assay 
The frequency of IFN-γ secreting T cells was measured (section 2.2.5.3b) by performing an 
ELISPOT Assay. Multiscreen-IP filter plates (Millipore) were coated with anti-IFN-γ 
antibodies (clone AN18; MabTech, Thomastown, Victoria, Australia) at 5 μg/ml and incubated 
overnight at 4°C. The plates were washed and blocked with R10 for 2 hours at 37°C. Red blood 
cell depleted splenocytes were added to duplicate wells at 5 × 105 cells per well and stimulated 
with 4 μg/ml of either HCV core, E1 or E2 peptides (HCV type 1b J4 Peptides, core catalogue 
number: NR3737, E1 catalogue number: NR3738, E2 catalogue number: NR3739, provided by 
BEI Resources, NIAID, Bethesda, MD) for 36 hours at 37°C. The core and E1 peptides 
consisted of one pool each containing 28 peptides. The E2 peptides were divided into 2 pools 
containing 28 (peptide 1 to 28) and 27 (peptide 29 to 55) peptides (referred to as E2 pool 1 and 
E2 pool 2 respectively). The addition of phytohemagglutinin (PHA) represented a positive 
control and R10 media alone represented the negative control. Anti-mouse IFNγ-biotin (clone 
R4-6A2; MabTech) was added for 2 hours at RT in the dark. Plates were then incubated with 
streptavidin-alkaline phosphatase (Sigma Aldrich) for 1 hour at RT in the dark. Spots were 
formed by the addition of BSigmaFast CIP/NBT (Sigma) and left to develop in the dark for up 
to 30 minutes. The plates were allowed to dry, and were read on an AID EliSpot Reader 
(Autoimmun Diagnostika) and analysed using the AID EliSpot software (Autoimmun 
Diagnostika). The average number of spots (spot forming units; SFU) from the negative control 
was subtracted from each stimulated sample and the data adjusted to SFU/106 splenocytes. 
2.2.6.3 Intracellular cytokine staining 
Multicolor intracellular cytokine staining (ICS) was performed to analyse immune responses in 
the spleen (section 2.8.3.1) of vaccinated mice. 4×106 cells were incubated with R10 alone or 
stimulated with 4 µg/ml HCV core, E1 and E2 peptides and incubated with 3 μg/ml protein 
transport inhibitor (Brefeldin A) or 0.7µl/ml GolgiStop (BD Biosciences) for 12 hours at 37°C. 
The cells were then washed and stained with surface marker antibodies; CD4-BV510 
(eBioscience), CD8-APCe780 and CD44-APC. The cells were then fixed/permeabilised using 
fluorescence-activated cell sorting (FACS) Cytofix/Cytoperm (BD Biosciences) and stained 
with the intracellular antibodies; IL-2-PerCP-Cy5.5, TNF-α-PE, IL4-BV421 and IFN-γ-FITC. 
The cells were resuspended in 5 % FCS/PBS and analysed immediately. After processing, 
samples were acquired on a BD FACSCanto II flow cytometer and analysed using FlowJo 
software (Treestar Incorporated). Analysis was performed by subtracting the background in the 
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unstimulated splenocytes from the frequency in the peptide-stimulated samples. 
Phytohaemagglutinin (PHA) was used as a positive control for cytokine producing T cells.  
Lymphocyte were gated based on their forward scatter-area (FSC-A) and side scatter-area 
(SSC-A) characteristics. Single events within lymphocytes gate were then gated based on their 
FSC-A and FSC-H (forward-scatter-height) linear relationship. Single-colour labelled cells 
were used as control for adjusting compensation for multi-colour analysis. In all cases, positive 
gates were drawn relative to fluorescence minus one controls (FMO). At least 500,000 events 
were acquired for each sample. 
2.2.6.4 inhibition of binding of HCV VLPs toHuh7 cells by immunized mice sera 
The inhibition of binding assay was performed as previously described [420, 421]. Briefly, 
50ng HCV-VLPs of genotype 1b were labelled with FITC. The labelled VLPs were pre-
incubated with different dilutions of serum (1:50, 1:20 and 1:10) for 1 hour at 37°C and the 
complex was allowed to bind to Huh 7 cells for 3 hours at RT. Cell-bound fluorescence was 
analysed using FACS calibur flow cytometer (BectonDickinson) using Winmdi II software to 
calculate the mean fluorescence intensity (MFI) of the cell population, which directly relates to 
the surface density of Alexa-labelled HCV-LPs bound to hepatocytes. The MFI values of cells 
with or without HCV-LPs were compared and percentage binding was determined as per 
following equation: 
%binding of VLP to Huh7 cells =
experimental MFI − negative control(only cells) MFI
positive control MFI − negative control(only cells) MFI
× 100 
2.2.6.5 Mapping of antibody epitopes by peptide ELISA.  
Epitope mapping was done using a series of overlapping peptides covering the E1E2 region of 
the HCV isolate J4 sequence. The peptides consisted of 18-mers with an overlap of 11 amino 
acids covering the E1 or E2 HCV glycoprotein region (BEI Resources, NIAID, Bethesda, MD). 
Briefly, plates were coated with 5μg/ml of peptide, blocked with 4% BSA/PBS, and incubated 
with sera for 4 hours and binding was detected in an ELISA format as described above in section 
2.2.6.1. 
2.2.6.6 HCV competition ELISA 
ELISA plates were coated with E1E2 recombinant proteins as described in section 2.2.6.1. 
Pooled serum from vaccinated mice was diluted (1/50) and then added to the wells and 
incubated for 1 hour at 37°C. Monoclonal antibodies were then added to the same well at a 
concentration resulting in 70% maximal binding to E1E2, as determined in prior titration 
experiments, and incubated at 37°C for 3 hours. Binding of the MAbs was detected with anti-
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human HRP-conjugated secondary antibodies. Percentage reduction in absorbance of the 
monoclonal antibodies was calculated and plotted as % competition.  
2.2.7 Statistical analyses 
Data presented as mean ± SEM were generated with GraphPad Prism version 6 (GraphPad 
Software). Statistical significance was determined using the non-parametric Mann-Whitney U 
test; with a value of p<0.05 denoted by *, p<0.01 denoted by ** and p < 0.001 denoted by ***. 



















Chapter 3. Construction and immunogenicity of DNA vaccines 
encoding HCV-core, E1, E2 and perforin 
3.1 Introduction 
Despite the development of potent antiviral drugs, HCV remains a major health problem as 
approximately 200 million people worldwide are persistently infected [80]. Although the virus 
persists in a majority of patients, at least 20-30% of patients clear the virus spontaneously, 
suggesting that immunity to HCV can develop and that the development of a vaccine may be 
an achievable goal. 
Most vaccines currently approved for use in humans rely on the induction of NAbs to prevent 
or limit infection. Recent studies have suggested that NAbs play an important role in controlling 
HCV infection as induction of NAb correlate with HCV clearance during infection [129, 422]. 
NAbs typically recognize tertiary and quaternary structures [423] and therefore a vaccine 
platform aimed at inducing NAbs require expression of the target proteins, often envelope 
proteins, in their correct conformation. Several approaches to HCV vaccine development to 
elicit NAb have been studied and include DNA vaccines. In recent years, novel DNA-based 
vaccine formulations, which include expression of virus-like particles (VLPs), have also 
generated promising outcomes. VLPs are attractive candidate to elicit NAbs because they 
structurally resemble the wildtype virus from which they are derived but are much safer. They 
offer the opportunity to display envelope proteins in their native surface conformation. VLPs 
displaying HCV envelope proteins have been reported to induce cross NAb in an animal model 
[146]. Furthermore, immunisation with plasmid DNA-forming (plasmo-retro) VLPs 
pseudotyped with HCV E1 and E2 proteins has been shown to induce both humoral and cellular 
immune responses in mice [424]. 
Despite the many advantages associated with the use of DNA vaccines, to date no DNA 
vaccines are approved for use in humans, mainly attributed to the lack of potent 
immunogenicity in humans [266]. Various forms of adjuvant have been used to increase the 
immunogenicity of vaccines in general and the use of a genetically encoded adjuvant might be 
beneficial in a DNA vaccine strategy. Following necrotic cell death, activation of the innate 
immune system induces inflammation in response to DAMPs released by the dying cells and 
also alerts the adaptive immune system to potential danger. Dendritic cells (DCs) [266] are 
central to this process as they are able to cross-present exogenous proteins and activate naïve 
CD8+ T cells. Therefore, inducing necrotic or lytic cell death in antigen-positive cell in vivo 
would result in the expression and/or release of DAMPs and represent an attractive adjuvant 
candidate for a DNA vaccine. To date only a few studies have investigated the use of this 
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mechanism to enhance the immune response to vaccines [383-387]. A DNA construct encoding 
Listeriolysin O fused to SIV gag was used to enhance immunogenicity to the vaccine [409]. 
Other studies have focused on the use of molecules such as Fas [410], and caspases 2 and 3 
[381] to induce cell death. The Gowans laboratory has previously shown that targeted killing 
of viral antigen-positive cells using DNA vaccines that also encode perforin (PRF), a cytolytic 
mediator that disrupts cellular membrane to result in cell death, resulted in improved 
immunogenicity of the vaccines [414, 416-418]. These results suggest that the use of cytolytic 
proteins represents an effective mechanism to induce inflammation and activate DCs which are 
crucial for the activation of the adaptive immune response to vaccine antigens [89, 415, 425]. 
More importantly, this mechanism may be used to induce lytic cell death which would result in 
the release of intracellular VLPs, thereby, combining the immunogenicity of VLPs with the 
ease of production of plasmid DNA. 
 3.2 Aims 
The aims of this chapter were to:  
1. Construct cytolytic DNA vaccines encoding the HCV structural proteins core, E1 and 
E2 as well the cytolytic protein, perforin.  
2. Examine protein expression and VLP formation from these constructs in vitro.  
3. Assess the immunogenicity of these vaccine candidates in mice. 
3.3 Results 
3.3.1 DNA Vaccine formulation 
All the DNA vaccines constructs were formulated based on a bicistronic vector (pJ) that was 
produced by modifying the commercially available plasmid, pVAX1 (Life Technologies). 
pVAX1 contains a constitutive cytomegalovirus (CMV) promoter, a multiple cloning site [426] 
and the bovine growth hormone (BGH) polyadenylation site. To produce the bicistronic pJ 
vector, pVAX1 was modified to include a second promoter from Simian Virus 40 (SV40), a 
novel MCS and the SV40 polyadenylation site (SV40 pA) [416, 425]. The genes encoding the 
HCV proteins core, E1 and E2 were cloned under the control of the CMV promoter while the 
PRF gene was inserted downstream of the SV40 promoter, which is estimated to be 10-fold 
weaker in terms of driving gene expression compared to the CMV promoter [415, 427]. This 
strategy (Figure 3.1) was designed to express reduced levels of PRF relative to HCV structural 
proteins expressed from the CMV promoter and therefore provide an optimum combination of 
antigen and cytolytic protein expression, as intracellular VLPs resulting from expression of 
core, E1 and E2 are expected to be produced before the threshold of PRF expression required 





























Figure 3.1. The strategy used to insert the HCV-CE1E2 gene downstream of the CMV 
promoter to produce (A) p-CE1E2-PRF and (B) p-CE1E2-PRF(DA). The numbering 
corresponds to the amino acid position in the polyprotein of the genotype 1 HCV strain. DNA plasmid 
sizes are shown in brackets. 
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3.3.2 Production of the DNA vaccine constructs 
For effective target cell death, a truncated version of PRF with a 12 amino acid deletion at the 
C terminus (referred to as PRF in this chapter for simplicity) was used [428]. This mutation 
resulted in PRF retention in the ER and the induction of cell death. PRF is required to bind to 
calcium in order to oligomerize and form pores in the cellular membrane, resulting in cell lysis. 
A D483A mutation in the key calcium binding residue has been shown to result in loss of PRF 
cytolytic ability by preventing PRF pore formation and therefore allow the cell to survive [89, 
428]. Consequently, as controls for PRF-induced cell lysis, constructs encoding this mutant 
version of PRF, referred to in this chapter as PRF(DA), were generated.  
3.3.2.1 Construction of p-CE1E2-PRF and p-CE1E2-PRF(DA) 
Codon-optimised genes encoding the HCV structural proteins (GenBank accession number 
AF139594.2) were generated by subjecting the sequence to the GeneOptimizer bioinformatic 
algorithm, followed by synthesis of the codon-optimized genes (GeneArt, Regensburg, 
Germany). The genes were codon optimised for expression in mammalian cells, contained a 
Kozak sequence, and start and stop codons. The synthesised genes were used as template to 
generate DNA products encoding CE1E2 by PCR, using primers Core fwd and E2 rev 
(appendix I) containing the NheI and EcoRI restriction sites respectively. The PCR products 
were analysed by gel electrophoresis to detect the amplified fragments (Fig. 3.2A). A plasmid 
encoding Luciferase and PRF (p-Luc-PRF – Fig. 3.1A) was similarly digested to facilitate 
ligation. The ~5.5kb band corresponding to p-CMV-SV40-PRF or p-CMV-SV40-PRF(DA) 
was excised from the gel and the DNA was extracted as described in Chapter 2 – section 2.2.2.6, 
followed by ligation and transformation into E. coli (DH5α) cells. Positive clones were 
identified by colony PCR using the primer pair Core-fwd and E2-rev (Fig. 3.2C) and further 
analysed in a series of restriction enzyme digestion studies (Fig. 3.2D). The orientation of the 
CE1E2 genes was not a concern since two different restriction enzyme sites were used for 
cloning (directional cloning). The correct sequences of the positive clones were confirmed by 
DNA sequencing.  Constructs encoding the core protein alone or the E1E2 envelope proteins 
as a single polyprotein were produced to assess the formation of VLP by p-CMV-SV40-PRF, 
as these proteins are not expected to self-assemble into VLPs when expressed separately [429]. 
These control constructs also encoded either PRF or PRF(DA). The strategy used to produce 
these constructs is described in chapter 2 – section 2.2.2. A complete catalogue of plasmid maps 































Figure 3.2. The production of p-CMV-CE1E2-SV40-PRF. A) Gel electrophoresis analysis of 
the HCV-CE1E2 gene amplified by PCR. B) The digestion of HCV-CE1E2 and p-Luc-PRF with 
NheI and EcoRI restriction enzymes. C) Random colonies, lane 1 and 2, were picked from agar 
plates and colony PCR was performed to identify positive clones. The colony PCR products were 
analysed by gel electrophoresis analysis on a 0.8% agarose gel. D) Restriction enzyme digestion 





















3.3.3 HCV structural protein expression from DNA vaccine constructs 
Prior to vaccination studies, it was necessary to confirm protein expression from the DNA 
constructs described above. Each construct was transfected into HEK293T before analysis by 
western blot or immunofluorescence as stated in chapter 2 – section 2.2.3. 
3.3.3.1 Detection of HCV structural proteins 
SDS-PAGE analysis of lysates of HEK293T cells followed by immunoblot analysis (western 
blot) was performed to detect HCV-core, E1 or E2 proteins expressed in cells transfected with 
the DNA constructs p-Core-PRF, p-Core-PRF(DA), p-E1E2-PRF p-E1E2-PRF(DA), p-
CE1E2-PRF or p-CE1E2-PRF(DA).  
Figure 3.3. Plasmid maps of DNA constructs used in this chapter. A) DNA plasmids produced 
by inserting core into the pJ-SV40-PRF or pJ-SV40-PRF(DA) constructs. B) DNA vaccine 
constructs produced by inserting E1E2 into the pJ-SV40-PRF or pJ-SV40-PRF(DA) constructs. C) 
DNA plasmids encoding HCV-CE1E2 and PRF or PRF(DA) generated to compare the levels of 
VLP formation and release. The numbering corresponds to the amino acid position in the HCV 
polyprotein. DNA plasmid sizes are shown in brackets. 
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Immunoblotting with anti-core antibodies revealed an expected band of approximately 21 kDa 
in lysates of cells transfected with p-CE1E2-PRF, p-CE1E2-PRF(DA), p-Core-PRF, p-Core-
PRF(DA) (Fig. 3.4A). No bands were detected in cell lysates of untransfected cells, cells 
transfected with pVax, p-E1E2-PRF or p- E1E2-PRF(DA) (Fig. 3.4A). Equal loading was 























Figure 3.4. Expression of HCV structural proteins from the DNA vaccines. HEK293T cells 
were transfected with p-Core-PRF, p-Core-PRF(DA), p-E1E2-PRF, p-E1E2-PRF(DA), p-CE1E2-
PRF or p-CE1E2-PRF(DA). At 72 hours post transfection, the cells were lysed as described in 
chapter 2 – section 2.2.3. The cell lysates were then subjected to SDS-PAGE and immunoblotting 
(IB) with anti-core (A) anti-E1 (B) or anti-E2 (C) antibodies. Molecular masses (in kilodaltons) of 
protein molecular weight (MW) markers are indicated on the left; HCV-specific proteins are 
indicated on the right. The untransfected cells and pVax-transfected cells represent controls for 
non-specific bands, and the β-actin acted as a loading control. 
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Cell lysates were also analysed for expression of E1 (Fig. 3.4B) and E2 (Fig. 3.4C). The blots 
stained with anti-HCV E1 showed a band of ~35kD corresponding to E1 (Fig. 3.4B), while 
anti-HCV E2 revealed a band of ~66kD corresponding to E2 (Fig. 3.4C), in the lysate of cells 
transfected with p-CE1E2-PRF, p-CE1E2-PRF(DA), p-E1E2-PRF or p-E1E2-PRF(DA). No 
bands corresponding to E1 or E2 were detected in samples from untransfected cell controls, or 
pVax, p-Core-PRF or p-Core-PRF(DA) transfected cells (Fig. 3.4B).  
For completeness, the expression of the HCV structural proteins in HEK293T cells transfected 
with the DNA vaccine constructs was also demonstrated by immunofluorescence analysis using 
anti-HCV core, or E1/E2 antibodies in addition to anti-HCV serum from HCV-infected patients 
(Fig. 3.5 and Fig. 3.6) as described in Chapter 2 – section 2.2.3.4. After staining with anti-core 
antibodies, fluorescence staining was observed in cells transfected with p-Core-PRF, p- Core-
PRF(DA), p-CE1E2-PRF or p-CE1E2-PRF(DA) (Fig. 3.5). No core-specific fluorescence 
staining was detected in cells transfected with pVax, or in cells transfected with pVAX-GFP 
(results not shown), pVax, p-E1E2-PRF or p-E1E2-PRF(DA). 
HEK293T cells were stained with anti-HCV-E1 or anti-HCV-E2 antibodies and 
immunofluorescence staining was observed in the cells transfected with p-E1E2-PRF, p-E1E2-
PRF(DA), p-CE1E2-PRF or p-CE1E2-PRF(DA). No fluorescence was observed in cells 
transfected with pVax, p-Core-PRF, p-Core-PRF(DA) (Fig. 3.5 – middle and right panels) as 
expected. The immunostaining analysis also revealed that the expression of HCV structural 
proteins was mostly confined to the cytoplasm and plasma membrane. 
3.3.4 Expression of perforin from vaccine constructs 
3.3.4.1 Perforin expression  
Each of the DNA constructs described above encoded either PRF or the control PRF(DA) in 
addition to the immunogen and therefore it was necessary to confirm PRF expression. 
HEK293T cells were transfected with the DNA constructs and incubated for 48 hours post 
transfection. PRF expression was detected by immunofluorescence as described in Chapter 2 – 
section 2.2.3.4, using anti-PRF antibodies and anti-HCV (pooled HCV genotype 1b patient 
sera). The results of this experiment showed that PRF was expressed in the cells transfected 
with DNA construct encoding PRF or PRF(DA) and more importantly in cells transfected with 
the vaccine constructs p-CE1E2-PRF and p-CE1E2-PRF(DA) (Fig. 3.6) and in cells transfected 
with a construct in which PRF expression was controlled by the stronger CMV promoter (p-
CMV-PRF). This not only served as a positive control for PRF expression (Fig. 3.6) but also as 
a positive control for PRF-induced cell lysis (Fig. 3.7). PRF expression was not observed in 
cells transfected with pVax or the untransfected cell controls (data not shown). As expected the 
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levels of PRF expression (evident by fluorescence intensity) were higher in cells transfected 
with p-CMV-PRF. The results also showed that the expression of PRF correlated with the 
expression of the HCV proteins (Fig. 3.6), confirming that these are co-expressed with PRF in 
























Figure 3.5. Immunofluorescence of HCV structural proteins expressed in HEK293T cells. 
Fluorescence micrograph after transfection of HEK293T cells with p-Core-PRF, p-Core-
PRF(DA), p-E1E2-PRF, p-E1E2-PRF(DA), p-CE1E2-PRF or p-CE1E2-PRF(DA). At 48 hours 
post-transfection, the cells were fixed and processed as described in chapter 2 – section 2.2.3.4. 
Protein expression was analysed with anti-core, anti-E1 or anti-E2 antibodies. Cells transfected 





























Figure 3.6. Immunofluorescence of HCV structural proteins and perforin expression in 
HEK293T cells. Fluorescence micrograph after transfection of HEK293T cells with pVax, pJ-Core-
PRF, pJ-Core-PRF(DA), pJ-E1E2-PRF, pJ-E1E2-PRF(DA), pJ-CE1E2-PRF, pJ-CE1E2-PRF(DA) 
or p-CMV-PRF(DA). 72 hours post transfection, the cells were fixed/permeabilised and probed with 
anti-HCV (pooled HCV genotype1 patient sera, green), anti-PRF (red) and DAPI staining for 
nuclei (blue). p-CMV-PRF(DA) served as positive control for PRF expression and cells transfected 
with pVax were used as background control. Fluorescence was observed using a ZEISS LSM 700 
microscope (magnification: 400×).  
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3.3.4.2 Assessment of perforin cytolytic activity 
The cytolytic activity of PRF was investigated by monitoring lactate dehydrogenase [430] [430] 
released from cells transfected with the vaccine constructs. In this assay, the LDH remains 
intracellular in viable or apoptotic cells but is released into the extracellular milieu if the cell 
dies in a lytic or necrotic manner. LDH was assayed as described in chapter 2 – section 2.2.3.7.  
Cells transfected with the control p-CMV-PRF released a significantly higher (44.8% relative 
to maximum release control) level of LDH compared to the apoptosis-inducing doxorubicin 
(4.5%) (Fig. 3.7). p-CE1E2-PRF transfection resulted in the release of LDH similar to that of 
the positive control (36.6%). Cells transfected with p-CE1E2-PRF(DA) did not result in 
significant LDH release above the negative controls pVax (16.2% and 16.5% respectively – 
Fig. 3.7). Collectively, these results demonstrate that PRF expression results in cell membrane 

















Figure 3.7. LDH release following transfection of HEK293T cells with VLP vaccine 
constructs. HEK293T cells were transfected with VLP vaccine constructs and 72hr P.T the 
supernatant was collected and LDH release was analysed. Cells transfected with p-CMV-PRF 
served as positive control for PRF lytic activity. Cells treated with Doxorubicin which induces 
apoptosis served as negative controls for LDH release. The percentage cytotoxicity was 
calculated by subtracting the LDH activity of the untreated normal cells (Spontaneous LDH 
Release) control from the LDH activity of transfected cells, divided by the total LDH activity 
[(maximum LDH release control activity) – (spontaneous LDH release control activity)], and 
multiplied by 100.  Data pooled from 2 independent experiments showing the mean (n = 6) ± 
SEM. Mann-Whitney non-parametric t-test was performed where appropriate. Significance 
tested against p-CE1E2-PRF(DA) control. * P ≤ 0.05, ** P ≤ 0.01. 
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3.3.5 HCV-VLP formation from DNA constructs 
3.3.5.1 Co-immunoprecipitation of Core and E2 proteins 
VLPs are typically purified using methods such as sucrose or caesium chloride gradient 
ultracentrifugation [431]. In this chapter, the expression of VLPs was assessed as described 
previously using iodixanol gradient ultracentrifugation [420, 421] (chapter 2 – section 2.2.4.2). 
Briefly, HEK293T were transfected with p-CE1E2-PRF or p-CE1E2-PRF(DA) as these 
constructs are expected to result in the expression and formation of VLPs. 48 hours post 
transfection, the cell culture medium was collected and concentrated while the cells were lysed 
using the freeze-thaw method. The concentrated cell culture medium or cell lysis supernatant 
were layered on to a 10 – 40% continuous iodixanol gradient and centrifuged at 16o C for 16 h 
at 25 000 rpm in an SW40 rotor followed by the collection of 12 fractions. However, proteins 
were present at low concentrations in each of the collected fractions, which made their recovery 
difficult, subsequently, hampering the assessment of formed particles by western immunoblot 
analysis. 
Alternatively, to determine whether the HCV proteins expressed from the vaccine constructs 
were capable of assembling into VLPs, the association of the core and E2 proteins was 
investigated. HEK293T cells were transfected with p-CE1E2-PRF or p-CE1E2-PRF(DA) and 
lysed using the freeze-thaw method to allow assessment of VLP formation from both constructs 
as PRF(DA) does not induce cell death. The cell culture medium was also collected and 
concentrated. The protein in the lysates (Fig. 3A & B) and cell culture medium (Fig. 3C & D) 
was subjected to immunoprecipitation (IP) with anti-E2, anti-core antibodies or normal human 
serum (NHS). The immunoprecipitated proteins were in turn subjected to SDS-PAGE and 
immunoblotting (IB) with anti-core or anti-E2 antibodies. Bands of approximately 50 kDa and 
26 kDa in size were detected during IB, corresponding, respectively, to the heavy (HC) and 
light (LC) IgG chains of the antibodies used for immunoprecipitation. Immunoprecipitation with 
anti-E2 resulted in the detection of core and E2 in the immunoprecipitated complexes when 
probed with anti-core (Fig. 3.8A & C, left panels) or anti-E2 (Fig. 3.8B & D, left panels) 
antibodies respectively, consistent with immunoprecipation of a VLP. Bands from concentrated 
supernatants generally showed a weaker signal compared to cell lysates due to low protein 
recovery. As expected, core and E2 bands were more pronounced in immunoprecipitated 
samples from the supernatant of p-CE1E2-PRF transfected cells compared to p-CE1E2-
PRF(DA) (Fig 3.8C &D – left panels). Only a faint band corresponding to the core protein was 
detected when anti-core immunoprecipitated complexes were probed with anti-core antibodies 
(Fig. 3.8A, middle panel). This was possibly a result of free core protein that is detectable in 
the supernatant and not part of VLP. No bands specific to either core or E2 were detected in 
87 
 
anti-core immunoprecipitated samples probed with anti-E2 (Fig. 3.8B & D, middle panels) or 
in samples immunoprecipitated with normal human serum (Fig. 3.8A-D, right panels). These 
results revealed the coimmunoprecipitation of core and E2 with anti-E2 consistent with the 



































3.3.6 Immunisation of mice with cytolytic DNA vaccine 
3.3.6.1 Vaccination schedule 
In order to evaluate the potential efficacy of the p-CE1E2-PRF and p-CE1E2-PRF(DA) 
plasmids as DNA vaccines, BALB/c mice were injected intradermally (in the ear pinnae) with 
50μg of the respective plasmid, followed by 5 booster injections at 2 weekly intervals (Fig. 3.9). 
Blood samples were collected (retro-orbital bleed) two days prior to each vaccination and 








3.3.6.2 Induction of HCV specific humoral response by CE1E2-PRF 
3.3.6.2.1 Purification of HCV-E1E2 protein for use in ELISA 
The HCV envelope proteins were expressed in HEK293T following transfection with the p-
tPAtE1tE2-histag construct (Fig. 3.10A), purified then used to coat ELISA plates to evaluate 
the levels of antibody titres in vaccinated mice. The development of the p-tPAtE1tE2 construct 
and the expression and purification of the 6×His-tagged E1E2 protein is described in more 
Figure 3.8. Coimmunoprecipitation of HCV structural proteins in HEK293T cells. HEK293T 
cells were transfected with (lane 2) p-CE1E2-PRF(DA) or (lane 3) p-CE1E2-SV40-PRF. 36 hours 
post-transfection, the cells were lysed and the cell-culture media was collected and concentrated by 
ultrafiltration through a 70,000-molecular-weight cutoff filter (70K MWCO; Amicon). The (A&B) 
cell lysates and (C&D) supernatant samples were subjected to immunoprecipitation (IP) with an anti-
core, anti-E2 antibodies or normal human serum as indicated. The immunoprecipitated proteins were 
subjected to SDS-PAGE and immunoblotted (IB) with anti-core (A&C) or anti-E2 antibodies (B&D) 
as indicated. Untransfected cells (lane 1) were used as control for non-specific banding. Molecular 
masses (in kilodaltons) of protein molecular weight (MW) markers are indicated on the left; HCV-
specific proteins are indicated on the right in red. The heavy chain (HC) and light chain (LC) of the 
antibodies used for immunoprecipitation are indicated on the right. 
Figure 3.9. The DNA vaccination regimen in 6-8 weeks old female Balb/C mice. The mice were 
vaccinated six times at two weekly intervals with 50μg DNA.  Blood was collected prior to each 




detail in Chapter 2 - section 2.2.3.1, and chapter 4 – section 4.3.1. To confirm the identity of 
the purified recombinant protein, a western blot was performed using anti-HCV (genotype 1b 
HCV-positive human serum). The results clearly demonstrated a band at ~60 kDa in elution 1 
and 2 from the nickel column but not in the flowthrough (Fig. 3.10B). Therefore, this ~60 kDa 
protein was used for coating ELISA plates to evaluate E1 and E2-specific antibodies. 
 
3.3.6.2.2. Detection of HCV-envelope-specific antibodies 
The serum levels of anti-E1E2 antibodies were monitored by ELISA following each 
vaccination and recorded as positive if they were two standard deviations above the mean titre 
in pVax-vaccinated mice. The results showed that vaccination with p-CE1E2-PRF resulted in 
the highest anti-E1E2 antibody levels while the antibody response peaked and reached a plateau 
following the 4th booster vaccination (Fig. 3.11A). The antibody titres were also measured 14 
days following the last vaccination. All p-CE1E2-PRF vaccinated mice showed a significant 
anti-E1E2 response with end-point titres ranging from 1/20 to 1/63.2 (Fig. 3.11B), while p-
Figure 3.10. Expression and purification of secreted HCV-E1E2 protein determined by 
western blot analysis. A) Schematic of DNA construct encoding secreted E1E2 protein showing 
the location of the CMV promoter, the tPA leader sequence E1 and E2 proteins and the C-terminal 
poly-His tag. B) HEK293T cells were transfected with p-tPAtE1tE2-Histag. At 48 hours post 
transfection, cell culture supernatants containing secreted glycoproteins were filtered, 
concentrated, affinity purified, and then subjected to the SDS-PAGE and western blotting as 
described in chapter 2 – section 2.2.3.3, before detection with anti-HCV antibody. Markers are 
shown on the left.  
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3.3.6.3. Induction of HCV-specific cell mediated response by CE1E2-PRF 
The cell-mediated immune response to core, E1 and E2 following vaccination with p-CE1E2-
PRF or p-CE1E2-PRF, was initially assessed by ELISPOT to detect IFNγ-secreting cells in the 
mouse spleen. Splenocytes were harvested from the vaccinated mice two weeks after the last 
immunization and were stimulated with genotype 1b core, E1 and E2 peptides in vitro as stated 
in chapter 2 section 2.2.6.2. The number of IFN-γ-secreting T-cells was determined by counting 
spot-forming units (SFUs) in an ELISpot assay. 
 
Figure 3.11. Induction of anti-E1 and anti-E2 antibodies by p-CE1E2-PRF and p-CE1E2-
PRF(DA) in mice. A) Serum antibody response specific for HCV E1E2 proteins. Serum from 
vaccinated mice was diluted (1/50) and anti-E1E2-specific antibodies were measured by ELISA at the 
indicated time points. Values represent mean responses in each group (n = 7) ± SEM.  Black arrows 
represent points when the vaccines were administered. B) Two weeks after the final immunisation, 
serum from individual mice was serially diluted, and endpoint binding titers for immunised mouse 
sera were calculated. Values for individual mice are shown (n = 7) and bars represent the mean ± SEM. 
Mann-Whitney non-parametric t-test was performed to assess significant p-values between the 
vaccinated groups, **p ≤ 0.01, ***p ≤ 0.001. The data were derived from three independent 
experiments performed in duplicate. Positive results were determined by values greater than two 





























Figure 3.12. HCV-specific IFN-γ production by splenocytes determined by ELISPOT. Mice 
were vaccinated 7 times at 2 weekly intervals with 50μg doses of DNA. The spleens were harvested 
14 days post final vaccination and the splenocytes were stipulated with core, E1 or E2 pool 1 or E2 
pool 2 peptide pools. The graphs show IFNγ T cell responses to core (A), E1 (B) and E2 pool 1 
(C) and E2 pool 2 (D) in mice vaccinated with pVax, p-CE1E2-PRF or p-CE1E2-PRF(DA). The 
number of IFNγ secreting T cells was adjusted to spot forming units (SFU) per 106 cells. The 
number of SFU in unstimulated splenocytes was subtracted from the number in peptide-stimulated 
cells to generate the net HCV response. Data are plotted from 4-7 individual mice per group, 
showing the mean SFU (±SEM). Mann-Whitney non-parametric t-test was performed. Significance 
tested against p-CE1E2-PRF(DA) control. Note that the Y-axes may differ 
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As shown in figure 3.12, although the responses were generally poor, mice vaccinated with p-
CE1E2-PRF showed significant numbers of IFN-γ-secreting T-cells (p-value = 0.0268) 
following stimulation with E2-peptide pool 2 compared to p-CE1E2-PRD(DA)-immunised 
mice (Fig. 3.12D). Although IFNγ SFUs were consistently higher in p-CE1E2-PRF-vaccinated 
mice, as opposed to p-CE1E2-PRD(DA)-vaccinated mice, following stimulation with core (Fig. 
3.12A), E1 (Fig 3.12B) and E2 peptide pool 1 (Fig 3.12C), these differences were not 
statistically significant. As expected, the control mice vaccinated with pVax failed to generate 
any IFNγ-positive cells against each of the peptide pools (Fig. 3.12).  
To examine the cell mediated response more quantitatively, ICS was performed on splenocytes 
from the immunised mice to analyse intracellular cytokine production at the level of a single 
cell to identify single, double, triple or quadruple cytokine-producing T cells. In chronic HCV 
infections, such multifunctional T cells have been associated with protective immune responses 
[432]. Splenocytes isolated from vaccinated mice at week 12 were stimulated in vitro with core, 
E1 or E2-derived peptides and stained for surface and intracellular markers (Chapter 2 section 
2.2.6.4).  
The splenocytes were analysed using forward/side scatter and gated on the lymphocyte 
population. Single events within the lymphocytes gate were then gated based on their FSC-A 
and FSC-H (forward-scatter-height) linear relationship. Single events were gated on the CD44 
marker to identify activated memory lymphocytes and then on CD4 and CD8 surface markers 
(Fig. 3.13A). The frequencies of CD4+ or CD8+ T cells secreting IL2, IFNγ or TNFα, Th1-
associated cytokines previously identified as important in control of HCV infection, were then 
assessed. The frequency of IL4 was also assessed as a marker of a Th2-like cellular immune 
response (Fig 3.13B). 
When stimulated with core peptides, the frequency of cytokine-producing T cells was highest 
in p-CE1E2-PRF vaccinated mice. The frequency of single cytokine-producing T cells peaked 
at 1.8% for INFγ producing CD4+ T cells (Fig. 3.14A) and 2.2% for CD8+ T cells (Fig. 3.14E), 
while the frequency of double cytokine-producing T cells peaked at 0.12% for TNFα/IFN-γ 
producing CD4+ T cells (Fig. 3.14B) and 0.065% for TNFα/IFN-γ producing CD8+ T cells 
(Fig. 3.14F). The frequency of triple-cytokine producing T cells peaked at 0.07% for IFN-
γ/IL2/IL4 producing CD4+ T cells (Fig. 3.14C) and 0.013% for CD8+ T cells (Fig. 3.14G). The 
frequency of TNFα/IFN-γ/IL2/IL4 producing T cells reached 0.003% for CD4+ T cells (Fig. 
3.14D) and 0.002% for CD8+ T cells (Fig. 3.14H) following stimulation with core peptides. 
However, none of these populations reached significance (Fig. 3.14A-H). 
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Following stimulation with E1 peptides, the frequency of cytokine-producing T cells was also 
highest in p-CE1E2-PRF-vaccinated mice. The frequency of single cytokine-producing T cells 
reached 0.4% for INFγ producing CD4+ T cells (Fig. 3.15A) and 0.55% for CD8+ T cells (Fig. 
3.15E). The frequency of double cytokine-producing T cells peaked at 0.05% for TNFα/IFN-γ 
producing CD4+ T cells (Fig. 3.15B) and 0.04% for TNFα/IFN-γ producing CD8+ T cells (Fig. 
3.15F), while the frequency of triple-cytokine producing T cells peaked at 0.022% for IFN-
γ/IL2/IL4 producing CD4+ T cells (Fig. 3.15C) and 0.015% for CD8+ T cells (Fig. 3.15G). The 
frequency of TNFα/IFN-γ/IL2/IL4 producing T cells reached 0.009% for CD4+ T cells (Fig. 
3.15D) and 0.011% for CD8+ T cells (Fig. 3.15H). However, none of these results was 



















Figure 3.13. The frequency of T cell subsets in mice vaccinated with DNA vaccine, as determined 
by flow cytometry. Mice were vaccinated with pVax, p-CE1E2-PRF or p-CE1E2-PRF(DA) seven 
times at two weekly intervals with 50 μg doses and the spleens were collected 14 days later. 
Splenocytes were re-stimulated with core, E1, E2 pool 1 or E2 pool 2 peptides. A) The population 
gating for surface staining by flow cytometry. The splenocytes were initially gated on the lymphocyte 
gate based on the forward/side scatter and CD44+ lymphocytes, and then either on CD8+ or CD4+. B) 
The frequencies of IL2+, IL4+, IFNγ+ or TNFα+ T cells were determined by flow cytometry. The 





Similar results were obtained following stimulation with E2 pool 1 peptides. The frequency of 
single, double, triple and quadruple cytokine-producing CD4+ T cells (Fig. 3.16 A-D) and 
CD8+ T cells (Fig. 3.16 E-H) was slightly higher in p-CE1E2-PRF-vaccinated mice. However, 
these results were not significant. 
Following stimulation with E2 pool 2 peptides there was a trend towards increased frequency 
of cytokine-producing T cells in p-CE1E2-PRF-vaccinated mice compared to those vaccinated 
with p-CE1E2-PRF(DA) (Fig. 3.17). The frequency of single cytokine-producing T cells 
peaked at 0.48% for TNFα producing CD4+ T cells (Fig. 3.17A) and 0.5% for CD8+ T cells 
(Fig. 3.17E). The frequency of double cytokine-producing T cells reached 0.05% for 
TNFα/IFN-γ producing CD4+ T cells (Fig. 3.17B) and 0.03% for TNFα/IFN-γ producing CD8+ 
T cells (Fig. 3.17F). The frequency of triple-cytokine producing T cells peaked at 0.02% for 
IFN-γ/IL2/IL4 producing CD4+ T cells (Fig. 3.17C) and 0.018% for CD8+ T cells (Fig. 3.17G). 
The frequency of TNFα/IFN-γ/IL2/IL4 quadruple producing T cells reached 0.004% for CD4+ 
cells (Fig. 3.17D) and 0.006% for CD8+ cells (Fig. 3.17H) following stimulation with core 
peptides. However, these results were also non-significant (Fig. 3.17A-H). 
In summary, significant IFNγ release was observed in mice vaccinated with p-CE1E2-PRF 
following stimulation with E2 peptide pool 2. Although the highest cytokine levels were 
generally observed in p-CE1E2-PRF-vaccinated mice, compared to other vaccinated groups, 
there was no significant difference in the frequency of HCV-specific CD8 and CD4 T cells 
secreting IL2, IL4, or TNFα after stimulation with core, E1 or E2. Despite these disappointing 




Figure 3.14. The frequency of cytokine producing T cells in mice vaccinated with DNA vaccine 
following stimulation with HCV-core peptides, determined by flow cytometry. 14 days post 
vaccination, splenocytes were re-stimulated with core peptides. The frequency of (A&E) single, (B&F) 
double, (C&G) triple, (D&H) quadruple producing T cells. The results are graphed from between 4-7 




Figure 3.15. The frequency of cytokine producing T cells in mice vaccinated with DNA vaccine 
following stimulation with HCV-E1 peptides, determined by flow cytometry. 14 days post 
vaccination, splenocytes were re-stimulated with E1 peptides. The frequency of (A&E) single, 
(B&F) double, (C&G) triple, (D&H) quadruple producing CD4+ and CD8+ T cells. The results are 




Figure 3.16. The frequency of cytokine producing T cells in mice vaccinated with DNA 
vaccine following stimulation with HCV-E2 pool 1 peptides, determined by flow 
cytometry. 14 days post vaccination, splenocytes were re-stimulated with E2 pool 1 peptides. 
The frequency of (A&E) single, (B&F) double, (C&G) triple, (D&H) quadruple producing 
CD4+ and CD8+ T cells. The results are graphed from between 4-7 individual mice per group 




Figure 3.17. The frequency of cytokine producing T cells in mice vaccinated with DNA 
vaccine following stimulation with HCV-E2 pool 2 peptides, determined by flow cytometry.  
14 days post vaccination, splenocytes were re-stimulated with E2 pool 2 peptides. The frequency 
of (A&E) single, (B&F) double, (C&G) triple, (D&H) quadruple producing CD4+ and CD8+ T 





3.4.1 Generation of DNA vaccine constructs 
The use of a DNA vaccine is an attractive approach to generate antigen-specific immunity to 
various pathogens due to its stability and simplicity of delivery. DNA vaccines also have the 
ability to induce humoral and cell-mediated immune responses. Currently, there is no approved 
DNA vaccine for use in humans mainly due to the lack of potent immunogenicity [266]. HCV-
VLPs pseudotyped with HCV structural proteins have been shown to induce strong neutralising 
and cell mediated immune responses in macaques [146]. Previous studies conducted in our 
laboratory have demonstrated that DNA vaccines adjuvanted with a cytolytic protein, perforin, 
have resulted in increased immune responses to the antigen [414, 415, 418, 425]. Therefore, the 
current chapter aimed to combine the immunogenicity of VLPs and the ease of production of 
plasmid DNA, by designing DNA vaccines expressing VLPs consisting of HCV-core, E1 and 
E2 proteins. The vaccine also encodes PRF to cause necrotic cell death and ensure the release 
of the VLPs from vaccine targeted cells simultaneously with DAMPs, which act as natural 
adjuvants to mimic the highly immunogenic effect of lytic viral infections [414, 415, 418, 425].  
This chapter showed that DNA vaccines encoding Core/E1/E2 expressed from the CMV 
promoter and PRF or PRF(DA) expressed from the weaker SV40 promoter were successfully 
generated. This approach is necessary to ensure intracellular accumulation of HCV-VLPs 
before the threshold of PRF expression required to induce cell lysis (allowing VLP release) is 
reached. 
3.4.2 HCV protein expression from the DNA vaccine constructs 
Vaccine-derived protein expression was detected using HEK293T cells after transfection with 
plasmid DNA. Protein expression was then analysed with anti-core, anti-E1 or anti-E2 
antibodies and bands of approximate molecular weight of ~20kDa, ~35kDa and ~66kDa were 
detected, corresponding to core, E1 and E2 respectively. These results correlated with the 
previously reported molecular weights of core, E1 and E2 [146, 420, 433-438]. The expression 
of these HCV-structural proteins was further confirmed by immunofluorescence analysis using 
core, E1 and E2 antibodies, which were shown to be confined to the cytoplasm and plasma 
membrane consistent with previous observations [437]. Therefore, the vaccine constructs 
generated in this chapter successfully expressed the HCV structural proteins 
3.4.3 Perforin expression and cytolytic activity 
Perforin is a cytolytic protein found in the granules of CTLs destroy target cells mainly through 
a perforin-dependent mechanism [439]. Transfection with the DNA vaccine resulted in 
successful expression of HCV-structural proteins and perforin. The results also showed that 
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perforin and HCV-proteins were found to be co-expressed in the same cells (Fig. 3.6, overlay). 
The cytolytic activity of PRF was assessed using the LDH release assay which demonstrated 
that cells transfected with constructs encoding PRF released significantly higher levels of LDH 
compared with cells transfected with the mutated PRF(DA) which has lost its cytolytic activity 
[440]. Additionally, cells treated with the pro-apoptotic doxorubicin released significantly low 
LDH levels consistent with the finding that PRF-induced cell death is likely to be necrotic rather 
than apoptotic [418]. Overall these results show that perforin induced cell lysis in target cells 
after expression, and in principle this should result in the release of VLPs that assembled 
intracellularly. The results also demonstrated that the mutated PRF(DA) represents an 
appropriate control for PRF-induced cell lysis and thus should serve as a control for the release 
of VLPs. 
3.4.4 HCV-VLPs formation 
VLPs comprised of HCV-structural proteins, are self-assembled, non-replicating, genome-free 
particles similar in size and shape to the intact virions and are useful tools for immunological 
studies. Before attempting to confirm VLP formation in vitro, the interaction of HCV structural 
proteins expressed in HEK293T cells was investigated by means of immunoprecipitation and 
immunoblotting. 
Co-immunoprecipitation of HCV structural proteins would indicate an association of the 
structural proteins and potential VLP assembly. The results revealed an association between 
core and E2 that was detected by immunoprecipitation with anti-E2 but not anti-core antibodies. 
Thus, as core was precipitated with anti-E2 while E2 was not precipitated with anti-core, this 
suggest the formation of a particle in which the core protein was protected from direct 
interaction with anti-core antibodies, indicative of VLP formation. Based on these results, it 
can be concluded that the co-immunoprecipitation of core and E2 proteins was the result of an 
association of the structural proteins. These results correlate with findings of previous studies 
[433-436] and provide supportive data suggesting the assembly of expressed HCV structural 
proteins into VLPs. Moreover, the core-E2 protein association was also strongly detected in the 
supernatant of p-CE1E2-PRF cells suggesting the release of formed particles following PRF-
induced cell lysis (Fig. 3.8C &D). Future experiment however should be conducted to further 
directly confirm the formation and release of these VLP using electron microscopy. 
3.4.5 Immune responses 
DNA vaccines are able to induce both humoral and cell mediated immune responses. However, 
no DNA vaccines have been licensed for use in humans and this has been attributed largely to 
the lack of immunogenicity. Previously, the Gowans laboratory has shown that the addition of 
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perforin as a genetically encoded adjuvant within the DNA vaccine has the ability to increase 
the immune response to HCV-NS3 [414]. The hypothesis underlying the work described in this 
chapter was that PRF-induced necrotic cell death will not only enhance the HCV-specific-immune 
responses but will also result in release of the VLPs. Mice were immunised with p-CE1E2-PRF or 
p-CE1E2-PRF(DA) and the HCV-specific antibody and cell mediated responses were assessed. 
3.4.5.1 HCV envelope-specific antibody titres 
The titres of E1E2-specific antibodies were measured in mice vaccinated with DNA encoding 
CE1E2 plus PRF or PRF(DA). Up to 4 boosters were required to maximally induce the anti-
E1E2 response which then began to plateau (Fig. 3.11A). Vaccination with p-CE1E2-PRF 
resulted in significantly higher E1E2-specific antibody titers compared to p-CE1E2-PRF(DA) 
vaccinated mice. Due to the low levels of E1E2-specific antibodies observed, HCV-positive 
patient sera, as well anti-E1 and anti-E2 commercial antibodies were used as a positive control 
to confirm that the E1/E2 protein-coated ELISA plates were correctly formatted. 
As previously noted, it was important to compare the E1E2-antibody titers with other vaccine 
strategies. Similar to the T cell responses, the E1 E2-antibody responses reported in this chapter 
were lower (mean E1E2-antibody titer of 1/35.8) compared to those reported in other studies 
[146, 420, 437, 438]. For example, a study using modified HCV VLPs in combination with 
recombinant adenovirus encoding HCV structural proteins (rAd5-CE1E2 – genotype 3a) as 
final booster, induced an anti-HCV titer of approximately 1/4000 [420], and a study using HCV 
VLPs (genotype 1a) also induced significant anti-HCV VLPs and anti-E2 responses (titers of 
approximately 1/3800) following vaccination in mice [421]. Furthermore, these antibodies were 
found to be neutralizing. This indicates that the p-CE1E2-PRF DNA vaccine is not highly 
effective when delivered by the ID route compared to other vaccine strategies currently under 
development. 
Overall, these results showed that multiple injections of p-CE1E2-PRF showed low efficacy in 
inducing HCV-specific cell mediated and antibody responses. For this reason, and because the 
p-CE1E2-PRF induced E1E2-specific antibodies were unlikely to neutralize HCV particles, 
subsequent virus neutralisation experiments were not performed. It would however be 
interesting to investigate the effect of the p-CE1E2-PRF vaccine constructs in a prime-boost 
strategy, for example using a rAd5-CE1E2-based HCV vaccine or purified HCV VLPs [420], 
as this may further enhance HCV-specific immune response to levels similar to those reported 
in the literature. 
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3.4.5.2. Cell mediated immunity 
IFNγ secretion is a marker of a Th1 type antigen-specific cellular immune response that plays 
a key role in fighting virus infection. Vaccination with p-CE1E2-PRF increased the HCV-
specific cell-mediated immune response relative to p-CE1E2-PRF(DA), as measured by IFNγ 
ELISPOT and intracellular cytokine staining. Specifically, p-CE1E2-PRF vaccination 
enhanced IFNγ ELISPOT responses to E2 pool 2 peptides (Fig. 3.12D). Vaccination with p-
CE1E2-PRF also increased the frequencies of single, double, triple or quadruple cytokines 
producing CD8+ and CD4+ T cells secreting IL-2, IL-4, IFNγ or TNFα simultaneously (Fig. 
3.14 – 3.17), representing an increase, although not significant, in multi-functional T cells 
which have been shown to be associated with protective immune responses during chronic HCV 
infection [432]. 
This chapter shows that encoding PRF in the vaccine construct resulted in an increase in HCV-
specific immune responses, compared to PRF(DA), after ID DNA vaccination. However, it is 
important to consider these results in the context of other studies, and to determine how they 
compare to other novel vaccine strategies currently under development. The core, E1 and E2-
specific ELISPOT results described in this chapter were of a low frequency (up to an average 
of 58 SFU/106 cells for E1 peptides) and did not compare well to those reported in other studies 
using CE1E2 antigen from genotype 1a [441]; 1b [420, 441, 442] or 3a [420]. This low response 
could be attributed to various factors, including an insufficient uptake of the DNA vaccine in 
vivo by cells in the intradermal environment or an insufficient or partial release of the VLPs in 
vivo following PRF-induced cell death, leading to insufficient priming of the HCV-specific 
response. 
The multiple-cytokine responses measured by flow cytometry were difficult to compare with 
other publications because most studies of HCV vaccines encoding core, E1 and E2 failed to 
assess the HCV-specific cytokine profile of T cells, at least to the degree it was assessed in this 
study. However, recent studies have reported total HCV-specific IFNγ-positive cell frequencies 
of 0.3-8% of total CD8+ T cells [420, 441, 442] and in the experiments described in this chapter, 
the IFNγ-positive frequencies were 0.2-2.5%. Data on the frequency of TNFα, IL-2, IL-4, 
double, triple or quadruple cytokine-positive T cell following immunisation with a vaccine 
encoding core, E1 and E2 proteins were not available in the literature. 
3.5 Conclusion 
The results in this chapter describe the synthesis of bicistronic DNA vaccine constructs 
encoding HCV structural proteins and the cytolytic gene perforin (controlled by the SV40 
promoter) which has the ability to i) induce necrotic cell death, ii) result in release of the 
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assembled VLPs into the extracellular environment and iii) serve as an adjuvant. p-CE1E2-
PRF-vaccinated mice generated higher responses than those vaccinated with p-CE1E2-
PRF(DA), confirming an adjuvant effect by PRF. However, these responses were weak 
compared to those reported in the literature and are unlikely to be effective. This project 
originally intended to induce neutralising antibodies using p-CE1E2-PRF. However, given the 
low antibody titers observed with these DNA vaccine constructs, it was decided to use novel 














































Chapter 4. Generating and assessing the immunogenicity of DNA 
vaccine constructs encoding secreted HCV-E1 and E2 coupled to 
IMX313 
4.1 Introduction 
The HCV virion is composed of a nucleocapsid surrounded by a cell-derived membranous 
envelope that contains the glycoproteins E1 and E2. The envelope proteins are the target of 
neutralising antibodies (NAbs) because they are exposed on the surface of the virion and are 
involved in essential initial steps in the replication cycle of the virus including viral 
attachment/entry or membrane fusion. Therefore, E1 and E2 represent the most 
immunologically significant HCV antigens and have been the main focus of various HCV 
vaccine development studies [146, 420, 443-445]. Antibodies that can prevent E1/E2 from 
binding to HCV receptor/entry factors are thought to be neutralising. HCV glycoproteins E1 
and E2 are type I membrane proteins with a C-terminal TMD anchored in the virion 
phospholipid envelope [446]. In their functional form, E1 and E2 form a non-covalent 
heterodimer, and their TMDs are essential for heterodimerisation [447, 448]. 
Immunolocalization studies and glycan analyses have shown that the HCV glycoproteins are 
located in the endoplasmic reticulum (ER) of infected cells [449, 450].  
Deletion of the transmembrane (TM) domains of E1 and E2 resulted in the secretion of these 
truncated forms of HCV glycoproteins into the extracellular medium [451-454] and a decrease 
in the cellular immune response to the antigen [455]. Others have shown that in its secreted 
form, the E2 antigen leads to an increased humoral response in mice [456]. Conversely, it is 
difficult to elicit anti-E1 responses which require the dissociation of E1E2 expression, 
suggesting that E2 is immunodominant or that immunogenic E1 epitopes are masked in the 
presence of E2 [146]. This is further supported by a recent study using a vaccine candidate 
based on chimeric HBV-HCV envelope particles, in which specific anti-E1 and anti-E2 
antibody responses were profoundly impaired in animals immunized with vaccine particles 
harbouring an E1E2 heterodimer with respect to animals immunized with particles harbouring 
E1 and E2 separately [147]. Additionally, the anti-E1 and anti-E2 antibodies were reported to 
have additive neutralizing properties that increased the cross-neutralization of heterologous 
strains of various HCV genotypes, highlighting the importance of including E1 and E2 as 
separate immunogens to induce a dual anti-E1 and anti-E2 response [147].  
Oligomerisation is employed by many natural proteins to increase protein valency, binding 
affinity and structural stability [457]. The complement inhibitor C4b-binding protein (C4 bp) 
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is a potent circulating soluble inhibitor of the classical and lectin pathways of complement by 
controlling the relative levels of c3 convertase [458]. This protein is produced by hepatocytes 
and is mainly found in the plasma of many organisms including humans [459]. The major form 
of C4 bp in plasma consists of seven identical α-chains and one β-chain linked at the C-terminus 
[458]. Both types of subunits are composed of complement control protein (CCP) domains, 
eight such domains make up one α-chain [460].  In addition, the 57 amino acids of the C-
terminus of the α-chain contains an amphiphatic α-helix region that is required for 
polymerisation [459]. These protein oligomers are stabilised by the cysteine residues located 
within the α-chains [458]. Studies assessing the efficacy of vaccines containing protein antigens 
fused to the C4 bp protein as an adjuvant showed promising results [461-463]. The most 
effective domain was found to be a hybrid C4 bp, known as IMX313, which was genetically 
modified to contain a chicken C4b-p motif and < 20% similarity to human and murine C4 bp 
[461]. Fusion of protein antigens to the IMX313 oligomerisation domain, was shown to 
spontaneously form soluble heptameric structures following expression, resulting in improved 
antibody response compared to the same dose of monomeric antigen [461-463]. Furthermore, 
mice vaccinated with the malaria vaccine candidate MSP119 fused to IMX313 were protected 
against challenge with a lethal dose of Plamodium yoelii parasites [461]. Other studies have 
demonstrated that immunisation of mice with the Mycobacterium tuberculosis antigen 85A 
fused to IMX313 in both DNA and viral vector vaccines resulted in consistently increased 
CD4+ and CD8+ T cell responses in mice and improved magnitude of the immune response in 
mice and non-human primates without a reduction in quality [462]. While oligomerisation may 
be an important element, the mechanism by which the C4b-p enhances immunogenicity is still 
not well understood [461, 464]. Nevertheless, some studies have suggested that the C4 bp 
protein acts as a cofactor to the serine protease factor 1, required for the proteolytic activation 
of C4b, preventing the formation and reconstitution of the classical C3-convertase (C4bC2a) 
[460, 465]. A recent phase I clinical trial of a viral vector encoding 85A-IMX313 in healthy 
BCG (Bacillus Calmette-Guerin)-previously vaccinated UK adults revealed that the vaccine 
was well tolerated and immunogenic [426] (clinicaltrials.gov ref. NCT01879163). The Gowans  
laboratory has developed a potential Tat-based HIV DNA vaccine, encoding HIV-tat fused to 
IMX313, capable of eliciting high titer anti-Tat NAbs and CMI [466].  
4.2 Aims 
This aims of this chapter are to: 
1. Construct DNA vaccines encoding secreted E1 and E2 fused to IMX313 





3. Assess the immunogenicity of E1 and E2 proteins as separate immunogens or as a 
single E1E2 polyprotein when fused to IMX313.  
 
4.3 Results 
4.3.1 Plasmid construction 
To generate the plasmid encoding secreted forms of E1 and E2 fused to the IMX313, the TMDs 
of E1 and E2 were removed in a series of overlapping PCRs (Fig. 4.1 – Chapter 2 -section 
2.2.2.3) using primers designed to generate individual fragments with overlapping overhangs 
which were used to fuse the fragments together (Fig. 4.2). Similarly, the signal peptide sequence 
of the tissue plasminogen activator (tPA) was introduced as a leader sequence to drive E1/E2 
proteins into the cellular secretion pathway. Fragments encoding tPA, E1, E2 and IMX313 
fusion proteins were cloned into pVax. The expression of the secreted E1 and E2 proteins and 
the oligomerisation of IMX313 was examined in vitro prior to immunogenicity studies in mice. 
The plasmids p-tPA-HIVTat-IMX313 [466] and p-CE1E2-PRF were used as templates to 
generate six PCR fragments with overlapping overhangs. p-tPA-HIVTat-IMX313 was used to 
amplify tPA and IMX313 sequences while p-CE1E2-PRF was used to generate the truncated 
E1 (tE1), E2 (tE2) genes lacking the TMDs.  
The different fragments with overlapping ends were subsequently used in an overlap-fusion 
PCR (Fig. 4.1) to generate DNA fragments encoding tPAtE1, tPAtE2, tPAtE1tE2, 
tPAtE1IMX313, tPAtE2IMX313 or tPAtE1tE2IMX313 containing the NheI and EcoRI 
restriction enzyme sites. Following digestion with NheI and EcoRI these fragments were 
individually inserted downstream of the CMV promoter in pVax. DH5α cells were transformed 
using the ligation mix and colony PCR was performed to identify clones with the desired 
amplicon. Positive clones were further analysed by restriction enzyme digestion. The sequences 
of the positive clones were confirmed by DNA sequencing. A complete catalogue of plasmid 





















Figure 4.2. The production of chimeric tPA, truncated E1 and E2 and IMX313 genes. Gel 
electrophoresis analysis of the tPA, truncated HCV-E1 and E2 and IMX313 genes amplified by PCR 
with chimeric overhangs shown in brackets. These fragments were fused in a subsequent PCR to generate 
single PCR products. To generate tPAtE1IMX313, fragment 1, 3 and 7 were used. Fragment 2, 5 and 8 
were used to generate tPAtE2IMX313, while fragments 1, 4, 6 and 8 were used to generate 
tPAtE1tE2IMX313. Fragments without the IMX313 gene were amplified using p-tPAtE1IMX313, 





4.3.2 Detection of HCV envelope proteins and IMX313 oligomerisation 
The expression of E1 and E2 in HEK293T cells transfected with p-tPAtE1, p-tPAtE2, p-
tPAtE1tE2, p-tPAtE1IMX313, p-tPAtE2IMX313 or p-tPAtE1tE2IMX313 was initially 
assessed by immunofluorescence analysis using anti-HCV serum from infected patients (Fig. 
4.4). Staining was observed in cells transfected with all DNA constructs, apart from the pVax 
(empty) control as expected. Cells transfected with the same DNA constructs were stained with 
normal human serum to detect non-specific background staining (Fig. 4.4 - right panels). 
To confirm expression of the HCV envelope proteins and oligomerisation of E1/E2-IMX313 
fusion proteins, HEK293T cells were transfected with the plasmid DNA constructs, and western 
blot analysis was performed on supernatant fluids from p-tPAtE1, p-tPAtE2, p-tPAtE1tE2, p-
tPAtE1IMX313, p-tPAtE2IMX313 or p-tPAtE1tE2IMX313 transfected cells under reducing 
(Fig. 4.5A) and non-reducing conditions (Fig. 4.5B). The proteins migrated as monomers under 
reducing conditions with molecular weights of ~35 kDa for E1 and ~68 kDa for E2. In non-
reducing western blot, high-molecular weight forms of E1 and E2 were detected with molecular 
Figure 4.1. Schematic of the strategy used to generation of secreted truncated E1/E2-IMX313 
genes. During an extension PCR individual fragments encoding tPA, truncated E1 and E2 and 
IMX313 are amplified using primers with overlap sequences to allow fusion. The amplified fragments 
were ligated at the overlap segments during the overlap PCR forming a single large construct. The 
ligated products are then amplified (purification PCR) using another set of primers containing 
restriction enzyme site to generate tPAtE1IMX313, tPAtE2IMX313 or tPAtE1tE2IMX313 products. 
Figure 4.3. Plasmid maps of DNA constructs used in this chapter. A) DNA plasmids encoding 
secreted and truncated E1 and E2 B) DNA vaccine constructs produced by fusing the IMX313 
multimerization domain to the 3’ end of the genes encoding secreted tE1 or tE2 proteins. The 
numbering corresponds to the amino acid position in the HCV polyprotein. DNA plasmid sizes are 
shown on the right. 
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weights exceeding 250 kDa in samples which contained HCV envelope-IMX313 fusion 
proteins. Under non-reducing conditions, proteins from p-tPAtE1, p-tPAtE2 and p-tPAtE2tE2 
transfected cells showed bands of approximately ~50 kDa for E1 and ~80 kDa for E2. 
Additionally, faint bands of approximately ~75 kDa for p-tPAtE1 and ~120 kDa for p-tPAtE2 
and p-tPAtE2tE2 were also observed (Fig. 4.5B). No HCV-specific bands were detected in 
pVax-transfected cells or in the cell controls. Overall these results demonstrate that soluble 
versions of tE1/tE2 fused to the IMX313 domain were efficiently produced and secreted into 





















Figure 4.4. Immunofluorescence of HCV envelope proteins in HEK293T cells. Fluorescence 
staining of HEK293T cells transfected with p-tPAtE1, p-tPAtE2, p-tPAtE1tE2, p-tPAtE1IMX313, p-
tPAtE2IMX313 and p-tPAtE1tE2IMX313. Approximately 48 hours post transfection cells were 
fixed/permeabilised and probed with Anti-HCV (pooled HCV genotype1 patient sera, green) and anti-
NHS (normal human serum) as a control for cross reaction and unspecific background. Untransfected 





























Figure 4.5. Expression of HCV envelope proteins from the DNA vaccines. HEK293T cells 
were transfected with p-tPAtE1, p-tPAtE2, p-tPAtE1tE2, p-tPAtE1IMX313, p-tPAtE2IMX313 
or p-tPAtE1tE2IMX313.  At 72 hours post transfection, cell culture media was harvested, 
centrifuged to remove detached cells then filtered through a 0.22 µm filter to remove remaining 
cell debris. Clarified supernatants were concentrated by ultrafiltration through a 70,000-
molecular-weight cutoff filter (70K MWCO; Amicon). The protein samples were then subjected 
to SDS-PAGE and immunoblotting under (A) reduced and (B) non-reduced conditions, and 
stained with anti-HCV antibodies. Molecular masses (in kilodaltons) of protein molecular 
weight (MW) markers are indicated on the left; HCV-specific proteins are indicated on the right. 





4.3.3 Animal vaccinations 
Female mice, aged 6-8 weeks old were grouped into 7 mice per group and were vaccinated with 
a cocktail of p-tPAtE1 + pVax, p-tPAtE2 + pVax, p-tPAtE1 + p-tPAtE2, p-tPAtE1IMX313 + 
pVax, p-tPAtE2IMX313 + pVax, p-tPAtE1tE2IMX313 + pVax or p-tPAtE1IMX313 + -
tPAtE2IMX313. pVax was included in the vaccine cocktail to ensure that all animals received 
an equimolar concentration of DNA to those vaccinated with p-tPAtE1 + p-tPAtE2 or p-
tPAtE1IMX313 + p-tPAtE2IMX313. The remaining mice were administered pVax (empty) as 
a control (Fig. 4. 6A).  Mice were vaccinated 6 times every 3 weeks via the intradermal route 
(Fig. 4. 6B). Each group of animals was vaccinated with a total of 20.65 picomoles per dose 
per animal. The vaccine dose was determined using 50μg DNA of the smallest construct, p-
tPAtE1, to establish the baseline molecular mass for vaccinations as stated in chapter 2 - section 
2.2.5.2. This ensured that each group received equimolar doses of each plasmid. Mice were 
bleed on a weekly basis and the serum was analysed for the presence of antibodies against HCV 
VLPs. Mice were sacrificed 21 days after the final vaccination, the spleen removed and 













Figure 4.6. Vaccination in 6-8 weeks old female Balb/C mice.  Vaccination groups (A) 
and immunisation schedule of animals (B). Female Balb/C mice (n= 7/group) were 
inoculated intradermally with 20.65 picomoles of respective plasmids at three weekly 
intervals. pVax was included in the vaccine cocktail to ensure that all animals were 
vaccinated with an equimolar concentration of DNA. Blood was collected weekly and 




4.3.4 Immune responses 
4.3.4.1 Humoral immune responses elicited by DNA vaccines encoding secreted 
E1/E2-IMX313 
To determine whether the DNA vaccine encoding secreted E1/E2-IMX313 fusion protein 
elicited antibody responses in mice, mouse sera collected after each vaccination were analysed 
for E1E2-specific antibodies by ELISA. The results showed that, of the constructs without the 
IMX313 oligomerisation domain, vaccination with p-tPAtE2 combined with pVax resulted in 
the highest anti-E1E2 response while the antibody levels peaked and reached a plateau 
following the 3rd booster immunisation (Fig 4.7A). However, titers measured 3 weeks post the 
last vaccination only showed an average titer of 1/5.7 while mice vaccinated with a cocktail of 
p-tPAE1 + ptPAtE2 showed an average titer of 1/8.5 (Fig. 4. 7B). The antibodies generated by 
immunisation with the DNA vaccine constructs also bound to full length E1E2 protein in an 
immunofluorescence analysis of HEK29T cells transfected with p-CE1E2-PRF(DA) using sera 
from vaccinated mice as the primary antibody (Fig. 4.7C and Fig. 4.8C). 
Following vaccination with a DNA vaccine encoding secreted E1/E2-IMX313 fusion protein, 
animals that received a cocktail of p-tPAtE2IMX313 + pVax, p-tPAtE1IMX313 + p-
tPAtE2IMX313 or p-tPAtE1tE2IMX313 + pVax resulted in the highest anti-E1E2 responses 
(Fig. 4. 8A). The antibody levels also peaked and reached a plateau following the 3rd booster 
immunisation. As shown in Figure 4.9B, antibody titers measured 3 weeks after the final 
vaccination revealed that immunisation with a cocktail of p-tPAtE1IMX313 + p-
tPAtE2IMX313 resulted in the highest anti-E1E2 antibody response with an average titer of 
1/110.7, followed by p-tPAtE2IMX313 + pVax-vaccinated mice (average titer 1/63), p-
tPAtE1tE2IMX313 + pVax (average titer 1/18.4) and finally p-tPAtE1IMX313 + pVax 
(average titer 1/3.7) (Fig. 4. 8B). The antibodies from the cocktail DNA vaccinated mice were 
also shown to bind to full length E1E2 polyprotein as a heterodimer in an immunofluorescence 
analysis (Fig. 4. 8C). Collectively, the data presented in this chapter indicate that DNA vaccines 
encoding E1/E2-IMX313 were able to elicit antibody responses to the HCV envelope proteins, 


































Figure 4.7. Induction of anti-E1 and anti-E2 antibodies following vaccination with p-
tPAE1, p-tPAtE2 or p-tPAtE1tE2. A) Serum antibody response specific for HCV E1E2 
proteins. Serum from vaccinated mice was diluted (1/50) and anti-E1E2-specific antibodies were 
measured by ELISA at the indicated time points. Black arrows indicated when the vaccine was 
administered. Values represent mean responses in each group (n = 7) ± SEM.  B) Three weeks 
after the final immunisation, serum from individual mice was serially diluted, and endpoint 
binding titers were calculated. Values for individual mice are shown (n = 7) and bars represent 
the mean ± SEM. Mann-Whitney non-parametric t-test was performed to assess significant p-
values between the vaccinated groups. C) Immunofluorescent analysis of the presence of 
antibodies specific for full-length E1 and E2 proteins in immune sera. HEK293T were 
transfected with p-CE1E2-PRF(DA) encoding full length E1E2 and pooled sera from vaccinated 





























Figure 4.8. Induction of anti-E1 and anti-E2 antibodies following vaccination with p-
tPAE1IMX313, p-tPAtE2IMX313 or p-tPAtE1tE2IMX313. A) Serum antibody response specific 
for HCV E1E2 proteins. Serum from vaccinated mice was diluted (1/50) and anti-E1E2-specific 
antibodies was measured by ELISA at the indicated time points. Black arrows indicated when the 
vaccine was administered. Values represent mean responses in each group (n = 7) ± SEM.  B) Serum 
from individual mice (3 weeks after the final immunisation) was serially diluted, and endpoint titers 
for immunised mouse sera were calculated. Values for individual mice are shown (n = 7) and bars 
represent the mean ± SEM. Mann-Whitney non-parametric t-test was performed and significant p-
values between the vaccinated groups are shown. *p<0.05, **p<0.01. C) Immunofluorescent analysis 
of the presence of antibodies specific for full-length E1 and E2 proteins in immune sera. HEK293T 
were transfected with p-CE1E2-PRF(DA) encoding full length E1E2 proteins and pooled sera from 
mice immunised with p-tPAE1IMX313, p-tPAtE2IMX313 or p-tPAtE1tE2IMX313 were used as the 
primary antibody at a 1:50 dilution. 
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4.3.4.2 Cells mediated immune responses elicited by DNA vaccine encoding secreted 
E1/E2-IMX313 in mice 
Induction of cellular immune responses against the E1 or E2 proteins was assessed by IFNγ 
ELISPOT. Splenocytes were harvested 2 weeks after the final immunization and stimulated 
with HCV peptide pools representing the E1 or E2 proteins. In general, vaccination with p-
tPAtE1 + pVax or p-tPAtE2 + pVax generally resulted in slightly higher E1- or E2-specific cell 
mediated responses compared to vaccination with p-tPAtE1 + p-tPAtE2 (Fig. 4.9). Similarly, 
the groups vaccinated with a combination of p-tPAtE1IMX313 + pVax or p-tPAtE2IMX313 + 
pVax developed higher SFUs than the groups vaccinated with ptPAtE1tE2IMX313 or the 
combination of ptPAtE1IMX313 + ptPAtE2IMX313 (Fig. 4.10). As expected when stimulated 
with E1 peptides, p-tPAtE2 and p-tPAtE2IMX313 vaccinated animals showed significantly 
lower IFNγ responses (Fig. 4.9A and Fig 4.10A). Similarly, p-tPAtE1 + pVax and p-
tPAtE1IMX313 + pVax vaccinated mice respectively generated significantly lower IFNγ 
responses following stimulation with E2 peptides (Fig. 4. 9B & C and Fig 4.10B & C). 
Following stimulation with E1 peptides, mice immunised with p-tPAtE1 + pVax or p-tPAtE1 
+ pVax showed significant numbers of IFN-γ-secreting T cells with 77.3 SFU/106 cells and 
111.3 SFU/106 cells respectively. The highest overall response was seen in splenocytes from 
mice vaccinated with ptPAtE1IMX313 + pVax (203 SFU/106 cells), followed by mice that 
received the combination of ptPAtE1IMX313 + ptPAtE2IMX313 (115 SFU/106 cells) or 
ptPAtE1tE2IMX313 + pVax (91 SFU/106 cells) (Fig. 4.10A). The pVax(empty), ptPAtE2 + 
pVax or ptPAtE2IMX313 + pVax groups all showed significantly lower IFNγ responses as 
expected.  
After the stimulation of the cells with the E2 pool 1 peptides, significant responses were 
detected in p-tPAtE2 + pVax (67 SFU/106 cells) and p-tPAtE1 + p-tPAtE2 (38 SFU/106 cells) 
vaccinated animals (Fig. 4.9B). The p-tPAtE2IMX313 + pVax group showed the highest 
responses after splenocyte stimulation with E2 pool 1 (90 SFU/106 cells) (Fig. 4.10B), while 
the ptPAtE1tE2IMX313 + pVax group and the group vaccinated with ptPAtE1IMX313 + 
ptPAtE2IMX313 showed 5 SFU/106 cells and 18 SFU/106 cells respectively (Fig. 4.10B). The 
pVax(empty), p-tPAtE1IMX313 and ptPAtE1tE2IMX313 groups responses were low as 
expected. A single mouse in the p-tPAtE1IMX313 + pVax group however showed an 
unexpectedly high response (150 SFU/106 cells) following stimulation with E2 pool 1 











Figure 4.9. HCV-specific cellular immune responses against HCV immunogens in the mice 
immunised with p-tPAtE1, ptPAtE2 or ptPAtE1tE2. CMI detected by ELISpot. ELISpot 
assay of splenocytes after stimulation with HCV peptide pools representing E1 and E2. The data 
are expressed as spot forming units (SFU) per 106 cells responses to different peptide pools and 
presented as the mean ±SEM for seven mice per group. The number of SFU in unstimulated 
splenocytes was subtracted from the number in peptide-stimulated cells to generate the net HCV 
response. Mann-Whitney non-parametric t-test was performed and significant p-values between 





























Figure 4.10. HCV-specific cellular immune responses against HCV immunogens in the 
ptPAtE1IMX313, ptPAtE2IMX313 and ptPAtE1tE2IMX313 immunisation groups. CMI 
detected by ELISpot. ELISpot assay of splenocytes after stimulation with HCV peptide pools 
representing E1 and E2. The data are expressed as spot forming units (SFU) per 106 cells 
responses to different peptide pools and presented as the mean ±SEM for seven mice per group. 
The number of SFU in unstimulated splenocytes was subtracted from the number in peptide-
stimulated cells to generate the net HCV response. Mann-Whitney non-parametric t-test was 
performed and significant p-values between the vaccinated groups are shown. *p<0.05, 




Vaccination with p-tPAtE2 + pVax or p-tPAtE1 + p-tPAtE2 resulted in significant IFNγ 
responses to E2 pool 2 peptides (195 SFU/106 cells and 63 SFU/106 cells respectively) (Fig. 
4.9C). The highest response was detected in mice immunised with ptPAtE2IMX313 + pVax 
with an overall response of 451 SFU/106 cells, followed by p-tPAtE1IMX313 + p-
tPAtE2IMX313 group (240 SFU/106 cells) and p-tPAtE1tE2IMX313 + pVax groups (58 
SFU/106 cells), while pVax(empty) and p-tPAtE1IMX313 + pVax responses were lower as 
expected. These results indicate that the secreted E1/E2-IMX313 vaccine strategy can 
efficiently stimulate CMI responses to HCV E1 and E2.  
4.4 Discussion 
As described in the introduction in this chapter, E1 and E2 were selected as the vaccine 
immunogens of choice as they are presented on the surface of the virion and are clearly target 
for NAb [142, 148, 149, 467, 468]. However, the ideal mode of processing and presenting these 
immunogens is yet to be determined. In this chapter, a DNA vaccine strategy based on secreted 
truncated HCV E1 or E2 glycoproteins (tE1 or tE2 respectively) fused to the IMX313 
multimerization domain as a molecular adjuvant was examined, to compare the use of the tE1 
and tE2 proteins as separate immunogens with their use as a single tE1tE2 polyprotein, in terms 
of immunogenetic potential. 
 HCV E1 and E2 glycoproteins are type I transmembrane proteins anchored in the lipid 
envelope by C-terminal TMDs [448, 469, 470]. To generate secreted forms of these proteins, 
their TMDs were removed and a signal peptide sequence of the tissue plasminogen activator 
(tPA) was inserted as a leader sequence to drive a E1/E2 protein into the cellular secretion 
pathway. The IMX313 oligomerisation domain was also included downstream of these proteins 
to facilitate the oligomerisation of the secreted proteins. Plasmid DNA encoding three forms of 
the fusion proteins were generated (tPA-tE1-IMX313, tPA-tE2-IMX313, and tPA-tE1tE2-
IMX313) along with control DNA constructs which did not encode the IMX313 domain. These 
genes were cloned into pVax and the respective proteins expressed and assessed by 
immunofluorescence and western blot analysis following transfection of HEK293T cells with 
the vaccine constructs. 
Secreted HCV-envelope proteins were successfully detected in the cell culture media in 
monomeric and multimeric forms. Under non-reducing conditions protein samples from p-
tPAtE1, p-tPAtE2 and p-tPAtE1 migrated as monomers. Faint bands corresponding 
approximately in molar mass to dimers (~75 kDa for p-tPAtE1 and ~120 kDa for p-tPAtE2 and 
p-tPAtE2tE2, Fig. 4.6B) were also observed. Supernatant fluid collected from cells transfected 
with DNA constructs encoding the IMX313 domains showed bands of molecular mass 
120 
 
exceeding 250 kDa suggesting successful oligomerisation of the secreted tE1/tE2-IMX313 
complexes.  
The titers of the E1E2-specific antibody response were measured in the serum of vaccinated 
mice. The antibody responses reached a plateau after the fourth immunisation. Vaccination with 
a cocktail of p-tPAtE1IMX313 + p-tPAtE2IMX313 induced a superior E1E2 serum antibody 
response compared to vaccination with p-tPAtE1tE2IMX313 + pVax. These antibodies were 
also able to recognise E1E2 proteins in their native heterodimer form as evident by 
immunofluorescence of HEK293T cells transfected with p-CE1E2-PRF(DA) encoding full 
length core, E1 and E2 proteins. Mice immunised with p-tPAtE1 + pVax or p-tPAtE1IMX313 
+ pVax generated weak antibody responses consistent with previous reports suggesting that E1 
is poorly immunogenic [146, 471]. However, vaccination with p-tPAtE1IMX313 in 
combination with p-tPAtE2IMX313 resulted in an increase in E1E2-specific antibody 
responses, suggesting a synergistic effect when these two proteins were used as separate 
immunogens as the response was lower in animals vaccinated with p-tPAtE1tE2IMX313. 
These results also correlated with previous observation that E1 and E2 are less immunogenic 
when expressed as a single polyprotein and anti-E1 responses are efficiently induced only when 
E1 is dissociated from E2 [146, 147]. Although significant anti-E1E2 responses were generated 
in the p-tPAtE1IMX313 + p-tPAtE2IMX313 group, this response was lower compared to those 
reported by others [420, 445, 472]. Nonetheless the neutralising ability of these antibodies 
should be assessed to determine whether DNA vaccination with p-tPAtE1IMX313 + p-
tPAtE2IMX313 or p-tPAtE1tE2IMX313 + pVax is an effective means of eliciting NAb 
responses. 
In addition to strong humoral responses, robust CMI responses have been proposed to be 
essential for clearance of HCV during acute infections in humans and chimpanzees [26, 199, 
316, 473]. To determine if vaccination with the DNA constructs generated in this chapter was 
able to elicit CD8+ T cell responses, CMI responses in splenocytes from vaccinated mice were 
assessed using IFNγ ELISPOT analysis against HCV peptides. The production of IFNγ from 
CD8+ T cells is an indication of a Th1 type immunity.  The results in this chapter indicate that 
vaccination with DNA constructs encoding secreted E1/E2 or E1/E2-IMX313 could indeed 
elicit Th1 type responses against E1 and E2 peptides three weeks after the final immunisation. 
Mice vaccinated with cocktails of DNA constructs encoding tE1 and/or tE2 fused to IMX313 
elicited a stronger CMI response compared to mice vaccinated with a similar construct lacking 
the oligomerisation domain. Animals vaccinated with p-tPAtE1IMX313 + pVax or p-
tPAtE2IMX313 + pVax generated the highest IFNγ responses after stimulation with E1 or E2 
peptides respectively. However, no synergistic effect was observed as the IFNγ response was 
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reduced when these constructs were administered together as a p-tPAtE1IMX313 + p-
tPAtE2IMX313 cocktail. Nonetheless, similar to the antibody responses, vaccination with p-
tPAtE1IMX313 + p-tPAtE2IMX313 consistently induced superior IFNγ responses compared 
to immunisation with p-tPAtE1tE2IMX313 + pVax. The reduction in p-tPAtE1tE2IMX313 
immunogenicity could possibly be due to failed or partial oligomerisation of the proteins in vivo 
or the masking of immunodominant epitopes as a result of the oligomerisation of the larger 
tPAtE1tE2IMX313 protein. The E1E2-specific ELISPOT results reported in this chapter 
compared well to those reported in other studies [424, 443, 445], indicating that the E1/E2-
IMX313 DNA vaccine is effective in inducing CMI responses even when compared with VLPs 
or viral vectors. 
4.5 Conclusion 
The results presented in this chapter demonstrate the successful construction of DNA vaccines 
encoding secreted forms of HCV envelope proteins fused to the multimerization domain 
IMX313. Following intradermal DNA vaccination, constructs encoding IMX313 (and thus able 
to oligomerise) generated superior antibody and CMI responses compared to their monomeric, 
non-oligomerised counterpart. Immunisation with p-tPAtE1IMX313 + p-tPAtE2IMX313 
cocktail was more effective at inducing both antibody and CMI immune responses compared 
to immunisation with p-tPAtE1tE2IMX313 + p-Vax. The antibody responses describe here will 
need to be further investigated to assess their neutralising ability. To further increase the E1E2 
antibody titer, additional vaccine formulations encoding E1/E2 fused to a modified version of 





































Chapter 5. The immunogenicity of DNA vaccine encoding secreted 
HCV-E1/E2 coupled to IMX313P 
5.1 Introduction 
Neutralising antibodies and cellular immune response both play essential roles in the clearance 
of HCV infection. The envelope proteins E1 and E2 are major targets for the production of 
NAbs against HCV. Authentic antigen conformation and repetitive antigenic structures are 
essential features to induce NAbs [457, 474]. DNA vaccines possess various advantages 
compared to conventional recombinant protein of peptide immunogens [1, 475]. However DNA 
vaccines have been reported to have relatively poor immunogenicity, particularly in larger 
animals, and therefore require adjuvants for maximum effect [475]. Co-administration or co-
expression of DNA vaccine along with a plasmid encoding immunomodulatory proteins, such 
as IL-12, is a popular strategy employed to enhance antigen-specific immune responses [266, 
475]. As illustrated previously, genetic adjuvants such as PRF can also boost the host immune 
response after DNA vaccination [414, 418, 476].  
A series of oligomerisation domains from the complement inhibitor C4b-binding protein 
(C4bp) have been shown to act as adjuvants and IMX313 was shown to induce the highest 
antigen-specific humoral and cell mediated immune responses of all the domains tested [426, 
461-463, 466]. Chapter 4 demonstrated the production of DNA vaccine constructs encoding 
E1/E2 fused to the oligomerisation domain IMX313. The titers of anti-E1E2 specific antibodies 
from mice immunised with constructs encoding E1/E2 fused to IMX313 were significantly 
higher than those from mice immunised with constructs encoding E1/E2 and lacking the 
IMX313. Moreover, immunisation with these constructs increased E1/E2-specific IFNγ 
secretion by lymphocytes upon in vitro stimulation with E1 and E2 peptides compared to 
immunisation with constructs without the IMX313 domain. Taken together, these results imply 
that fusing secreted E1/E2 to the IMX313 domain is an effective strategy to enhance E1E2-
specific humoral and cellular immune response. However, higher magnitude immune responses 
will likely be required to achieve useful cross-protective efficacy. In this chapter, new HCV 
DNA vaccines encoding E1/E2 antigens fused to a modified oligomerisation domain from the 
chicken complement inhibitor C4bp termed IMX313P (E1/E2-IMX313P), which was 
developed by our commercial collaborator simultaneously with the experiments performed in 
Chapter 4, were generated. The mechanism by which IMX313P enhances immunogenicity is 
still not well understood. However, similarly to IMX313, oligomerisation may be an important 
element in IMX313P adjuvanticity [461, 464]. The efficacy of these DNA vaccines in eliciting 




The aims of this chapter are to: 
1. Generate DNA vaccine constructs encoding HCV-envelope proteins fused to the 
IMX313P oligomerisation domain.  
2. Confirm HCV-envelope protein expression and IMX313P oligomerisation. 
3.  Assess the immunogenicity of these constructs in vivo 
5.3 Results 
5.3.1 Plasmid construction 
To generate the plasmid encoding secreted forms of E1 and E2 fused to the IMX313P domain 
(Fig. 5.1A), tPA fwd and IMX313P rev primers (appendix I) were used to generate individual 
PCR fragments encoding tPAtE1IMX313P, tPAtE2IMX313P, tPAtE1tE2IMX313P using the 
p-tPAtE1IMX313, p-tPAtE2IMX313, p-tPAtE1tE2IMX313 plasmids generated in chapter 4 as 
templates, respectively.  These fragments were digested using the restriction enzymes EcoRI 
and NheI and then ligated into pVax previously digested with the same restriction enzymes. 
E.coli (DH5α) cells were transformed using the ligation mix and colony PCR was performed 
to identify clones. Positive clones were further analysed using restriction enzyme digestion and 
the correct sequences of the positive clones were confirmed by DNA sequencing (Chapter 2 – 










5.3.2 Protein expression and oligomerisation 
Immunofluorescence analysis was conducted using anti- HCV (serum from HCV-infected 
patients) to assess the expression of E1 and E2 in HEK293T cells transfected with p-
Figure 5.1. C4bp oligomerization domains and plasmid maps of DNA constructs used in this 
chapter. A) Alignment of the amino acid sequences of C4bp oligomerization domains IMX313 and 
IMX313P. Differences in amino acid sequence are underlined in bold. B) DNA constructs produced by 
fusing the IMX313P oligomerisation domain to the 3’ end of the genes encoding secreted tE1 or tE2 
proteins. The numbering corresponds to the amino acid position in the HCV polyprotein. DNA plasmid 
sizes are shown on the right. 
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tPAtE1IMX313P, p-tPAtE2IMX313P or p-tPAtE1tE2IMX313P. As expected positive 
fluorescence was observed in cells transfected with all DNA constructs, but not in cells 
transfected with the pVax control (Fig. 5.2 – top far-left panel). Cells transfected with the same 
DNA constructs were stained with normal human serum (anti-NHS) as control for non-specific 
background staining (Fig. 5.2 - bottom panels). 
The oligomeric state of the E1/E2-IMX313P fusion proteins in purified and concentrated cell 
culture media collected from HEK293T cells transfected with p-tPAtE1IMX313P, p-
tPAtE2IMX313P or p-tPAtE1tE2IMX313P was investigated by western blot analysis under 
reducing (Fig. 5.3A) and non-reducing (Fig. 5.3B) conditions. Each of the proteins migrated as 
monomers under reducing conditions with molecular weight of ~35 KDa for E1 and ~68 KDa 
for E2 (Fig. 5.3A). The HCV envelope-IMX313P fusion proteins migrated under non-reducing 
conditions as a broad oligomeric band of molecular mass greater than 250 kDa. These high 
molecular mass species were not observed in supernatant from cells transfected p-tPAtE1, p-
tPAtE2 or p-tPAtE2tE2 (Fig. 5.3B). These proteins migrated, under non-reducing conditions, 
as monomers of approximately ~50 kDa for E1 and ~80 kDa for E2. Bands of approximately 
~75kDa for p-tPAtE1 and ~120 kDa for p-tPAtE2 and p-tPAtE1tE2 corresponding to protein 
dimers were also observed (Fig. 5.3B). No HCV-specific bands were detected in pVax control 
and cell only samples. These data suggest that p-tPAtE1IMX313P, p-tPAtE2IMX313P or p-
tPAtE1tE2IMX313P transfection results in successful expression and formation of protein 












Figure 5.2. Immunofluorescence of HCV envelope proteins in HEK293T cells. Fluorescence 
staining of HEK293T cells transfected p-tPAtE1IMX313P, p-tPAtE2IMX313P or p-
tPAtE1tE2IMX313P. Approximately 48 hours post transfection cells were fixed/permeabilised and 
stained with Anti-HCV (pooled HCV genotype1 patient sera, green) and anti-NHS (normal human 
serum) as a control for cross reaction and unspecific background. pVax transfected cells were used as 





























Figure 5.3. Expression and oligomerisation of HCV envelope proteins from the DNA 
vaccines. HEK293T cells were transfected with p-tPAtE1, p-tPAtE2, p-tPAtE1tE2, p-
tPAtE1IMX313P, p-tPAtE2IMX313P or p-tPAtE1tE2IMX313P.  At 72 hours post transfection, 
cell culture media was harvested, centrifuged to remove detached cells then filtered through a 
0.22 µm filter to remove remaining cell debris. Clarified supernatants were concentrated by 
ultrafiltration through a 70,000-molecular-weight cut off filter (70K MWCO; Amicon). The 
protein samples were then subjected to SDS-PAGE and immunoblotting under (A) reduced and 
(B) non-reduced conditions, and stained with anti-HCV antibodies. Molecular masses (in kDa) 
of protein molecular weight (MW) markers are indicated on the left; HCV-specific proteins are 
indicated on the right. The untransfected cells and pVax-transfected cells represent controls to 




5.3.3 Animal vaccinations 
Female Balb/C mice, aged 6-8 weeks old were grouped into 7 mice per group. Each group was 
administered pVax, or a combination of pVax with p-tPAtE1IMX313P, p-tPAtE2IMX313P or 
p-tPAtE1tE2IMX313P (Fig. 5.4A). The remaining mice received a combination of p-
tPAtE1IMX313P and p-tPAtE2IMX313P. Mice were immunised 6 times at 3 week intervals 
via the intradermal route in the ear pinnae (Fig. 5.4B). Each group of animals was vaccinated 
with a total of 20.65 picomoles per dose per animal. The vaccine dosage was determined using 
50μg DNA of the p-tPAtE1 as the baseline molecular mass for vaccinations. Blood was 
collected on a weekly basis and the serum analysed for the presence of anti-E1/E2 antibodies. 
Mice were sacrificed 21 days after the final vaccination, the spleen removed and prepared for 













5.3.4 Immune responses 
5.3.4.1 Humoral responses 
To determine the antibody responses elicited following vaccination with the DNA vaccine 
encoding secreted E1/E2-IMX313P fusion protein, mouse serum was collected after each 
vaccination and analysed for E1E2-specific antibodies by ELISA.  
As shown in Figure 5.5A, the antibody levels peaked and plateaued following the 3rd booster 
immunisation. Antibody titers measured 3 weeks post the final vaccination showed that 
Figure 5.4. Vaccination in 6-8 weeks old female Balb/C mice.  Vaccination groups (A) 
and immunisation schedule of animals (B). Female Balb/C mice (n= 7/group) were 
inoculated intradermally with 20.65 picomoles of the respective plasmids at three weekly 
intervals. pVax was included in the vaccine cocktail to ensure that all animals were 
vaccinated with an equimolar amount of DNA. Blood was collected weekly and spleens 
were harvested 21 days post the final vaccination.  
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immunisation with a cocktail of p-tPAtE1IMX313P + p-tPAtE2IMX313P resulted in the 
highest anti-E1E2 antibody response with an average titer of 1/1749, followed by p- 
tPAtE2IMX313P + pVax-vaccinated mice (average titer 1/1707), p-tPAtE1tE2IMX313P + 
pVax (average titer 1/1346) and p-tPAtE1IMX313P + pVax (average titer 1/2.5) (Fig. 5.5B). 
These antibodies were also capable of binding to the E1E2 heterodimer in an 
immunofluorescence analysis (Fig. 5.5C). Moreover, the E1E2-specific antibody titers induced 
following immunisation with these constructs were significantly higher when compared to titers 
induced following immunisation with constructs encoding E1/E2 fused to IMX313 (Fig 5.5D, 
see Chapter 4 – section 4.3.4.1). Collectively, the data indicate that DNA vaccines encoding 
E1/E2-IMX313P are able to elicit robust HCV E1E2-specific antibody responses and this 















































Figure 5.5. Induction of anti-E1E2 antibodies following vaccination with p-tPAE1IMX313P, p-
tPAtE2IMX313P or p-tPAtE1tE2IMX313P. A) Serum antibody response specific for HCV E1E2 
proteins. Serum from vaccinated mice was diluted (1/50) and anti-E1E2-specific antibodies were 
measured by ELISA at the indicated time points. Black arrows indicated when the vaccine was 
administered. Values represent mean responses in each group (n = 7) ± SEM.  B) Serum from individual 
mice (3 weeks after the final immunisation) was serially diluted, and endpoint titers for immunised 
mouse sera were calculated. Values for individual mice are shown (n = 7) and bars represent the mean 
± SEM. Mann-Whitney non-parametric t-test was performed and significant p-values between the 
vaccinated groups are shown. *p<0.05, **p<0.01, *** p < 0.001. C) Immunofluorescent analysis of 
the presence of antibodies specific for full-length E1 and E2 proteins in immune mouse sera 
(magnification 200×). HEK293T were transfected with p-CE1E2-PRF(DA) encoding full length E1E2 
proteins and pooled sera from mice immunised with p-tPAE1IMX313P + pVax, p-tPAtE2IMX313P + 
pvax, p-tPAtE1tE2IMX313P + pVax or p-tPAE1IMX313P + p-tPAtE2IMX313P were used as the 
primary antibody at a 1:50 dilution.  
Figure 5.6. Induction of anti-E1E2 antibodies following vaccination with DNA construct 
encoding E1/E2 fused to IMX313 or IMX313P. Serum from individual mice (3 weeks after the final 
immunisation) was serially diluted, and endpoint titers for immunised mouse sera were calculated. 
Values for individual mice are shown (n = 7) and bars represent the mean ± SEM. All experiments 
were performed simultaneously. Mann-Whitney non-parametric t-test was performed and significant 




5.3.4.2 Cell mediated immune responses 
IFNγ ELISPOT was conducted to assess the induction of cellular immune responses against the 
E1 and E2 proteins. Two weeks following the final dose, splenocytes were harvested and 
stimulated with HCV peptide pools representing E1 or E2 proteins. When stimulated with E1 
peptide, mice vaccinated with ptPAtE1tE2IMX313P + pVax showed the most IFN-γ-secreting 
T cells with an average of 580.5 SFU/106 cells. Mice that received ptPAtE1IMX313P + pVax 
showed an average of 380.5 SFU/106 cells followed by and ptPAtE1IMX313P + 
ptPAtE2IMX313P (mean 242.8 SFU/106 cells) (Fig. 5.7A). Both pVax(empty) or 
ptPAtE2IMX313 + pVax vaccination groups showed significantly lower IFNγ responses as 
expected.  
After stimulation of splenocytes with the E2 pool 1 peptides, significant IFN-γ secretion was 
detected in p-tPAtE1tE2IMX313P + pVax (222.7 SFU/106 cells), p-tPAtE2IMX313P + pVax 
(132.5 SFU/106 cells) and p-tPAtE2IMX313P + p-tPAtE2IMX313P (86.1 SFU/106 cells) 
vaccinated animals (Fig. 5.7B). The pVax, p-tPAtE1IMX313P + pVax groups were low as 
expected with 19.7 SFU/106 cells and 16.2 SFU/106 cells respectively (Fig. 5.7B). 
The highest response following splenocytes stimulation with E2 pool 2 peptides was detected 
in mice immunised with p-tPAtE2IMX313P + pVax with an overall response of 1049.5 
SFU/106 cells (Fig. 5.7C). Immunisation with p-tPAtE1IMX313P + p-tPAtE2IMX313P 
induced 972.5 SFU/106 cells followed by p-tPAtE1tE2IMX313P + pVax immunised group 
(645 SFU/106 cells). While pVax and p-tPAtE1IMX313P + pVax responses were lower as 
expected. Overall these results indicate that the secreted E1/E2-IMX313P vaccine strategy can 
efficiently stimulate CMI responses to HCV E1 and E2. 
The HCV-specific cellular immune responses results shown here were expressed as fold 
increase over the pVax control group and compared to the data reported in chapter 4 section 
4.3.4.2 (Fig. 5.8).  E1-stimulated cells from mice vaccinated with DNA constructs encoding 
IMX313P induced higher INFγ release with a 42.7 INFγ SFU fold increase (relative to pVax 
control) for p-tPAtE1tE2IMX313P + pVax vaccinated mice compared to 6.7 INFγ SFU fold 
increase for p-tPAtE1tE2IMX313 + pVax (Fig. 5.8A). p-tPAtE1IMX313P + p-
tPAtE2IMX313P vaccinated mice showed a 17.8 INFγ SFU fold increase of IFNγ-secreting 
cells compared to mice vaccinated with p-tPAtE1IMX313 + p-tPAtE2IMX313 that showed a 
8.3 INFγ SFU fold increase (Fig. 5.8A). 
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A similar trend was observed in E2 pool 1-stimulated cells in which p-tPAtE1tE2IMX313P + 
pVax and p-tPAtE1IMX313P + p-tPAtE2IMX313P vaccinated mice induced a higher response 
(30.17 INFγ SFU fold increase for p-tPAtE1tE2IMX313P + pVax and 11.6 INFγ SFU fold 
increase for p-tPAtE1IMX313P + p-tPAtE2IMX313P) compared to mice immunised with p-
tPAtE1tE2IMX313 + pVax (0.3 INFγ SFU fold increase) or p-tPAtE1IMX313 + p-
tPAtE2IMX313 (2.5 INFγ SFU fold increase) (Fig. 5.8B).  
As shown in Figure 5.8C, following stimulation with E2 pool 2 peptides, a 15.4 INFγ SFU fold 
increase was observed in the p-tPAtE1tE2IMX313P + pVax group as opposed to a 1.32 INFγ 
SFU fold increase in mice immunised with p-tPAtE1tE2IMX313 + pVax (Fig. 5.8C). p-
tPAtE1IMX313P + p-tPAtE2IMX313P vaccinated mice showed a 23.3 INFγ SFU fold increase 
compared to 5.6 INFγ SFU fold increase for mice vaccinated with p-tPAtE1IMX313 + p-
tPAtE2IMX313 (Fig. 5.8C). Overall, the results shown in Figure 5.8 revealed that vaccination 
with a DNA construct encoding E1/E2 proteins fused to the IMX313P domain induced superior 
cell mediated immune responses when compared to vaccination with DNA construction 











































Figure 5.7. HCV-specific cellular immune responses against HCV immunogens in the mice 
immunised with p-tPAtE1IMX313P, ptPAtE2IMX313P or ptPAtE1tE2IMX313P. CMI detected 
by ELISpot of splenocytes after stimulation with HCV peptide pools representing (A) E1 and (B & C) 
E2. The data are expressed as spot forming units (SFU) per 106 cells responses to different peptide 
pools and presented as the mean ±SEM for seven mice per group. The number of SFU in unstimulated 
splenocytes was subtracted from the number in peptide-stimulated cells to generate the net HCV 
response. Mann-Whitney non-parametric t-test was performed and significant p-values between the 






































This chapter describes a DNA vaccine strategy based on secreted truncated tE1 or tE2 fused to 
the IMX313P oligomerisation domain as a molecular adjuvant. The IMX313P oligomerisation 
domain was introduced downstream of the tE1/tE2 proteins to generate p-tPAtE1IMX313P, p-
tPAtE2IMX313P and p-tPAtE1tE2IMX313P. Successful E1/E2 protein expression was 
evaluated by immunofluorescence and oligomerisation of the proteins was evaluated using 
western blot analysis following transfection of HEK293T cells with the vaccine constructs. 
E1/E2 proteins were successfully detected in HEK293T cells transfected with the vaccine 
constructs using immunofluorescence using anti-HCV-positive human serum. Western blot 
analysis demonstrated that secreted HCV envelope proteins were successfully detected in the 
cell culture media in monomeric and multimeric forms. Under non-reducing conditions, 
supernatant collected from cells transfected with p-tPAtE1IMX313P, p-tPAtE2IMX313P or p-
tPAtE1tE2IMX313P showed bands of molecular mass exceeding 250 kDa while protein 
samples from p-tPAtE1, p-tPAtE2 and p-tPAtE1 migrated as monomers. Under non-reducing 
conditions, bands corresponding approximately in molar mass to dimers (~75 kDa for p-tPAtE1 
and ~120 kDa for p-tPAtE2 and ~170 kDa for p-tPAtE2tE2, Fig. 5.3B) were also observed. 
Overall these results suggest the successful oligomerisation of the secreted tE1/tE2-IMX313P 
protein complexes.  
The levels of tE1tE2-specific antibodies in vaccinated mice were measured using ELISA. The 
antibody response peaked after the fourth immunisation in all the vaccination groups apart from 
pVax and p-tPAtE1IMX313P + pVax vaccinated mice. Vaccination with a cocktail of p-
tPAtE1IMX313P + p-tPAtE2IMX313P induced a superior tE1tE2 serum antibody response 
compared to vaccination with p-tPAtE1tE2IMX313P + pVax. The ELISA results were also 
validated using immunofluorescence and showed that these antibodies were also able to 
recognise E1E2 proteins in their native heterodimer form (Fig. 5.5C). Mice immunised with p-
tPAtE1IMX313P + pVax generated weak antibody responses consistent with results obtained 
in chapter 4 (Fig. 4.7 & Fig 4.8), suggesting that E1 could be weakly immunogenic [146, 471]. 
However, a synergistic effect was observed when mice were vaccinated with p-
Figure 5.8. HCV-specific cellular immune responses in mice immunised with DNA 
vaccines encoding E1/E2 fused to IMX313 or IMX313P domains. IFNγ response detected 
by ELISpot of splenocytes after stimulation with (A) E1, (B) E2 pool 1 and (C) E2 pool 2 peptide 
pools. Data are plotted as mean (n = 7) SFU fold increase (+SEM) relative to pVax control. 
Mann-Whitney non-parametric t-test was performed and significant p-values between the 




tPAtE1IMX313P in combination with p-tPAtE2IMX313P resulting in an increase in E1E2-
specific antibody responses. Using recombinant E1 or E2 proteins separately to coat wells in 
ELISA would clarify whether vaccination with p-tPAtE1IMX313P + p-tPAtE2IMX313P or p-
tPAtE1tE2IMX313P + pVax induced predominantly anti-E2 antibodies, or a combination of 
both anti-E1 or anti-E2 antibodies. Nevertheless, the antibody responses generated by 
vaccination with these constructs were comparable to those reported in the literature [420, 445, 
472]. Further studies are required to determine the functional activity of these antibodies.  
To determine the production of IFNγ from CD8+ T cells following vaccination with the DNA 
constructs, IFNγ ELISPOT analysis against HCV peptides was conducted. Animals vaccinated 
with p-tPAtE1tE2IMX313P + pVax generated the highest IFNγ responses after stimulation with 
E1 peptide or E2 peptide pool 1, while p-tPAtE2IMX313P + pVax generated the highest IFNγ 
responses when stimulated with the E2 peptide pool 2. No significant differences in IFNγ 
responses were observed between p-tPAtE1IMX313P + p-tPAtE2IMX313P and p-
tPAtE1tE2IMX313P + pVax vaccinated mice, following stimulation with E1 or E2 peptides. 
The E1E2-specific ELISPOT results reported in this chapter compared well to those reported 
in other studies [424, 443, 445], indicating that the E1/E2-IMX313P DNA vaccine is effective 
in inducing CMI responses. 
Fusion of E1/E2 to IMX313P resulted in significantly higher tE1tE2 antibody and cell mediated 
immune responses compared to fusion of the same proteins to IMX313. Interestingly, unlike 
fusion of E1/E2 to IMX313 which showed an increase in antibody titer following p-
tPAtE1IMX313 + p-tPAtE2IMX313 vaccination (Chapter 4 – section 4.3.4.1), no differences 
in tE1tE2 antibody responses were observed in animals vaccinated with p-tPAtE1tE2IMX313P 
+ pVax compared to animals vaccinated with p-tPAtE1IMX313P + p-tPAtE2IMX313P. A 
similar trend was observed in terms of cell mediated immunity suggesting that fusing E1/E2 to 
IMX313P is a  more effective means of enhancing HCV specific responses in animals compared 
with IMX313. 
The significant differences in immunogenicity following fusion of HCV proteins to IMX313 or 
IM313P suggest that oligomerisation might not be the only important element responsible for 
the enhanced E1/E2-specfic responses. The difference in immune responses might have been 
facilitated by different E1/E2 presentation when they fused to IMX313 or IMX313. Other 
factors such as increased serum half-life, improved antigen uptake and/or prolonged antigen 
processing might have contributed to the observed effects [462]. The mode of action of the 




DNA vaccines encoding secreted E1/E2-IMX313P fusion proteins produced in this chapter 
generated significant antibody and CMI responses. No significant differences were observed 
following immunisation with p-tPAtE1IMX313P + p-tPAtE2IMX313P cocktail compared to 
immunisation with p-tPAtE1tE2IMX313 + pVax. Furthermore, the data demonstrated that E1 
and E2 proteins are much more immunogenic when fused to the IMX313P domain as opposed 
to fusion with IMX313. Therefore, the IMX313P domain represents a more effective adjuvant 
that enhances the immunogenicity of HCV-E1E2 based DNA vaccines. However, despite the 
remarkable capacity of these DNA constructs to induce and boost E1/E2-specific humoral and 
cell mediated immunity, higher frequency responses are likely to be necessary to achieve 
effective neutralisation and protection. Chapter 6 aims at increasing E1/E2-specific responses 
















Chapter 6. Improving the immunogenicity of secreted HCV-E1/E2-
IMX313P DNA vaccines with a VLP or recombinant E1E2 protein 
boost 
6.1 Introduction 
DNA-based vaccination offers a unique alternative method of immunisation. DNA vaccines 
can induce both humoral and cellular immunity, persistent expression of heterologous antigen, 
and a memory response against the infectious disease. Additionally, DNA vaccines are safe in 
humans, and are easy and cost effective to produce on a large-scale [302, 477].  However, DNA 
vaccines still need to be improved as they induce only poor immune responses in large animals 
despite being effective in mice [1]. A possible reason for this could be that, compared to mice, 
the naked DNA vaccine is less efficiently transduced in vivo in humans, leading to low antigen 
expression. Therefore, the introduction of a DNA vaccine encoding HCV-E1/E2-IMX313P into 
the clinic would likely require a further enhancement of its immunogenicity.  
Considerable efforts are being made to improve the immune responses evoked from DNA 
immunisation, either through addition of various immuno-stimulatory mediators, and /or 
through formulation and delivery [478-482]. Heterologous prime-boost vaccination is a means 
of priming the immune system by administration of a target antigen via one type of vector, with 
subsequent boosting of immunologic memory by re-administration of the antigen in the context 
of a different vector that optimally confers higher antigen levels than during priming [478, 483, 
484]. The DNA prime–protein boost regimen is known to be one of such effective protocols. 
DNA-based priming vaccination followed by recombinant protein booster immunisation with 
relevant soluble antigens has been shown to be well tolerated and elicited both cellular and 
humoral immune responses in HIV and Plasmodium infected patients [484-488].  
Chapter 5 demonstrated that immunisation with p-tPAtE1IMX313P + p-tPAtE2IMX313P or p-
tPAtE1tE2IMX313P + pVax resulted in the induction of E1/E2-specific humoral and cell-
mediated immunity.  In this chapter, the immunogenicity of this DNA prime/DNA boost 
approach is compared against DNA prime/protein boost or DNA prime/VLP boost approaches. 
6.2 Aims 
The major aims of this chapter are to: 
4. Evaluate the immunogenicity of DNA prime/DNA boost, DNA prime/E1E2 
recombinant protein boost or DNA prime/HCV VLP boost regimens, using DNA 
encoding E1/E2 fused to IMX313P, E1E2 recombinant protein and HCV VLPs. 
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5. Assess the neutralising ability of the antibodies generated by the different vaccination 
regimens. 
6.3 Results 
6.3.1 Plasmid construction and protein expression. 
The p-tPAtE1IMX313P, p-tPAtE2IMX313P, p-tPAtE1tE2IMX313P plasmids (Fig. 6.1) were 
generated and evaluated as stated in chapter 5 - section 5.3. The secreted tE1tE2 poly-His-
tagged fusion proteins were affinity purified and analysed by western blotting as described in 
chapter 2 section 2.2.3.1 and chapter 3 – section 3.6.3.1. The production and purification of the 
genotype 1 HCV VLPs (kindly provided by Professor Joseph Torresi) have been described 








6.3.2 Animal vaccinations 
Female Balb/C mice, aged 6-8 weeks old were grouped into 7 mice per group. One group was 
immunised with pVax, three groups were immunised with combinations of p-tPAtE1IMX313P 
and p-tPAtE2IMX313P while the remaining 3 groups were administered a combination of pVax 
+ p-tPAtE1tE2IMX313P (Fig. 6.2A). The mice were immunised 4 times with DNA at 3-week 
intervals (Fig. 6.2B), before receiving a DNA boost (groups 2 & 3; Fig. 6.2A), a tE1tE2 
recombinant protein boost (groups 4 & 5; Fig. 6.2A) or a HCV VLP boost (groups 6 & 7; Fig. 
6.2A). The inoculations were administered via the intradermal route in the ear pinnae. Each 
group of animals was vaccinated with a total of 20.65 picomoles DNA per dose per animal and 
boosted with 50µg of recombinant tE1tE2 proteins or 25µg of HCV VLPs. Blood was collected 
two days prior to each vaccination and 21 days after the final vaccination when the mice were 
sacrificed. The spleen was removed, splenocytes prepared for IFN-γ ELISPOT analysis and 
serum analysed for the presence of anti-E1/E2 antibodies. 
 
Figure 6.1. Plasmid maps of DNA constructs used in this chapter. A) DNA plasmids encoding 
secreted, truncated E1 and E2 fused to IMX313P. The numbering corresponds to the amino acid 



















6.3.3 Immune responses 
6.3.3.1 Humoral responses 
6.3.3.1a Serum antibody responses 
To determine the antibody responses, mouse serum samples were collected and analysed for 
E1E2-specific antibodies by ELISA. As previously observed (chapter 5 section 5.3.4.1), the 
antibody levels peaked and plateaued following the 3rd booster immunisation in the group 
receiving DNA prime/DNA boost regimens (Fig. 6.3A). Vaccination with a cocktail of p- 
tPAtE2IMX313P + pVax and boosting with E1E2 protein resulted in the highest tE1tE2-
specific antibody levels, followed by p-tPAtE1IMX313P + p-tPAtE2IMX313P prime/ E1E2 
protein boost and p-tPAtE2IMX313P + pVax prime/ HCV VLP boost (Fig 6.3A). 
The antibody titers measured 3 weeks post the final vaccination showed that boosting with the 
tE1tE2 proteins following immunisation with a cocktail of p- tPAtE1tE2IMX313P + pVax 
resulted in the highest anti-E1E2 antibody response with an average titer of 1/4678, followed 
Figure 6.2. Prime/boost vaccination regimens in 6-8 week old female Balb/C mice.  Vaccination 
groups (A) and immunisation schedule of animals (B). Female Balb/C mice (n= 7/group) were 
inoculated intradermally with 20.65 picomoles of the respective plasmids at three weekly intervals and 
boosted with DNA, recombinant HCV tE1tE2 protein or HCV VLPs. pVax was included in the vaccine 
cocktails to ensure that all animals were vaccinated with an equimolar amount of DNA. Blood was 
collected two days prior to each vaccination and 21 days post vaccination.  Spleens were also harvested 
21 days post the final vaccination.  
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by p-tPAtE1IMX313P + p-tPAtE2IMX313P-vaccinated mice (average titer 1/2004). The DNA 
prime/E1E2 protein boost vaccination regimens were significantly superior compared to 
boosting with DNA alone or HCV VLPs. There were no statistical differences in antibody titers 
against E1E2 between animals vaccinated with p-tPAtE1tE2IMX313P + pVax and boosted 
with tE1tE2 proteins or HCV VLPs (average titer 1/1386) (Fig. 6.3B). No significant 
differences were observed in E1E2-specific antibody titers between mice vaccinated with p-
tPAtE1tE2IMX313P + pVax or p-tPAtE1IMX313P + p-tPAtE2IMX313P and boosted with the 
same DNA or HCV VLPs (average titer 1/1386) (Fig. 6.3B). These antibodies were also capable 
of binding to full length E1E2 as a heterodimer as determined by immunofluorescence (Fig. 
6.3C). Collectively, the data indicate that recombinant E1E2 protein provides a superior boost 
compared to DNA or HCV VLPs and is capable of enhancing HCV E1E2-specific antibody 








































6.3.3.1b Serum antibody characterisation 
The specificities of the antibody responses to continuous and discontinuous epitopes on E1E2 
were mapped by overlapping peptides and competition ELISA. To map antibody responses to 
continuous epitopes, a library of E1E2 overlapping peptides (18-mers with 11-amino-acid 
overlaps) was used in an ELISA (Fig. 6.4). There was little difference in reactivity with the E1 
continuous epitopes located in the ectodomain in all the immunised groups; sera from animals 
immunised with the p-tPAtE1tE2IMX313P + pVax DNA prime/ E1E2 protein boost regimen 
or the DNA prime/ HCV VLP boost regimen showed a slightly higher reactivity compared to 
Figure 6.3. Induction of anti-E1 and anti-E2 antibodies following vaccination with DNA 
prime/DNA boost, DNA prime/E1E2 protein boost or DNA prime/HCV VLP boost regimens. 
A) Serum antibody response specific for HCV E1E2 proteins. Serum from vaccinated mice was 
diluted (1/50) and anti-E1E2-specific antibodies were measured by ELISA at the indicated time 
points. Black arrows indicated when the DNA vaccine was administered, blue arrow indicate when 
the DNA, protein or VLP boosts were administered. Values represent mean responses in each 
group (n = 7) ± SEM.  B) Three weeks after the final immunisation, serum from individual mice 
was serially diluted, and endpoint binding titers were calculated. Values for individual mice are 
shown (n = 7) and bars represent the mean ± SEM. Mann-Whitney non-parametric t-test was 
performed to assess significant p-values between the vaccinated groups. *p<0.05, **p<0.01, *** 
p < 0.001. C) Immunofluorescence analysis of the presence of antibodies specific for full-length 
E1 and E2 proteins in immune sera. HEK293T were transfected with p-CE1E2-PRF(DA) 
encoding full length E1E2 and pooled sera from mice vaccinated with DNA prime/DNA boost, 
DNA prime/E1E2 recombinant protein boost or DNA prime/HCV VLP boost regimens were used 
as the primary antibody at a 1:50 dilution. 
142 
 
other immunised groups (Fig. 6.4A). There were no differences in reactivity to the E1 peptides 
from the transmembrane domain across all vaccination groups. However, the sera showed 
greater reactivity against the E2 glycoprotein than the E1 glycoprotein and reacted with aa 412 
to 522 and aa 541 to 713 (Fig.6.4B). All vaccinated groups showed little reactivity toward 
hypervariable region 1 (HVR1) aa 384 to 411 and E2 TMD region aa 716 to aa 747 but some 






























To map antibody specificities to discontinuous epitopes, a panel of human monoclonal 
antibodies (MAbs), (HC33.1, HCV1, AR3C, 2AI2 and HC84.27– kindly provided by Professor 
Heidi Drummer), capable of binding to the E2 protein were used in competition ELISA 
(Fig.6.5). These MAbs target the regions of E2 that form the CD81 receptor binding site to 
block the interaction between E2 and CD81 [152, 160, 192, 490-492]. Competition ELISA was 
used to determine if similar epitopes were targeted by vaccine-elicited antibodies. Preliminary 
titration experiments with the MAbs in E1E2-binding ELISAs were performed and the 
concentration of the MAbs resulting in 70% maximal binding was used in the competition 
studies (data not shown). The effects of serum from immunised mice on binding of the MAbs 
was assessed by first adding mouse serum to E1E2-coated ELISA plates, followed by the 
addition of the individual MAbs, as described previously [453, 493]. The reduction in 
absorbance of the monoclonal antibodies was then calculated. Animals vaccinated with p-
tPAtE1tE2IMX313P + pVax DNA prime/ DNA boost or p-tPAtE1tE2IMX313P + pVax DNA 
prime/ E1E2 protein boost showed the greatest reactivity toward the HC33.1 epitope with 
16.7% competition and 16.1% competition respectively (Fig. 6.5A), while p-tPAtE1IMX313P 
+ p-tPAtE2IMX313P DNA prime/ E1E2 protein boost showed the highest reactivity (16.2% 
competition) toward the HCV1 epitope (Fig. 6.5B). All vaccination regimens resulted in similar 
competition with the AR3C (Fig.6.5C), 2AI2 (Fig. 6.5D) and HC84.27 (Fig. 6.5E) antibodies. 
DNA prime/ VLP boost-immunised animals showed the lowest competition with all five MAbs 
(Fig.6.5A-D). Due to the lack of sera the MAb competition studies were only performed using 
a 1/50 dilution of the serum from the vaccinated mice. Nevertheless, the results show that sera 
from vaccinated mice recognise E2-neutralising epitopes originally defined by the HC33.1, 




Figure 6.4. Reactivity of sera from DNA prime/DNA boost, DNA prime/E1E2 protein boost 
or DNA prime/HCV VLP boost-immunized animals to E1E2 peptides. Serum antibody 
responses specific to a library of overlapping (A) E1 or (B) E2 peptides in ELISA three weeks 
after the last vaccination. Serum from vaccinated mice was diluted (1/50) and peptides were 
supplied by BEI Resources. Values represent mean responses in each group (n = 7) + SEM.  Mann-
Whitney non-parametric t-test was performed to assess significant p-values between the 
vaccinated groups.  **p<0.01. Data shown are representative of those from 3 independent 























6.3.3.2 Serum HCV neutralising activity 
To assess the neutralising ability of the antibodies generated by the different vaccination 
regimens, the ability of the sera to inhibit binding of HCV VLPs to Huh7 cells was investigated. 
This component of the study was performed by Professor Joseph Torresi.  Different dilutions 
of serum (1:5, 1:10 and 1:25) were incubated with fluorescent-labelled HCV VLPs, and the 
binding of the VLPs to Huh7 cells was monitored as stated in chapter 2 - section 2.2.6.4. 
Incubation of the HCV VLPs with PBS (VLP only) or normal mouse serum (Sigma) resulted 
in minimal inhibition of HCV VLP binding to hepatocytes (Fig. 6.6B-middle panel). The 
addition of anti-CD81 antibodies (Fig.6.6C), on the other hand, inhibited VLP binding to Huh7 
Figure 6.5. Competition ELISA of antibodies from vaccinated mice with human MAbs 
recognising five specific epitopes. Pooled serum from vaccinated mice was diluted (1/50) and first 
incubated for 1 hour on E1E2-coated plates, followed by the addition of the indicated MAb. 
Monoclonal antibodies were added at a concentration resulting in 70% maximal binding to E1E2, as 
determined in prior titration experiments. Binding of the MAbs was detected with anti-human HRP-
conjugated secondary antibodies. Percentage reduction in absorbance of the monoclonal antibodies 
was calculated and plotted as % competition. The data are reported as the mean + SEM of at least 2 
experiments performed in duplicate.  
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cells by >90% confirming that these VLPs use this molecule to facilitate binding to target cells, 
in a similar manner to HCV [68, 77, 126, 243, 494, 495].  
Dose-dependent inhibition of binding of the HCV VLPs by serum from the vaccinated mice 
was observed across all vaccination groups (Fig. 6.7A).  Although most of the samples showed 
some non-specific inhibition at a 1:5 dilution, at a 1:25 dilution which was considered to 
represent specific inhibition, neutralisation of binding of HCV VLPs to Huh7 cells was highest 
by sera obtained from mice immunised with a DNA prime/DNA boost or a DNA prime/tE1tE2 
boost (~71% for p-tPAtE1IMX313P + p-tPAtE2IMX313P prime/ DNA boost, ~64% for p-
tPAtE1tE2IMX313P + pVax prime/ DNA boost, 60% for p-tPAtE1IMX313P + p-
tPAtE2IMX313P prime/ E1E2 protein boost or 64% for p-tPAtE1tE2IMX313P + pVax prime/ 
E1E2 protein boost), compared to sera obtained from mice boosted with HCV VLPs (~41% for 
p-tPAtE1IMX313P + p-tPAtE2IMX313P prime/HCV VLP boost or ~30% for p-
tPAtE1tE2IMX313P + pVax prime/ HCV VLP boost; Fig. 6.7B).  Neutralisation of binding 
following boosting with HCV VLPs was surprisingly low (~27%) and similar to that of sera 
obtained from the pVax control group (Fig. 6.7B). The representative graphs used to calculate 
percentage inhibition are also shown (Fig. 6.7). These results show that antibodies generated 
against HCV genotype 1 E1/E2 proteins could neutralise the binding of VLPs to target cells, 
and that homologous DNA prime-boost vaccination with p-tPAtE1IMX313P + p-












Figure 6.6. Inhibition of binding of HCV-LPs to Huh7cells by mice sera, as determined by 
flow cytometry. Huh7 cells were incubated with A) fluorescent-labelled VLPs in the presence 
of B) normal mouse serum (NMS; Sigma) or C) anti-CD81 antibody. Cells were then washed 





























Figure 6.7. Neutralisation of VLP binding by sera from vaccinated animals after the final 
boost immunisation. Neutralisation of VLP binding was determined by pre-incubating 
fluorescent-labelled VLPs with 1:5, 1:10 or 1:25 dilution of immune sera from mice inoculated 
with the various prime-boost vaccination regimens. Supernatants were clarified by 
centrifugation and incubated with Huh7 cells. Cells were then harvested, and cellular 
fluorescence levels analysed by flow cytometry. A) Fluorescent-labelled HCV VLPs of 
genotype 1b were incubated with decreasing concentration (1:5, 1:10, and 1:25) of serum from 
vaccinated mice after the final immunisation. Y-axis depicts the percentage inhibition of 
binding of HCV-LPs to Huh7 cells; X-axis represents the different dilutions of serum. B) All 
bar graphs represent the percentage reduction in VLP entry following incubation with mouse 




In addition to their neutralising properties, antibodies can mediate host effector functions and 
facilitate the removal of a pathogen from a host. The Fc portion of immunoglobulin G2a 
(IgG2a) antibodies in particular, can interact with complement components [496] and Fc 
receptors [497-499]. This interaction can lead to cell death through complement fixation, 
stimulation of antibody-dependent cell-mediated cytotoxicity (ADCC) [500], and phagocytosis 
[501]. E1E2-specific total IgG and IgG2a isotyping demonstrated that the anti-E1E2 humoral 
response was predominantly comprised of IgG subclasses other than IgG2a (p < 0.01) (Fig. 
6.8), suggesting that these antibodies are unlikely to show ADCC activity or to be involved in 




















Figure 6.8. Levels of anti-E1E2 IgG and IgG2a following vaccination with DNA prime/DNA 
boost, DNA prime/E1E2 protein boost or DNA prime/HCV VLP boost regimens.  The 
magnitude of E1E2-specific total IgG or IgG2a isotype of immune sera from immunised mice was 
determined by ELISA, using secondary antibody recognising (blue bars) all IgG subclasses (total 
IgG) or (red bars) IgG2a isotype-specific secondary antibody. Values represent mean responses in 
each group (n = 7) + SEM.  Mann-Whitney non-parametric t-test was performed and significant 
p-values between groups are shown. **p<0.01.  
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6.3.3.3 Cell-mediated immune responses 
To compare CMI elicited by the different regimens, an IFNγ ELISPOT assay was performed 
using peptide pools representing HCV core, E1 or E2 proteins for re-stimulation (Fig. 6.9). As 
shown in figure 6.9A, mice boosted with HCV VLPs showed a higher frequency of IFN-γ-
secreting T-cells following stimulation with core peptides, with ~65 SFU/106 cells for the p-
tPAtE1IMX313 + p-tPAtE2IMX313 prime/ HCV VLP boost regimen and ~67 SFU/106 cells 
for the p-tPAtE1tE2IMX313 + pVax prime/ HCV VLP boost regimen (Fig. 6.9A) compared 
with mice that received the DNA prime/ DNA boost regimens or DNA prime/ E1E2 protein 
boost regimens. However, these differences were not statistically significant. As expected, since 
neither the DNA nor the E1E2 recombinant proteins encoded/expressed the core protein, the 
core-specific responses induced by the DNA prime/DNA boost or DNA prime/protein boost 
regimens were low, essentially baseline (Fig. 6.9A). In contrast, the IFNγ responses were high 
in mice from each vaccination regimen following stimulation with E1 (Fig. 6.9B) or E2 peptides 
(Fig 6.9 C, D & E) but no significant differences were observed between the different 
vaccination regimens. In an attempt to compare the responses elicited by the mice in this 
experiment with published data, a composite of the total responses to E2 pool 1 and pool 2 was 
generated (Fig 6.9E).  This showed that these responses compared well with those generated in 
other studies following vaccination with viral vectors (~140 to ~1600 SFU/106 cells for E1 and 
~120 to ~800 SFU/106 cells for E2 [438, 443, 445]), DNA (~480 SFU/106 cells for E1E2 [424]), 
or VLPs (~190 SFU/106 cells for coreE1E2 [421] or ~480 SFU/106 cells for E1E2 [424]).  As 
expected, the control mice vaccinated with pVax failed to generate any IFNγ-positive cells 






























































DNA vaccination is able to induce humoral and cellular immunity against various infectious 
agents. Despite this, poor immunogenicity in large animals remains one of the major limitations 
of DNA immunisation [502]. Multiple immunisations are commonly required to achieve a 
protective and sustained immune response. The DNA prime-protein boost strategy, in which 
the immune response is primed with a DNA vaccine and subsequently boosted with a protein, 
VLP or vector expressing the antigen, constitutes a promising approach to improve the 
efficiency of DNA immunisation [503-505].  
Figure 6.9. HCV-specific cellular immune responses detected in mice immunised with DNA 
prime/DNA boost, DNA prime/E1E2 protein boost or DNA prime/HCV VLP boost regimens. 
CMI detected by ELISpot. ELISpot assay of splenocytes after stimulation with HCV peptide pools 
representing (A) core, (B) E1 and (C & D) E2. (E) represents the combined responses after 
stimulation with E2 peptide pools 1 and 2. The data are expressed as spot forming units (SFU) per 
106 cells to different peptide pools and presented as the mean ±SEM for seven mice per group. The 
number of SFU in unstimulated splenocytes was subtracted from the number in peptide-stimulated 
cells to generate the net HCV response. Mann-Whitney non-parametric t-test was performed and 
significant p-values between the vaccinated groups are shown. *p<0.05, **p<0.01. Note that the Y-
axes may differ. 
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In this chapter, mice were immunised on four occasions with DNA vaccine constructs encoding 
tE1/tE2-IMX313P before boosting with DNA, E1E2 protein or HCV VLPs, and the efficacy of 
these vaccination strategies to elicit antibody responses and cell-mediated immunity against the 
HCV structural proteins was determined. It was observed that the DNA prime/DNA boost, 
DNA prime/E1E2 protein boost, and DNA prime/HCV VLP boost vaccination methods 
induced quite different immune responses. Among the three immunisation strategies, boosting 
with one dose of recombinant E1E2 protein induced the highest antibody levels as determined 
by ELISA. No significant differences were observed between boosting with DNA or HCV 
VLPs. 
The E2 HVR1 (aa 384 to 410) has been suggested to be an immunodominant region involved 
in viral escape of antibodies in infected chimpanzees and humans [140, 506-508]. There was 
little reactivity toward this region in the mouse sera, similar to the results of previous studies 
[453, 509, 510]. This suggests that the E2 HVR1 may be less immunogenic than considered 
previously and it is thought to be involved in shielding more conserved E2 epitopes [168, 170]. 
Alternatively, the E2 HRV1 region might have not been efficiently exposed in vivo to prime B 
cell resulting in low levels of HRV-specific antibodies. Additionally, NAb induced in mice 
have been suggested to recognise different epitopes to those induced in humans [511]. The 
mouse sera competed with MAbs HC33.1 [160], HCV1 [192, 490] AR3C [491], 2AI2 and 
HC84.27 [492] in binding to E1E2, suggesting that antibodies to the discontinuous antigenic 
regions were elicited.  
The ability of these antibodies to inhibit the binding of HCV VLPs to Huh7 cells was assessed 
and sera from mice vaccinated with the DNA prime/DNA boost or DNA prime/E1E2 protein 
boost regimens were able to prevent VLPs binding to Huh7 cells. This suggests that these 
antibodies are likely to possess neutralising properties. In contrast and somewhat surprisingly, 
the prime-boost protocol, in which the DNA vaccine was followed by a boost with HCV VLPs 
resulted in minimal inhibition of binding of HCV VLPs to Huh7 cells, suggesting that these 
antibodies were either of low affinity or bound to sites close to but distinct from the neutralising 
epitopes. These results contradict previous findings which demonstrated that immunisation with 
HCV VLPs induced HCV-specific NAbs, since the envelope proteins are presented on the 
surface of VLPs in their correct conformation during immunisation [420, 421]. An explanation 
for these disparities could be that the antigen dose in the E1E2 protein boost was higher than 
that expressed on the surface of VLPs resulting in higher immune responses following boosting. 
Antibody isotyping revealed that the anti-E1E2 antibody response was predominantly 
comprised of other IgG subclasses but not IgG2a which is a hallmark of a dominant Th1 
lymphocyte response, important for mediating complement and ADCC activities [496-501]. 
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However, the anti-E1E2 antibody subclass profiles were not comprehensively defined given 
that the assay used in this chapter focussed on isotyping E1E2-specific IgG2a antibodies. Future 
studies should further define the anti-E1E2 IgG subclasses as well as assess their involvement 
in complement activation and ADCC. The ability of the mouse sera to prevent HCV VLPs 
binding to Huh-7 cells should be assessed throughout the vaccination schedule to determine 
whether the limited inhibition of binding was a direct result of the HCV VLPs boost, to 
eliminate the unlikely possibility that this group of animals were immunocompromised or that 
the vaccination regimen was somehow inadequate. The presence of NAb acting at the post-
binding stages should also be assessed using the HCVcc and HCVpp model systems. It would 
also be useful to test the potential of the antibodies generated with all three regimens to 
neutralise HCV particles from other genotypes.  
Spontaneous resolution of HCV is also associated with an early and durable cytotoxic T-
lymphocyte response with IFN-γ+ production, and the presence of weak and/or functionally 
impaired CD8+ T cells is a characteristic feature of persistent infection [26, 93, 512-514]. To 
examine the production of IFNγ from T cells following vaccination with the DNA constructs, 
IFNγ ELISPOT analysis against HCV peptides was conducted. There were no significant 
differences in IFNγ responses following stimulation with E1 or E2 peptides in all vaccination 
regimens. The number of SFUs detected in the E1/E2-specific ELISPOT reported in this chapter 
compared well to those reported in other studies using viral vectors [438, 443, 445], DNA [424] 
or VLPs [421, 424].  
Overall, the results indicate that the DNA prime/E1E2 protein regimens described in this 
chapter elicited a stronger antibody response than DNA prime/DNA boost regimens or DNA 
prime/HCV VLP protein regimens, whereas the serum neutralising activities were slightly 
higher for the DNA prime/DNA boost regimens than the DNA prime/E1E2 protein regimens. 
No significant differences in CMI responses were observed between all three vaccination 
regimens. Recognised difficulties in HCV neutralisation assays [490, 515, 516] and the inability 
of current in vitro assays to identify effector mechanisms which correlate with protection, 
suggest that in vivo vaccination followed by challenge experiments are paramount to assess the 
efficacy of potential HCV vaccines.  
6.5 Conclusion 
In this chapter, mice vaccinated with p-tPAtE1IMX313P + p-tPAtE1IMX313P or p-
tPAtE1tE2IMX313P + pVax were boosted with DNA, E1E2 protein or HCV-VLPs in an 
attempt to further improve the immunogenicity of the tE1/tE2-IMX313P DNA constructs. All 
vaccination regimens induced high levels of HCV-specific cell mediated and antibody 
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responses. Most notably, the induced antibodies possessed neutralising properties. Boosting 
with E1E2 proteins improved the overall antibody responses as determined by ELISA, 
compared to boosting with HCV-VLPs or plasmid DNA, however this did not improve the 
neutralising potency of these antibodies or CMI responses. Overall, DNA prime/DNA boost 
regimens and DNA prime/E1E2 protein boost which induced humoral and cellular 


















































Chapter 7. General Discussion 
An effective vaccine is the best long-term and cost-effective solution to combat HCV globally. 
Studies in humans and non-human primates have provided insight into the possible correlates 
of protection, however the actual correlates remain poorly understood. It is generally accepted 
that an effective HCV vaccines should induce NAbs targeting envelope proteins as a minimum 
and elicit CMI against the non-structural proteins.  
This thesis reports the efficacy of vaccination strategies mainly aimed at eliciting humoral 
responses to HCV envelope proteins. The lytic VLP vaccine strategy described in chapter 3 
highlighted that p-CE1E2-PRF could induce HCV-specific immunity although the responses 
were lower than those reported in the literature. The thesis also demonstrated that vaccination 
using DNA encoding HCV envelope proteins fused to the oligomerisation domains IMX313 
(chapter 4) or IMX313P (chapter 5) significantly increased the HCV-specific humoral and cell-
mediated immune responses in vaccinated mice. Vaccination with DNA encoding HCV 
envelope proteins fused to IMX313P induced the highest humoral and cell mediated immunity 
and these DNA constructs were used in various prime-boost vaccination regimens in an attempt 
to increase the vaccine’s immunogenicity. Boosting with recombinant HCV proteins increased 
the E1E2-specific antibody titers but failed to increase the neutralisation activity of these 
antibodies compared to boosting with DNA. Thus, data generated in this PhD thesis provide 
insights for the further development of a HCV prophylactic vaccine. 
7.1 Improving HCV-VLP DNA vaccine immunogenicity using perforin as adjuvant 
Recombinant DNA vaccines offer several advantages over traditional vaccine strategies and 
can induce both humoral and cell mediated immune responses. However, no DNA vaccines 
have been licensed for use in humans and this has been attributed largely to the lack of 
immunogenicity. Nevertheless, recent studies have demonstrated that DNA vaccines against 
human papillomavirus (HPV) were well tolerated and elicited antigen-specific immunity that 
controlled HPV viral load and inhibited the progression of tumour lesions and cervical cancer 
in humans [517, 518]. These studies demonstrated that DNA vaccines can be effective in 
humans. VLPs, on the other hand, have provided highly encouraging results in clinical trials as 
effective immunogens due to their highly organised particulate structure [489, 519-521]. 
The addition of perforin as a genetically-encoded adjuvant within a DNA vaccine has been 
shown to increase the immune response to HCV-NS3 [418] and NS3,4 & 5 [414] and HIV gag 
[522]. The hypothesis underlying the work described in chapter 3 was that PRF-induced necrotic 
cell death would not only enhance the HCV-specific-immune responses via the induction of 
DAMPs, recognised natural adjuvants, but would also result in release of VLPs formed 
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intracellularly. It was considered that this strategy would combine the ease of production of 
DNA vaccines with the immuno-stimulatory properties of VLP vaccines. After administration 
of p-CE1E2-PRF or p-CE1E2-PRF(DA), mice developed E1E2-specific antibody and cell mediated 
immune responses. Unfortunately, these responses were weaker compared to those reported in the 
literature [146, 420, 437, 438] and therefore unlikely to be effective against HCV despite 
multiple administration of the vaccine. IFNγ secretion is a marker of a Th1 type antigen-specific 
T cell immune response that plays a key role in fighting virus infection, and multi-functional T 
cells have been shown to be associated with virus control in HCV infection [432]. Although 
vaccination with p-CE1E2-PRF induced a HCV-specific T cell-mediated immune response, as 
determined by IFNγ secretion, particularly to the E2 peptides, these results were weaker when 
considered in the context of other studies [420, 441, 442].  
Other researchers have focused on generating VLP-based DNA constructs, known as plasmo-
retroVLPs. These constructs have been engineered to generate in situ retroVLPs pseudotyped 
with E1 and E2 proteins after in vivo delivery of the DNA [483, 523, 524]. Unlike the results 
generated in chapter 3, administration of the plasmo-retroVLPs resulted in the induction of 
significantly higher antigen-specific responses and antiviral immune protection than standard 
DNA plasmids [523, 524]. These plasmo-retroVLPs DNA constructs were also shown, in 
heterologous prime-boost immunisation strategies, to be superior for boosting CMI and 
antibody responses in primed animals than control plasmids unable to form VLPs [483, 523]. 
Furthermore, vaccination with a cocktail of plasmo-retroVLPs pseudotyped with E1E2 from 
five HCV genotypes (1a, 1b, 2b, 3a, 4c and 5) and/or displaying NS3 antigen in capsid proteins 
resulted in immune responses against all five HCV genotypes [424]. Nonetheless, despite these 
promising results, even the plasmo-retroVLPs strategy required booster immunisations with 
purified HCV VLPs for maximum activity.  
The poor responses observed using the CE1E2-PRF strategy could be attributed to various 
factors, including an insufficient uptake of the DNA vaccine in vivo by cells in the intradermal 
environment or an insufficient or partial release of the VLPs in vivo following PRF-induced 
cell death, leading to insufficient priming of the HCV-specific response.  The delivery route 
and/or method of DNA-based vaccines is also a critical factor in determining vaccination 
outcome. The immunogenicity of the plasmo-retroVLPs DNA vaccine was shown to be 
influenced by the route of DNA injection and was increased by co-delivery of plasmid DNA 
encoding cytokines cytokine genes or CpG sequences [424, 523]. Administration of HCV DNA 
vaccines using in vivo electroporation has also been shown to enhance the vaccine 
immunogenicity by increased local DNA uptake, protein expression, inflammation, and 
infiltration of T cells [277, 321, 481]. Nonetheless, despite the ability of electroporation to 
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improve DNA delivery and immunogenicity of the encoded antigen, it was not used in this 
thesis as it is associated with considerable discomfort and tissue damage which might limit its 
long-term future in vaccination. Therefore, attempts should be directed towards optimisation of 
the delivery methods of DNA-based HCV VLP vaccines and the addition or co-delivery of 
other novel genetic adjuvants for maximum immune induction. The effect of the p-CE1E2-PRF 
vaccine constructs in a prime/boost strategy should also be investigated, for example using a 
rAd5-CE1E2-based HCV vaccine, HCV VLPs [420] or indeed the recombinant E1E2 proteins 
used in chapter 6, as this may further enhance HCV-specific immune response to levels similar 
to those reported in the literature. 
Although the CE1E2-PRF induced weak HCV-specific antibody responses, with further 
improvements to the vaccine composition and delivery methods, this strategy could still be used 
to generate immune responses against HCV.  
7.2 Increased DNA vaccine efficacy resulting from E1/E2 heptamer expression 
HCV envelope proteins are the target of NAbs because they are exposed on the surface of the 
virion and represent the most immunologically significant HCV antigens [146, 420, 443-445]. 
Consequently, these proteins were the main focus of the vaccine strategies described in chapters 
4 and 5 of this thesis. Previously, it has been shown that cell surface-expressed E1 and E2 
glycoproteins are more effective immunogens than the wild-type antigens [509, 525]. Secreted 
E1E2 proteins have also been shown to be significantly more immunogenic with a greater 
breath of reactivity than wild-type E1E2 [453]. Antigen oligomerisation has also been shown 
to improve vaccine immunogenicity [461-463]. The work presented in chapters 4 and 5 aimed 
at developing a DNA vaccine encoding E1 and E2 incorporated into heptamers by fusion with 
the oligomerisation domain of a chimeric C4 binding protein IMX313 or IMX313P. The 
immunogenicity of DNA vaccines encoding E1 and/or E2 proteins as separate immunogens or 
as a single E1E2 polyprotein when fused to IMX313 (chapter 4) or IMX313P (chapter 5) was 
assessed in mice.  
All groups immunised with the HCV DNA vaccines encoding E1E2 heptamers elicited 
significant levels of anti-E1E2 antibodies comparable to those reported in the literature [420, 
445, 472]. This may be the result of increased capture and processing of the heptamers by both 
local and distal antigen presenting cells, thus increasing the immunogenicity of the E1E2 
antigens [461-463, 509, 510, 526]. Moreover, these antibodies were also able to recognise E1E2 
proteins in their native heterodimer form in an immunofluorescence assay, on cells transfected 
with a DNA construct encoding the full-length coreE1E2 polyprotein [447, 448, 527]. 
However, the anti-E1-specific antibody responses were limited, in agreement with the poor 
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immunogenicity of E1 observed in previous studies [146, 453, 528]. In addition to strong 
humoral responses, robust CMI responses have been proposed to be essential for clearance of 
HCV during acute infections in humans and chimpanzees [26, 199, 316, 473]. Fusion of E1/E2 
to IMX313P resulted in superior E1/E2-specific antibody and CMI responses compared to 
fusion of the same proteins to IMX313. This suggested that, in addition to oligomerisation, 
other factors such as increased half-life, improved antigen uptake and/or prolonged antigen 
processing could be involved in the enhancement of the E1/E2-specfic responses.  X-ray crystal 
structure studies of the heptamers could provide more information of the mode of action of the 
IMX313 and IMX313P domains and improve our understanding of how these domains affect 
the immunogenicity of the fused HCV antigens. 
Other HCV vaccine strategies to elicit neutralising antibodies have focused on incorporating 
highly antigenic conserved epitopes in the vaccine formulation, rather than WT HCV 
sequences. This was considered to allow the induction of broadly reactive NAbs while 
eliminating deleterious sequences that may act as immune decoys and/or contribute to isolate-
specific structural variations. A recombinant E2-based prophylactic vaccine, was recently 
shown to generate potent cross-NAbs antibodies in guinea pigs [529]. This recombinant E2 
vaccine was generated by removing the variable regions HVR1, HVR2 and igVR from the E2 
receptor-binding domain (E2 Δ123) [529, 530]. This strategy generated high-molecular weight 
forms of E2 Δ123 capable of eliciting distinct antibody specificities with potent and broad 
neutralizing activity against all seven HCV genotypes [529]. However, the Δ123 protein 
preparation is predominantly comprised of monomers, together with a range of oligomers. 
These oligomeric species exhibited distinct antigenic characteristics and immunogenic potential 
with the high molecular weight species generating the highest NAbs titers. Despite these 
promising results scaling up the manufacturing process may present a limiting factor for the 
development of HCV vaccines using this strategy.   
The novel E1/E2-IMX313P DNA vaccine described in this thesis is an attractive candidate for 
a HCV vaccine that could be readily scaled up. A recombinant HCV E1E2 glycoprotein 
(genotype 1a) vaccine was shown previously to reduce the carrier rate in immunised 
chimpanzees and generate sterilising immunity in some individuals in response to homologous 
and heterologous 1a virus challenge [283, 531, 532]. Furthermore, other E1E2 candidate 
vaccines demonstrated broad NAb responses in vaccinated human volunteers [282, 493, 533, 
534]. Soluble forms of E2 can be produced from mammalian and insect cells [76, 178, 470, 
535], and represent the focus of efforts in the rational design of a universal B cell vaccine 
against HCV [536, 537]. However, it is important to note that cross-neutralising epitopes that 
contain E1 and E2 residues are not represented in soluble E2 proteins [142]. Furthermore, 
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recombinant gt1b E1, but not recombinant E2, provided protection to immunised chimpanzees 
from homologous genotype 1b viral challenge [538]. Finally, developing an E1E2-specific NAb 
response may be a perquisite to mount a successful CMI response for viral clearance [539, 540]. 
For these reasons, a DNA vaccine encoding E1/E2-IM313P remains a prime candidate for HCV 
vaccine development. 
Collectively, the data reported in this thesis indicate that fusing E1/E2 to IMX313P resulted in 
secretion of the oligomerised protein and significantly enhanced the immunogenicity of the 
E1E2-based HCV DNA vaccine, to a level similar to that of other HCV vaccine candidates in 
preclinical animal studies [26, 199, 316, 473] [424, 443, 445]. These results support the 
inclusion of IMX313P domain as a molecular adjuvant in a DNA vaccine as an attractive 
strategy for developing an effective E1E2-based HCV DNA vaccine. Unlike other vaccine 
strategies such as subunit or VLP vaccines, the p-tE1/tE2-IMX313P vaccine construct, being a 
DNA vaccine, will be stable and cheaper to manufacture on a large scale as it does not require 
protein or particle purification. 
7.3 Improving DNA vaccination using a prime/boost strategy. 
Early vaccination studies in chimpanzees using E1E2 glycoproteins expressed by HeLa cells 
infected with a recombinant vaccinia vector [283, 541] or with E1E2 expressed in Chinese 
hamster ovary cell lines [506, 542] induced NAbs with various neutralisation efficacies in 
different animal models [526, 532]. Vaccine candidates using E1E2 glycoproteins have been 
found to induce modest NAb responses in human vaccine trials [282, 533, 543], although the 
NAb titer required to protect against infection with homologous HCV is currently not known. 
DNA vaccination provides a convenient platform that can be used to induce humoral and 
cellular immunity to HCV glycoproteins expressed endogenously. Nevertheless poor 
immunogenicity in large animals remains one of the major limitation of DNA immunisation 
[502]. A DNA prime-protein boost strategy is a promising approach to improve the efficiency 
of DNA immunisation [503-505]. A series of DNA constructs encoding secreted, truncated 
E1/E2 fused to IMX313P were shown to elicit superior responses as described in chapter 5, 
while the work described in chapter 6 assessed the ability of HCV VLPs or a soluble form of 
E1E2 proteins to increase the E1E2-specific responses elicited by DNA vaccination encoding 
E1/E2-IMX313P fusion proteins. The immunogenicity of these vaccines was compared against 
homologous DNA prime/DNA boost vaccination. The data showed that all three vaccination 
regimens induced high levels of E1E2-specific cell mediated and antibody responses. Among 
the three immunisation strategies, boosting with recombinant E1E2 protein induced the highest 
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IgG levels while there were no significant differences after boosting with DNA or HCV VLPs. 
Furthermore, mice vaccinated with these different regimens developed NAbs to HCV VLPs.  
To date, virtually all successful viral vaccines have been based on the induction of NAbs, 
usually via the targeting of viral envelope proteins [544]. For HCV, complete neutralisation of 
incoming virions is difficult to achieve as the virus can be delivered as free virions or associated 
with different lipoproteins and immunoglobulins [545, 546]. Additionally, the presence of  
quasispecies with variable epitopes in the virus population is likely to contribute to evasion of 
the humoral response. Nevertheless, neutralisation of a proportion of incoming HCV virions 
might lead to a reduced viral load allowing the development of CMI in due time, promoting 
viral clearance. The data in Chapter 6 also highlighted the importance of selecting and/or 
combining appropriate immunogens in an optimised regimen to induce efficient immunity. The 
E1/E2-IMX313P DNA prime/ E1E2 recombinant protein boost vaccine strategy is consistent 
with current vaccination schemes involving priming with DNA and boosting with a 
recombinant protein or viral vectors that have emerged as the favoured approach to generate 
protective responses against many diseases, including HCV, HIV, malaria and cancer [547, 
548]. More importantly, the homologous DNA prime/DNA boost regimens elicited a NAb 
response similar to that achieved by boosting with recombinant proteins (Chapter 6) suggesting 
that the homologous DNA vaccination regimens are equally effective at inducing NAbs as 
boosting with E1E2 protein. 
Although no DNA vaccines have thus far been licensed for human use, many have been licensed 
for veterinary use [477]. DNA vaccines show no significant side effects in immunised 
individuals and therefore are regarded as safe [1, 477]. A recent phase 1, open-label first-in-
human trial of the candidate tuberculosis vaccine MVA85A-IMX313 in healthy adults 
demonstrated that the vaccine was well tolerated and immunogenic [426]. Moreover, no auto-
immunity was detected towards the oligomerisation domain of mouse [461] or human C4bp 
[426, 461]. This suggests that it is highly unlikely that auto-immunity towards IMX313/P will 
be induced by the vaccines used in this thesis. However, if this vaccine is to progress to clinical 
trials, it will be necessary to perform a preclinical study demonstrating that the immunogenicity 
of the DNA prime/DNA boost, DNA prime/E1E2 protein boost or DNA prime/HCV VLP boost 
regimens translate well in larger animal models (such as pigs, see section 7.4.5), and is safe.   
It is worth noting that the vaccine immunogenicity increased with the number of doses, 
suggesting that similar vaccine regimens might be required for p-tE1/tE2-IMX313P to be 
effective in larger animals or indeed in humans, and this might result in non-compliance. Thus, 
to prevent this, the delivery of these DNA vaccine should be optimised to increase the vaccine 
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effectiveness with fewer doses and this could result in further improvements in the immune 
responses generated by these vaccine constructs. Unfortunately, due to resource and time 
limitations, examination of the neutralising abilities of serum at various time points throughout 
the vaccination schedule was not performed. Clearly, further investigation is warranted to 
comprehensively address this crucial aspect of HCV vaccine development.  
Collectively, these results have important implications for the development of anti-HCV 
preventive vaccines, and they exemplify the flexibility and unique ability of the E1/E2-
IMX313/P strategy to generate HCV-specific immune responses after homologous and 
heterologous prime-boost immunisation. 
7.4 Future studies 
The results presented in this thesis support further testing of p-tPA-tE1/tE2-IMX313P both in 
mice and larger animal models (such as pigs or non-human primates). The results from these 
future studies will be crucial for the future evaluation of these vaccine in human clinical trials.  
7.4.1 Assessing the long-term immunity of E1/E2IMX313/P DNA vaccines 
This thesis did not investigate certain key aspects related to the immune responses generated 
following vaccination with p-tPA-tE1/tE2-IMX313P due to unavoidable constraints. For 
example, long term vaccine experiments were not conducted due to time constraints. These 
studies could have provided valuable information on the longevity of the E1E2-specific 
immunity in vaccinated mice. It is thus important to demonstrate that this desirable 
immunological characteristic is achieved in future studies.  
7.4.2 A DNA vaccine strategy to induce HCV-specific NAbs and CMI 
No clear correlates of protection against HCV have been defined so far. However, it is generally 
accepted that an effective HCV-vaccine should elicit both a potent humoral response able to 
neutralise virus as well as a strong, broad CMI, to limit virus amplification and spread [279, 
549] [195, 200, 550]. The Gowans laboratory has developed a novel a DNA vaccine capable of 
inducing strong CD4+ and CD8+ T cell responses against non-structural proteins 3, 4A, 4B, 
and 5B [414, 551] similar to those observed during resolution of acute HCV infection. Further 
experiments should be conducted to assess whether the DNA vaccine constructs reported in this 
thesis in combination with the DNA vaccine encoding NS proteins can elicit both anti-E1E2 
NAb and CMI responses to the NS proteins. This strategy will ensure that the induced 
antibodies will either prevent HCV infection of host cells or reduce the number of HCV-
infected hepatocytes. A T cell response to NS proteins could in turn detect and eliminate virus-
infected cells through their effector functions. For example many licensed flavivirus vaccines, 
such as those against yellow fever virus (YFV), Japanese encephalitis virus (JEV), and tick-
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borne encephalitis virus (TBEV), have been shown to elicit strong CMI responses in addition 
to antibodies [552-555]. The live-attenuated 17D yellow fever vaccine, in particular, can induce 
strong CD4 and CD8 T cell responses that correlate with antibody responses [556] and are also 
likely to contribute to the high level of protection afforded by this vaccine. 
7.4.3 Generating a multigenotype HCV vaccine 
Previous studies have demonstrated that vaccination can induce NAbs to HCV, however, the 
protection was restricted to homologous virus and was ineffective against heterologous virus 
challenge [283]. The induction of NAbs against highly variable viruses or different genotypes 
remains a significant challenge in HCV vaccine research. Nevertheless, recent studies have 
demonstrated that NAbs can efficiently protect humanised mice and chimpanzees against 
heterologous virus in passive transfer experiments [142, 152, 192], suggesting that it may be 
possible to develop a vaccine with broad coverage of HCV genotypes. The induction of a broad 
CMI may also be useful in mediating protection against homologous HCV infection, but may 
be seminal to protect against infection with heterologous HCV strains [557, 558]. Therefore,  a 
vaccine covering viral heterogeneity (including different genotypes and subtypes) able to 
induce a strong NAb response and a vigorous multispecific, broad CMI may be necessary to 
overcome viral immune escape [559, 560].  Recently, a trivalent vaccine containing soluble E2 
from genotype 1a, 1b and 3a elicited pangenotypic NAbs in mice and rhesus monkeys, which 
neutralised HCVcc of all the seven genotypes more potently than the monovalent counterpart 
[561]. Furthermore, the NAb generated acted synergistically to inhibit HCV infection. 
Consequently, the development of a multigenotypic vaccine may be best achieved by exploiting 
the advantages of DNA vaccination, by encoding multiple antigens from different HCV strains. 
In such a study, a DNA vaccine encoding consensus HCV antigens or a cocktail vaccine of 
individual DNA encoding antigens from the main HCV genotypes could be evaluated for their 
immune potential. 
7.4.4 Improving DNA vaccine delivery  
Cellular uptake of naked DNA is inefficient in vivo, requiring administration of large amounts 
of DNA. [562]. It is believed that the bulk of DNA injected by the intramuscular route remains 
extracellular [563]. Several doses of the DNA constructs generated in this thesis were required 
for effective vaccination. It is likely that similar vaccine regimens will be required for p-
tE1/tE2-IMX313P to be effective in larger animal models or humans. DNA vaccines have thus 
far only been licensed for veterinary use. All licensed DNA vaccines are administered as an 




Most common alternative strategies to increase the efficiency of DNA delivery in vivo include 
physical delivery methods such as gene gun delivery and electroporation. The Gene gun method 
uses accelerated particle carrier biocompatible heavy metals to deliver the DNA into the target 
cell and tissues [341, 342]. However, particle bombardment is restricted to local tissue 
expression and surgery is often necessary for direct exposure of target tissue. Electroporation 
uses controlled electrical fields to create pores in the cell membrane that allow uptake of 
injected DNA into the cell [339, 564]. Despite electroporation presenting an efficient physical 
DNA delivery system, it results in high cell mortality and the accessibility of electrodes to 
internal organs is limited. Furthermore, these strategies generally require specialised equipment 
that might not be universally accessible. Consequently, a convenient simple strategy to deliver 
DNA effectively in vivo is desirable. 
Many barriers exist for the efficient transfer of genes to cells, including the extracellular matrix, 
the endosomal/lysosomal environment, the endosomal membrane, and the nuclear envelope 
[565]. Over the past decade several strategies have been developed to improve the poor outcome 
of DNA vaccines by focusing on these obstacles. One such approach designed to overcome the 
plasma membrane is based on peptide transduction domains (PTDs) (also known as cell 
penetrating peptides (CPPs)) linked to a dsRNA-binding motif from the dsRNA-binding 
protein, protein kinase R (PKR) [566]. This study showed that the PTD-dsRNA binding fusion 
protein (PTD-DRBD) effectively delivered siRNA in vitro to a range of primary cells resulting 
in specific down regulation of different siRNA targets, proving that the siRNA remained 
functional after delivery by the PTD-DRBD. A siRNA-PTD-DRBD ratio of 1:5 was found to 
be most effective. Moreover, the siRNA-PTD-DRBD complex was also capable of delivering 
the siRNA effectively in vivo [567]. Oligomers of the HIV-1 Tat protein were shown to have 
the ability to transfer plasmid DNA into cells [568]. The PTD-DRBD fusion protein contains 
3x Tat CPP sequences and a human influenza hemagglutinin (HA)-tag (to follow expression 
and purification of the protein) fused with a dsRNA-binding protein. 
As a potential component of this thesis, I constructed an analogous PTD-dsDBD binding fusion 
protein that contains 3x Tat CPPs separated by a short linker sequence, the Lambda Repressor 
helix-turn-helix dsDNA-binding protein which can bind to a specific DNA sequence termed 
the λ operator or Or2 sequence [569], a V5 tag to permit protein detection, and a 6x His tag for 
protein purification. Two copies of the OR2 sequence [569] which binds the Lambda Repressor 
protein are required to be inserted into a DNA vaccine for this strategy to function effectively. 
Preliminary gel retardation experiments showed encouraging results since the PTD-dsDBD 
protein was able to bind DNA containing the OR2 sequence and retard the DNA in gel 
electrophoresis (data not shown). Using a DNA construct encoding LUC, the 2A autoprotease 
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from FMDV GFP and 2 copies of the OR2 sequence (pCMV-LUC-2A-GFP) would allow the 
PTD-dsDBD to bind to- and deliver- DNA in vitro and in vivo as determined by detection of 
GFP-positive cells using flow cytometry in vitro and in vivo by direct imaging of LUC in 
animals [416, 570]. However, preliminary in vitro delivery experiments, demonstrated the 
PTD-dsDBD protein was unsuccessful at facilitating pCMV-LUC-2A-GFP delivery in target 
cells, evident by the lack on GFP expression (data not shown), even at high DNA: pCMV-LUC-
2A-GFP ratios and this work was not pursued. 
DNA must enter the nucleus to be transcribed, replicated, and/or integrated, and consequently, 
the nuclear membrane represents a second major impediment to DNA delivery. Nuclear import 
of plasmid DNA through the nuclear pore complexes (NPCs) is a sequence-specific process, 
mediated by specific eukaryotic sequence elements [571]. Plasmids encoding a 72 bp fragment  
of the SV40 enhancer were shown to target DNA to the nucleus of most cells within several 
hours, whereas a plasmid lacking this 72 bp sequence either remained in the cytoplasm until 
cell division, or indefinitely if the cell was nondividing, until it was degraded [571, 572]. This 
sequence, termed the SV40 DNA nuclear targeting sequence (DTS), has been shown to mediate 
plasmid nuclear import in all cell lines tested, as well as in vivo [573-576]. In addition to 
encoding 2 copies of the Lambda Repressor binding site, an SV40 DNA nuclear targeting 
sequence might be incorporated into the DNA vaccine construct to further increase the delivery 
of DNA in target cells by facilitating their nuclear entry. Furthermore, since many of the DTSs 
identified to date are derived from cell-specific promoters, this raises the possibility of using 
these promoters to drive cell-specific nuclear import of the plasmids and transcription of the 
delivered gene.  
7.4.5 Preclinical evaluation of potential HCV vaccine efficacy 
Virus challenge represents the only measure of vaccine protective efficacy. Chimpanzees are 
considered the optimal animal model to test HCV vaccine efficacy as HCV naturally infects 
only humans and chimpanzees [210]. However, wild chimpanzees are endangered, and the use 
of captive chimpanzees is expensive and is subjected to stringent ethical consideration, limiting 
the use of these animals in preclinical trials for candidate HCV vaccines [211, 577]. This 
necessitates testing candidate HCV vaccines in other alternative small and larger animal models 
before progression to human clinical trials.  
A transgenic mouse model permissive for HCV infection was recently developed [229, 230].  
These mice express the HCV entry receptors CD81 and occludin and have been shown to be 
infected with HCV derived from cell culture and HCV-positive serum, resulting in complete 
replication of the virus, persistent infection in 80% of the mice and hepatopathological 
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consequences typical of HCV infection [229, 230].  It would be interesting to examine the viral 
load in these mice following vaccination with the DNA constructs described in this thesis and 
examine the ability of the vaccines to protect the mice against challenges with cell culture 
derived-HCV.  
The functions of the major organs, the immune system and body sizes are similar in pigs and 
humans, making these animals an alternative large animal model to assess the immunogenicity 
of HCV vaccines [578]. The Gowans laboratory has previously used the pig model to evaluate 
the immunogenicity of a candidate HCV vaccine [418]. Therefore, it would be useful to 
examine the immunogenicity of the candidate HCV vaccine described in this thesis in a pig 
model. Results from these experiments might influence the use of pigs as an alternative cost-
effective model to evaluate the immunogenicity of candidate prophylactic HCV vaccines.  
7.5 Conclusion 
To the best of my knowledge, this thesis reports the first use of the oligomerisation domains 
IMX313 and IMX313P as a molecular adjuvant to improve the immunogenicity of a E1E2-
based HCV DNA vaccine. In summary, with further studies, the DNA-based HCV vaccine 
regimens described in this thesis have the potential to be considered for future development of 
a cost-effective, safe and highly effective vaccine against HCV that can be accessed globally 








































Appendix I. Primers used for producing the DNA vaccine constructs 
Primers used for cloning 
Gene of interest 
primers were used 
to amplify  
Primer 
name 
Primer sequence (5' to 3') 
(Lowercase = restriction enzymes, italic 
= kozak sequence, bold = start or stop 
codons, underlined = region of homology 
to gene of interest) 
Restricti
on Site 












E1 (truncated to 
removed E1 TMD) 
E1 rev TC TCTGCAgaattcTCAGTGAGCGCCAG
CCACCATATCGATCA 
EcoRI 
E2 E2 fwd CTGgctagcGCCACCATGCACACACT
GACAACAGGCGGACATGCCGCCA 
NheI 
E2 rev GTATAgaattcTTAGGCCTCGG EcoRI 
E2 (truncated to 
removed E2 TMD) 






































5' to 3' primer sequence 
tPA-E2 
(Underlined = 





















































Primer name Primer sequence (5' to 3') 
BGH poly A BGH poly A rev CCATAGAGCCCACCGCATCCCCAGCATGC
C 
CMV  CMV enhancer fwd GCGATGTACGGGCCAGATATACGCGTT 
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